The Immunogenicity of Cholangiocyte Cellular Therapies by Tysoe, Olivia
 






Olivia Catherine Tysoe 
Gonville and Caius College 
Department of Surgery 




Mr Kourosh Saeb-Parsy & Prof Ludovic Vallier 







This dissertation is the result of my own work and includes nothing which is the outcome of work done 
in collaboration except as specified in the text. This dissertation is not substantially the same as any that 
I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at 
the University of Cambridge or any other University or similar institution. I further state that no 
substantial part of my dissertation has already been submitted, or, is being concurrently submitted for 
any such degree, diploma or other qualification at the University of Cambridge or any other University 
or similar institution. In accordance with the guidelines of the degree committee of Clinical Medicine 

























 The immunogenicity of cholangiocyte cellular therapies 
Olivia Catherine Tysoe 
 
Cholangiocytes are the epithelial cells of the biliary system, responsible for the transport and 
modification of bile. Cholangiocyte disorders, known as cholangiopathies, are a diverse group of life-
threatening conditions characterised by cholestasis, ductopenia and eventual liver failure. There are 
currently no curative treatments for cholangiopathies aside from liver transplantation and while 
individual cholangiopathies are rare, together they account for a third of adult and 70% of paediatric 
liver transplants. There is a scarcity of suitable organs for transplantation, however, so development of 
cholangiocyte cellular therapies capable of replacing or repairing damaged bile ducts would have 
significant therapeutic value. The safety of such therapies must be assessed before they are suitable 
for clinical translation and an essential component of that is an evaluation of immunogenicity. 
In this dissertation I investigated the immunogenicity of cholangiocyte organoids (COs) from an 
established system developed within the Vallier lab. I first assessed the survival of COs in vivo and 
generate CO lines expressing luciferase to allow for real-time bioluminescent imaging in vivo. I 
characterised the expression of HLA molecules on COs compared to primary cholangiocytes and after 
exposure to a series of pro-inflammatory environments and demonstrated that expression of HLA 
molecules is reduced in COs compared to primary cholangiocytes but that exposure to pro-
inflammatory cytokines restored high levels of HLA expression. I also showed that physiologically-
relevant concentrations of pro-inflammatory cytokines were sufficient to upregulate HLA class II 
expression on COs.  
To assess the immunogenicity of COs in a transplant environment I used two humanised mouse 
models. I demonstrated that these models can induce an immune response against allogeneic COs and 
compared the response to allogeneic and autologous COs in both models. I identified HLA-matched 
CO lines and immune cell donors and investigated the impact of HLA-matching on the 
immunogenicity of CO allografts in a humanised mouse model. Overall, the work presented in this 
dissertation advances the understanding of the immunogenicity of cholangiocyte organoids, both in 
terms of their expression of immunogenic antigens and the response towards COs within both an 
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CHAPTER 1. INTRODUCTION 
1.1 Cholangiocytes and cholangiopathies 
1.1.1 Cholangiocyte physiology and development 
 
Biliary anatomy 
Cholangiocytes are the epithelial cells of the intra- and extrahepatic bile ducts and are responsible for 
the modification of bile through the transport of water and soluble molecules into the bile duct lumen 1. 
The primary function of the biliary tree is to transport bile from the liver to the gallbladder, where it is 
stored and released into the duodenum to aid emulsification and absorption of fats. Bile is secreted from 
hepatocytes, which are arranged in hexagonal structures known as hepatic lobules, into the bile 
canalicular, narrow (0.5-2 µm) channels between hepatocytes that emerge into the canals of Hering, the 
connecting space between the hepatic lobules and the intreahepatic bile ducts2. The canals of Hering 
are lined with cuboid, immature cholangiocytes and are thought to contain a niche of bipotent hepatic 
progenitor cells3.  The canals of Hering merge into the biliary ductules which then continue into the 
intralobular intrahepatic bile ducts, which are between 15-100 µm in diameter. The intrahepatic biliary 
ducts grow progressively larger in diameter until they merge into two large ducts, the right and left 
intrahepatic ducts (both >800 µm in diameter). These two large intrahepatic ducts drain into the 
extrahepatic common hepatic duct, then the cystic duct, which transports bile to the gallbladder (figure 
1.1). When bile is required for digestion, the gallbladder is stimulated to contract and release the bile 




Figure 1.1: Schematic demonstrating the anatomy of the biliary tree 
Schematic adapted from www.cancer.net. 
 
Biliary physiology 
Cholangiocytes vary in size according to their location in the biliary tree and can be divided into two 
types- small cholangiocytes, located within the intrahepatic bile ductules (diameter <15 µm), and large 
cholangiocytes, located within the gallbladder, extrahepatic bile duct and the larger intrahepatic ducts 
(diameter >15 µm)2,4. Small and large cholangiocytes also differ in their morphology, physiological 
role and gene expression. Small cholangiocytes are cuboidal in shape with a high nucleus-to-cytoplasm 
ratio while large cholangiocytes have a columnar morphology and a small nucleus-to-cytoplasm ratio. 
Additionally, small cholangiocytes are less specialised; large cholangiocytes are more polarised and 
possess cilia on their apical membranes for chemo- and mechanosensing within the bile duct lumen2,4. 
Large cholangiocytes are responsible for cAMP-dependent bile modification in response to the hormone 
secretin5, while small cholangiocytes contribute to bile modification through a Ca2+-mediated pathway. 
Small cholangiocytes are less sensitive to liver injury than large cholangiocytes and are responsible for 
repopulating the biliary epithelium in cases of damage6.  
The primary function of cholangiocytes is to transport and modify bile, primarily in response to secretin, 
which is produced in the small intestine after food consumption2,4,7. This is mostly achieved through 
the cAMP-mediated secretin-dependent bicarbonate (HCO3
- ) secretion pathway. Secretin is produced 
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within the duodenum in response to chyme (food remnants after digestion in the stomach) entering the 
small intestine. Secretin then binds to the basolateral membrane of large cholangiocytes within the 
intrahepatic and extrahepatic bile ducts, prompting the phosphorylation of the cystic fibrosis 
transmembrane conductance regulator (CFTR). This results in the release of chloride ions (Cl-) into the 
bile duct lumen, activating the apical Cl-/HCO3
- anion exchanger 2 (AE2) and causing an influx of 
bicarbonate into the bile duct lumen. This serves two purposes, to form a layer protect the 
cholangiocytes from the harmful effects of concentrated bile acids and to increase the osmotic flow of 
water from the cholangiocytes to the bile duct lumen8,9. This bicarbonate-mediated influx of water is 
responsible for up to 40% of the bile flow volume. Damage to cholangiocytes, for instance through 
cholangiopathies such as primary schlerosing cholangitis and primary biliary cirrhosis, can lead to 
cholestasis (disruption or blockage of bile flow) due to the loss of this secretin-dependent bicarbonate-
mediated pathway resulting in inadequately dilute bile.  
 
Cholangiocyte development 
Intrahepatic and extrahepatic cholangiocytes develop independently, from two different origins. 
Intrahepatic cholangiocytes develop from hepatoblasts10, a liver progenitor cell type shared with 
hepatocytes, while extrahepatic cholangiocytes develop at an earlier stage from a common progenitor 
with pancreatic cells.  
The liver develops from definitive endoderm, one of the three initial germ layer cell types in the embryo 
following gastrulation. Definitive endoderm develops into the primitive gut tube10-13, with hepatic 
endoderm emerging specifically from the foregut region of this primitive gut tube. Following paracrine 
signalling of factors such as bone morphogenetic protein 4 (BMP4) and fibroblast growth factor (FGF) 
from cardiac mesoderm, foregut endoderm transitions into hepatoblasts10,12,13, bipotent progenitor cells 
expressing markers of both hepatic lineage (such as hepatic nuclear factor 4a (HNF4a) and alpha 
fetoprotein (AFP)) and biliary lineage (such as cytokeratin 19 (CK19))10. Cholangiocyte differentiation 
from hepatoblasts begins around 8 weeks post gestation and starts in the hilum of the liver, near the 
portal vein. Portal hepatoblasts, co-ordinated  by a wide variety of signalling pathways such as 
TGFβ/Activin/BMP, FGF, Wnt, and JAG/Notch, organise into a ductal plate10,14 and undergo 
commitment to a biliary identity through the expression of biliary markers such as CK19 and Sox9. 
Initially the ductal plate forms as a single layer of cells, then develops into a double layer and forms 
small tubular structures14-16, a process that is regulated through the Notch signalling pathway15. These 
tubules migrate into the surrounding mesenchyme and develops into individual bile ducts, branching 
out from the hilum into the parenchymal tissue. Non-canonical Wnt signalling through the planar cell 
polarity pathway is essential to keep the cholangiocytes of the developing bile ducts in a uniform 
orientation within the ductal plane17,18. This is necessary to maintains tubular architecture when bile 
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ducts are maturing and branching into the liver, and deficiencies in this pathway can lead to 
fibropolycystic liver diseases18.  
The developmental origins of extrahepatic cholangiocytes is less well understood, however they are 
known to originate in the ventral foregut, between the liver and the ventral pancreas. Extrahepatic 
cholangiocytes develop from a common progenitor with pancreatic cells, which expresses both the 
SRY-Related HMG-Box Transcription Factor Sox17 and the Pancreatic and Duodenal Homeobox 1 
(PDX1) transcription factor10,14,19.  Through the influence of Notch signalling, this progenitor cell type 
then differentiates into a cholangiocyte-like cell type, expressing Sox17 but not PDX1 and a pancreatic-
like cell type, expressing PDX1 but not Sox1710,14,19. Other signalling factors affecting the development 
of the extrahepatic biliary tree are Hhex, a factor required for the suppression of a duodenal lineage, 
and HNF6, HNF1a and FoxF1, which are all associated with gallbladder development10,14. Once the 
extrahepatic bile ducts begin to form, they emerge from the ventral pancreas towards the liver, where 
they merge with the intrahepatic biliary system at the liver hilum.  
 
1.1.2 Immunobiology of cholangiocytes 
Cholangiocytes, as the epithelial cells of the biliary tree, are exposed to a wide range of microbial 
antigens from the gastrointestinal tract and the portal vein. Under healthy conditions, cholangiocytes 
secrete IgA and antimicrobial peptides such as β-defensin 2, lactoferrin and cathelicidin into the bile 
duct lumen to protect against potential pathogens from the small intestine and to clear antigens from 
the bile20. Secretion of these antimicrobial molecules is upregulated during infection. Cholangiocytes 
also constitutively express a range of Pattern Recognition Receptors (PRRs), such as Toll-like receptors 
(TLRs), which are expressed on their luminal membrane and respond to Pathogen-Associated 
Molecular Patterns (PAMPs) such as lipopolysaccharide (LPS), a bacterial macromolecule20-22. Upon 
activation by PAMPs, TLRs stimulate a range of immune responses through the NF-κB and MAPK 
pathways, including the upregulation of adhesion molecules, secretion of pro-inflammatory cytokines 
such as TNF-α, upregulation of HLA molecules and secretion of antimicrobial peptides20-22.  
Cholangiocytes, like all nucleated cell types23, constitutively express HLA class I and are capable of 
presenting antigen to CD8+ cytotoxic T cells. Cholangiocytes do not express HLA class II within a 
normal, healthy environment, however, exposure to pro-inflammatory conditions, including 
cholangiopathies such as Primary Biliary Cholangitis (PBC) and Primary Schlerosing Cholangitis 
(PSC), and post-transplant conditions such as GVHD and allograft rejection can lead to de novo 
expression of HLA class II molecules24,25. This has also been reported in in vitro cultured cholangiocytes 
stimulated with inflammatory cytokines such as IFN-γ and TNF-α26. 
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Cholangiocytes can become “activated” in response to a wide variety of insults, such as infection, 
xenobiotics, ischaemia and injury20,22. This activated state is characterised by increased cholangiocyte 
proliferation and a pro-inflammatory and pro-fibrotic environment, through which the cholangiocytes 
attempt to repair the injury. Autocrine stimulation with regenerative factors such as IL-6 and VEGF 
promote cholangiocyte proliferation, while secretion of cytokines and chemokines such as CCL20 and 
IL-8 attract a range of immune cells such as T-cells and macrophages which in turn secrete pro-
inflammatory factors to aid in biliary repair20-22.  
Suboptimal repair or persistent biliary damage can result in a pathological state of continual increased 
inflammation and fibrosis, ultimately leading to biliary cirrhosis. This pathological activated state, and 
the corresponding influx of immune and mesenchymal cells, is known as ductular reaction and plays an 
important role in the progression of many cholangiopathies such as PBC and PSC20. 
 
1.1.3 Cholangiopathies 
Biliary conditions, typically referred to as cholangiopathies, are a diverse group of conditions affecting 
cholangiocytes. Cholangiopathies are typically progressive diseases characterised by bile duct 
inflammation, cholestasis, fibrosis and eventual ductopenia (destruction of the bile ducts). This can 
often result in end-stage liver failure or cholangiocarcinoma, with no current curative pharmacological 
interventions1,21,27. While individual cholangiopathies tend to be rare, the lack of effective long-term 
treatment other than liver transplantation for many conditions means that their collective impact on 
morbidity and mortality is significant. The aetiology of different cholangiopathies are wide-ranging and 
often complex or unclear, with causes ranging from single genetic mutations (e.g. cystic fibrosis), 
idiopathic (often with a suspected autoimmune component, such as primary biliary cholangitis) or 
malignant (e.g. cholangiocarcinoma). Some of the most prevalent cholangiopathies that can potentially 
be impacted by the development of intrahepatic or extrahepatic cholangiocyte cellular therapies are 
described below.  
 
Primary Schlerosing Cholangitis  
PSC is a cholangiopathy primarily affecting adult men, with a median age of approximately 40 years at 
presentation28. It is characterised by cholestasis and obliterative fibrosis of large and medium bile ducts, 
leading to stricture formation within the intra- and extrahepatic bile ducts resulting in eventual 
ductopenia and liver cirrhosis29,30. The pathogenesis of PSC is unknown and likely multifactorial, 
although it is strongly associated with inflammatory bowel disease (IBD), with between 65-90% of PSC 
patients also presenting with IBD28. One proposed aetiology of PSC is an immune response caused by 
exposure to intestinal pathogens such as lipopolysaccharide through the portal circulation, or aberrant 
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expression of adhesion molecules on cholangiocytes leading to homing of memory T-cells, resulting in 
portal inflammation29. PSC is a progressive disease with no current curative pharmacological 
therapeutic options31. Surgical endoscopic management can be used to treat biliary strictures, although 
liver transplantation is the only effective long-term treatment, with PSC currently being the fifth most 
common indication for liver transplant in the United States32.  
 
Primary Biliary Cholangitis 
PBC is an adult cholangiopathy, mostly affecting older women. The condition primarily affects the 
small bile ducts within the intrahepatic biliary system and is characterised by inflammation, damage to 
cholangiocytes and ductopenia, and infiltration of immune cells such as lymphocytes, macrophages, 
eosinophils and NK cells into the portal tract. PBC has an unclear aetiology but is considered an 
autoimmune condition, caused by development of autoantibodies to inner mitochondrial antigens 
(AMAs)33-35. AMAs primarily attack the pyruvate dehydrogenase complex, leading to an influx of 
immune cells to the affected cholangiocytes33,34. This results in cholangiocyte cell killing by cytotoxic 
T cells and NK cells, as well as the production of a pro-inflammatory environment due to the release of 
inflammatory cytokines by CD4+ T cells. Two therapeutic options currently exist for the treatment of 
PBC, Ursodeoxycholic Acid (UDCA), which can slow disease progression36,37 but is not curative, and 
liver transplantation38-40.  
 
Biliary Atresia 
Biliary atresia (BA) is a progressive, inflammatory cholangiopathy affecting neonatal infants. While 
BA is a rare condition, affecting 0.5-0.8 per 100,000 live births in developed nations, it is the most 
common cause of liver transplantation in infants39,41 and typically results in death within two years due 
to progressive liver cirrhosis if left untreated41-44. Biliary atresia is an idiopathic cholangiopathy44,45 
characterised by obstruction and fibrosing obliteration of the extrahepatic bile ducts. This leads to 
cholestasis, resulting in end-stage liver cirrhosis42,45. Intrahepatic bile ducts can also undergo fibrosis, 
inflammation and cholestasis- this is most commonly seen when the extrahepatic biliary system is 
obstructed at the level of the porta hepatis, which occurs in over 90% of all cases. The current preferred 
treatment for biliary atresia is Kasai portoenterostomy44, a surgical procedure whereby the duodenum 
is directly anastomosed to the porta hepatis, allowing for drainage of bile into the small intestine46.  This 
procedure alone allows up to 15% of recipients to live predominantly symptom-free lives47, while 50-
60% of all BA patients will require a liver transplant at some point in their life, even after a successful 




Alagille’s syndrome is a genetic condition caused by mutations in the Notch signalling pathway48,49. It 
is an autosomal dominance disorder affecting many areas of the body, although the severity of the 
disease varies between patients50. Approximately 97% of Alagille’s syndrome cases are caused by 
mutations in Jagged 1, a Notch signalling ligand, although mutations of the NOTCH2 gene can also be 
responsible. The prevalence of Alagille’s syndrome is estimated to be 1 in 70,00051, although this figure 
is considered to be an underestimate due to the variable penetrance of the condition50. Alagille’s 
syndrome can affect the cardiovascular system, kidney function, physical and mental development and 
cause abnormalities in the skeleton and facial features52, but the most common clinical feature is defects 
of the biliary tree, in particular ductopenia and chronic cholestasis50,52-54. Alagille’s syndrome is 
progressive, with 15% of patients developing cirrhosis and liver failure requiring a liver transplant50,54.  
 
1.1.4 Treatment of cholangiopathies  
The available treatments for cholangiopathies are limited. There are surgical options to treat some 
cholangiopathies, such as portoenterostomy for biliary atresia44, a procedure that involves anastomosing 
the jejunum to the liver above the portal vein to allow drainage of bile directly into the small intestine, 
and some pharmacological therapies such as Ursodeoxycholic Acid (UDCA) for PBC can slow disease 
progression36,37. 
Currently, however, the only curative treatment for end-stage cholangiopathies is liver transplantation, 
either whole-organ transplantation from a deceased donor or partial liver transplantation from a living 
or deceased donor. The number of people requiring liver transplantation, however, is greater than the 
number of available organs55. The high demand for donor organs has led to increased use of organs 
donated after circulatory death (DCD donors) in the UK and elsewhere, resulting in a modest increase 
in overall donations56. However the number of organ transplants performed annually still only accounts 
for approximately 10% of the global demand57. Additionally, there are considerable practical concerns 
with the use of solid organ transplants as the organ must undergo a period of ischaemia between removal 
from the donor and implantation into the recipient. This can result in cell death and reduce the quality 
of the organ, increasingly the likelihood of graft failure.  
The risk of rejection further complicates solid organ transplantation. While liver grafts are less likely to 
be rejected than other organs58, the risk is still present and recipients of liver transplants still require 
immunosuppression, in most cases for the rest of their lives59. Long-term immunosuppressive treatment 
is associated with an increased risk of cancer,  approximately double that of the general population60, 
as well as cardiovascular disorders61 and opportunistic infections62. One potential solution to the 
problems of solid organ transplantation is cellular therapies. It is hoped that cellular therapies will be 
able to provide a cost-effective, safe alternative to solid organ transplantation while reducing or 
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altogether avoiding the challenges of limited supply, graft failure and immune rejection that can occur 
in conventional organ transplantation. .  
 
 
1.2 Regenerative Cellular Therapies 
 
1.2.1 Overview 
Cellular therapies are a promising alternative to solid organ transplantation, either as a temporary 
‘bridging’ treatment until an organ transplant can be carried out, or, eventually, as a curative treatment. 
In order to become an effective and realistic alternative to organ transplantation, cellular therapies must 
meet several important criteria. They must be safe (non-tumorigenic and remain localised to only the 
intended anatomical site) and effective (able to perform all the necessary functions and significantly 
improve the clinical outcome for the patient). They should ideally also have low immunogenicity, 
requiring minimal or no immunosuppression. They should certainly not be more immunogenic than 
existing solid organ therapies. Lastly, cellular therapies must utilise cells that are abundant, readily 
available when required and result in therapies that are cost effective on a large scale. Currently there 
are two leading options for cellular therapies: those derived from stem cells and those derived from 
primary cells. Stem cell-based therapies can be further divided into those derived from adult stem cells, 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).  
 
1.2.2 Embryonic stem cells  
Embryonic stem cells are derived from the inner cell mass of blastocysts and are pluripotent; i.e., they 
able to differentiate into any of the three primary germ layers (mesoderm, ectoderm and endoderm) 
from which all adult cell types are derived. ESCs are capable of indefinite propagation as they express 
high levels of telomerase, allowing for continual repair of telomeres after cell division63. ESCs have a 
round shape, high nucleus-to-cytoplasm ratio and form tightly packed colonies in culture. ESCs were 
first isolated from mice in 198164, using techniques adapted from culturing teratocarcinoma lines, and 
subsequently from humans in 199865. Since then, progress has been made towards potential therapeutic 
use of ESCs for a range of diseases, such as age-related macular degeneration66, heart failure67,68, spinal 
cord injury69 and Parkinson’s disease70. ESCs were initially seen as a highly promising source for 
cellular therapies because of their pluripotency, their ability to be rapidly expanded from a small number 
of cells and their potentially reduced immunogenicity when compared to primary cells or solid organ 
transplants (due to a lower level of human leukocyte antigen (HLA) expression71). More recent studies, 
however, have suggested that ESCs and ESC-derived differentiated cells may be more immunogenic 
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than previously recognised, possibly on a level comparable with solid-organ transplants72. Additionally, 
research into and therapeutic use of ESCs has been complicated by ethical concerns, prompting many 
researchers to focus on iPCS, which do not require the use of human embryos.  
 
1.2.3 Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (iPSCs) are pluripotent cells that are generated from adult somatic cells 
but are genetically, morphologically and functionally highly similar to ESCs. iPSCs were first generated 
from mouse embryonic and adult fibroblasts in 200673 and then from adult human fibroblasts in 200774. 
Since then iPSCs have attracted a great deal of attention, as they offer the same clinical and scientific 
potential as ESCs while avoiding the ethical controversy of deriving cells from human embryos. iPSCs 
are generated through “reprogramming” adult somatic cells by inducing the overexpression of four 
pluripotency transcription factors - Oct3/4, Sox2, Klf4 and c-Myc, which alter the cell’s epigenome and 
induces expression of pluripotency associated genes such as Nanog, SSEA1 and Oct4, reverting it to a 
pluripotent state. The c-Myc transgene was found to increase the risk of tumour formation in iPSC-
derived chimeric mice75 and has since been shown to be dispensable in the reprogramming process76. 
This has resulted in many researchers no longer using c-Myc as a reprogramming factor when 
generating iPSCs for translational research77,78. The expression of reprogramming factors can be 
induced by a variety of different methods - initially a retroviral vector was used by the Yamanaka group 
to integrate the transgenes into the genome73 but due to the low efficiency and concerns over accidental 
integration of viral genes, other methods have been developed. These include the use of lentivirus 
vectors, which can integrate into non-dividing cell types and can be edited to include a Cre-recombinase 
cassette capable of excising any viral DNA integrated into the genome79, and Sendai virus vectors, 
which are RNA viruses and therefore incapable of genome integration80. Additionally, transgene-free 
methods of reprogramming have been investigated, including transfecting cells with mRNA81 for the 
reprogramming factors or introducing the reprogramming factors as protein into the cells directly82. 
Disadvantages of iPSCs as cellular therapies include the continued lack of an ideal reprogramming 
vector, uncertainty over the immunogenicity of iPSCs72,83, including from autologous donors83, and the 
current inability of iPSCs to fully differentiate into all cell types in vitro.  Additionally, there are 
concerns that incomplete epigenetic reprogramming and a lingering “epigenetic memory”84 may 
prevent iPSCs from being truly pluripotent and limit their ability to differentiate into all cell types, as 
well as safety concerns about the potential for iPSCs and iPSC-derived therapies to be tumourigenic, in 




1.2.4 Primary Cells 
Primary cells are adult somatic cells isolated from tissues. Human primary cells can be derived either 
from living donors though biopsies or blood donation or from deceased donors. A clear advantage of 
primary cell lines for cellular therapy is that the cells are already fully differentiated and functional and, 
as they do not undergo reprogramming, are free from many of the safety concerns associated with 
iPSCs. Additionally, some cell types have already been used for primary cell therapy for several years, 
such as the transplantation of pancreatic islets to treat type 1 diabetes mellitus86,87. A major limitation 
of primary cell therapy is the inability to culture many primary cell types for any significant length of 
time. While some cell types, such as fibroblasts, can be maintained and expanded in vitro for prolonged 
periods88, most complex cell types cannot be cultured for more than a few weeks89,90. Primary cells 
commonly dedifferentiate in culture91-93, although advances in co-culture and 3D culture systems can 
mitigate this to some degree94,95. As the majority of cell therapies are likely to involve transplantation 
of cells from allogeneic donors, many primary cellular therapies are likely to induce an immune 
response and require immunosuppression, in a similar manner to solid organ allografts.  
 
1.2.5 Organoids 
The development of the organoid culture system over the last decade has had a major impact on the in 
vitro culture of both primary cells and cells derived from pluripotent stem cells, with significant 
implications for the study of tissue and cell development, disease modelling, drug screening and 
regenerative cellular therapies. While the term “organoid” can be broad in its meaning96, it is typically 
used to refer to an in vitro culture of 3D cellular structures suspended within an artificial extracellular 
matrix, capable of self-organisation and long-term self-renewal96-98.  Organoids can be derived either 
from primary tissue or from pluripotent stem cells after differentiation towards a particular lineage. In 
the case of primary-derived organoids, another important requirement is that the organoids retain key 
characteristics of their original tissue in terms of their gene expression, functionality and genetic 
stability.  
The first example of an organoid culture system was developed in 2009 from intestinal stem cells 
found in the intestinal crypts of adult mice99. These stem cells expressed the marker leucine-rich 
repeat-containing G-protein-coupled receptor 5 (LGR5), allowing for their isolation and in vitro 
expansion. This original organoid system was developed after a series of key discoveries: firstly, the 
importance of the Wnt signalling pathway100 - a key signalling pathway regulating cell proliferation, 
cell fate determination and cell polarity in both embryonic and adult tissue101- in propagating adult 
intestinal stem cells102. Secondly,  the identification of LGR5 as an intestinal stem cell marker103 and, 
lastly, the discovery that the Wnt agonist R-spondin could bind to LGR5 to induce intestinal stem cell 
hyperplasia in vivo  in mice104.  
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These discoveries allowed the development of a 3D culture system relying on Matrigel - a laminin-
rich hydrogel derived from a murine sarcoma105-  to suspend the organoids within a 3D structure, and 
Wnt signalling, provided by the Wnt agonist Rspondin-1, to promote cell proliferation through the 
Wnt/β-catenin pathway. In addition, two final growth factors that had previously been demonstrated 
to play a role in intestinal cell proliferation, epidermal growth factor106 (EGF) and Noggin107 (a BMP 
inhibitor), were shown to be necessary for organoid proliferation and culture expansion.  
Importantly, these organoids contained all cell types of the intestinal epithelium and recapitulated the 
crypt and villus structure of the native intestinal tissue. These crypt and villus-like structures 
surrounded a central lumen in each organoid, with fully-differentiated epithelium comprising the 
villus-like areas and LGR5+ stem cells remaining in the crypt-like areas, as seen in native intestinal 
tissue.  
Since this initial work, many other organoid culture systems have been developed for a wide variety 
of different cell and tissue types, modifying the specific culture conditions and growth factors to 
promote the survival and proliferation of particular lineages 108-113. Furthermore, the organoid culture 
system has been applied to the culture of cells derived from pluripotent stem cells114-119 , with the aim 
of increasing the maturity of these differentiated cell types and compensating for the difficulty in 
accessing primary tissue120.  
The development of organoid culture technology has great potential for regenerative cellular therapies 
as it allows for the long-term culture of many primary cell types previously difficult to maintain in 
vitro, as well as improving the differentiation and expansion potential of many iPSC-derived cellular 
therapies. Due to the highly proliferative nature of most organoid systems, only a small amount of 
starting tissue is required to establish and expand primary-derived organoids, while many terminally 
differentiated iPSC-derived organoids can be passaged and expanded long-term, which is not typically 
the case for 2D differentiation systems. Furthermore, many organoid systems are increasing the 
potential of the technology through co-culture with other cell types, such as mesenchymal or 
endothelial cells121-123. Additionally, cells generated through organoid technology can be seeded on 
artificial scaffolds or decellularised tissue to produce bioengineered tissue for use in regenerative 
medicine. 
 A limitation of organoid culture systems is the continued requirement for an extracellular matrix 
derived from xenogenic material in order to maintain the 3D structure and allow for optimal cell 
proliferation. Matrigel and other basement membrane matrices are derived from murine tissue and are 
not chemically defined, making them non-compliant with good manufacturing practice (GMP) 
standards, a requirement for any product developed for clinical use. Chemically defined, non-
xenogenic artificial extracellular matrices are being developed to replace Matrigel, although this 
technology is not yet optimised and Matrigel remains in widespread use. Additionally, in the case of 
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primary-derived organoids, access to human tissue can be a logistical challenge, with many tissue 
types only available from deceased donors or through a biopsy. While iPSC-derived organoids can be 
generated from more readily available cells, the maturity of the resulting organoids is not always 
optimal.  
 Within the Vallier lab, we have developed a novel organoid culture system for the derivation and 
long-term expansion of cholangiocyte organoids (COs) 124,125. COs can be derived from both 
extrahepatic and intrahepatic biliary tissue125 and represent a population of mature, adult large 
cholangiocytes capable of survival and expansion for up to six months. COs display typical 
cholangiocyte morphology, including cilia, and express key cholangiocyte markers at levels consistent 
with primary tissue, even after long-term culture. They maintain standard cholangiocyte functionality 
such as alkaline phosphatase activity, gamma glutamyl transferase activity and ion transfer in 
response to hormones such as secretin. Importantly, we have demonstrated COs’ capacity to 
successfully generate artificial biliary tissue through seeding on tubular collagen scaffolds. These 
artificial bile ducts were able to rescue a model of murine extrahepatic biliary injury124 and work is 
ongoing to develop artificial bile ducts of a size appropriate for human transplantation. Additionally, 
assessment of the potential of COs to repopulate and repair damage to the intrahepatic biliary system 
is in progress. Given the potential for COs to be used as a regenerative therapy for cholangiopathies of 
both the extrahepatic and intrahepatic biliary system, it is important to fully characterise the 
immunogenicity of these organoids. This will determine the best strategy for translating this cellular 
therapy to the clinic, as well as potentially discovering methods of reducing or eliminating the 
alloimmune response to any CO cellular therapy or artificial tissue.  
 
 
1.3 The immune response 
 
1.2.2 Allograft rejection 
In solid-organ transplantation, there are three recognised pathways that mediate the alloimmune 
response to donor tissue - the direct, indirect and semi-direct allorecognition pathways 126. The indirect 
allorecognition pathway is the typical pathway of (allo)antigen recognition - recipient antigen 
presenting cells (APCs) endocytose HLA and other molecules from donor cells and process them into 
antigenic peptides which are then presented via HLA class II molecules on recipient APCs. Recipient 
CD4+ effector T helper cells (Th cells) then bind to recipient APC HLA class II molecules expressing 
donor alloantigen and to B7 (CD80/CD86; costimulatory molecules expressed on the APC) and undergo 
activation and clonal expansion. In a manner similar to the immune response to infections, the activated 
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Th cells produce pro-inflammatory cytokines and provide help to naïve B cells in the lymphoid tissue. 
This results in B-cell activation and the formation of germinal centres (GCs) within the secondary 
lymphoid tissue (spleen and lymph nodes)127. B-cells undergo maturation and antibody class-switching 
in GCs through somatic hypermutation, resulting in the production on highly specific IgG antibody. 
Activated recipient APCs can also activate CD8+ T cells, resulting in their maturation into cytotoxic T 
lymphocytes (CTLs) which then kill target cells, a process that is aided by Th cells.  
The direct allorecognition pathway involves the activation of recipient Th cells by intact donor HLA 
class II molecules, presented by donor APCs present in the graft. This pathway typically dominates 
during the early, acute response to organ transplantation and becomes less prominent with time as donor 
APCs are lost 128.  The putative semi-direct allorecognition pathway was discovered relatively recently 
and involves the transfer of intact HLA molecules from donor APCs to recipient APCs, which then 









Figure 1.2: Schematic demonstrating the three alloimmune recognition pathways 
Schematic representation of the three pathways of alloimmune recognition: the direct pathway (A), the 
indirect pathway (B) and the semidirect pathway (C). Schematic adapted from Sánchez–Fueyo and 
Strom (2011)130. 
 
In all allorecognition pathways, successful activation of effector T cells by APCs requires not only the 
interaction of HLA molecules with the T cell receptor (known as Signal 1) but also the interaction of 
costimulatory molecules (Signal 2). Signal 2 involves, amongst others, the interaction of CD80/CD86 
on the APC with CD28 on the Th cell. This results in production of IL-2, a pro-inflammatory cytokine 
which stimulates proliferation in T cells 131. If a T cell binds to HLA class I or II on an APC but does 
not receive signal 2 then the cell will undergo anergy 132,133. Under normal conditions, CD86 is 
expressed at low levels on APCs and both CD86 and CD80 are upregulated after exposure to pathogen-
associated molecular patterns (PAMPs) or, in the context of transplant, damage-associated molecular 
patterns (DAMPs). DAMPs bind to pattern recognition receptors (PRRs) 134 and induce a signalling 
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cascade resulting in the activation of the transcription factor NF-kB. This upregulates expression of 
HLA class II, CD80 and CD86.  
Allograft rejection can be divided into acute and chronic responses. Although these categories are based 
on the timeframe of rejection rather than the underlying mechanisms, acute rejection is typically 
mediated by T cells 135, although antibody-mediated hyperacute rejection and acute antibody-mediated 
rejection can also occur. Both CD4+ and CD8+ T cells contribute to acute rejection, although CD4+ T 
cells can be sufficient to induce acute rejection 136,137. Chronic rejection is often antibody-mediated; the 
recipient generates de novo antibodies against donor HLA class I and II molecules, resulting in fixation 
of complement and recruitment of macrophages and neutrophils to the graft 138,139. Memory T cells also 
contribute to chronic allograft rejection 140,141, including by direct-pathway interaction with graft 
endothelial cells 142.  
The optimal desired outcome in any allogeneic transplant setting is operational transplant tolerance. 
This is defined as the survival of a functioning graft within an immunocompetent recipient, without the 
need for immunosuppressive therapy and with no functional or histological signs of rejection 130. As 
alloantigens are not presented to immature T cells in the thymus during embryonic development, central 
tolerance towards allografts cannot be attained, although it is possible to develop peripheral tolerance 
through a two-step mechanism of deletion of alloreactive effector T cells and the proliferation of graft-
protective regulatory T cells (Tregs) 143. Initial deletion of effector T cells can be induced by 
costimulation blockade of CD28-B7 and CD40L-CD40 interaction, resulting in apoptosis of the 
alloreactive T cells 143 144. Deletion of effector T cells is followed by an increase in the proportion of 
Tregs, which in turn can further decrease the number of active effector T cells through mechanisms 
such as downregulating expression of costimulatory molecules on APCs through direct cell-cell 
interaction 145, interacting directly with effector T cells to induce anergy or apoptosis 146, secreting IL-
10 and TGF-β to downregulate APC function and IL-2 production by effector T cells 147 or to convert 
effector T cells into Tregs 148.  
 
1.2.3 Methods of preventing allograft rejection 
HLA matching is when donor organs are assigned to recipients based on a match between their HLA 
molecules. This matching is optimally performed at the level of specific HLA alleles, but before the 
advent of DNA-typing, HLA-matching was performed according to serotype, a much lower level of 
resolution149. There are six classical HLA molecules: HLA-A, HLA-B, HLA-C (HLA class I) and HLA-
DR, HLA-DP and HLA-DQ (HLA class II). HLA genes are all located on chromosome 6 and are highly 
polymorphic, with over 2550 HLA class I and II alleles currently identified150.  HLA matching has been 
demonstrated to be highly effective at improving long-term graft survival and patient survival in solid 
organ transplantation151,152 and is highly important in HSC transplantation153. The extent to which HLA-
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matching improves transplant outcomes varies according to organs, with the allograft survival of organs 
such as kidneys and hearts clearly linked to the degree of HLA compatibility between donor and 
recipient152, while the benefit of HLA matching in liver allografts remains unclear, with the majority of 
evidence suggesting it is has no impact on either graft or patient survival154,155. While HLA matching 
has been demonstrated to be effective for most organs, in cases of solid organ transplantation it is 
typically only performed for kidney grafts, as other organs have too few available grafts and too high a 
susceptibility to ischaemia for HLA matching to be practical152.  
The most common and effective method of preventing allograft rejection is administration of 
immunosuppressive agents to the transplant recipient. Immunosuppressive treatments can be broadly 
divided into three categories, induction immunosuppression, maintenance immunosuppression and 
treatment of acute rejection156. Immunosuppressive treatments can be either pharmacological agents 
such as calcineurin inhibitors such as (for example, cyclosporine A and tacrolimus) or biological agents 
such as monoclonal antibodies157.  
Immunosuppression is highly effective at stopping immune rejection in the early stages post-
transplantation but long-term use often has negative side-effects such as nephrotoxicity158, increased 
likelihood of cancer due to reduced ability of the immune system to detect and destroy transformed 
cells159 and an increased susceptibility to pulmonary infections160. Long-term immunosuppression is 
often essential, as it is unusual for a transplant recipient to ever gain full tolerance to their graft and 
low-level immunosuppression often needs to be maintained life-long157. Due to the harmful side effects 
of long-term immunosuppression, identifying an alternative method of ameliorating immunogenicity in 
cellular therapies would have a significant benefit to the health of patients receiving such therapies.   
1.2.4 Immunogenicity of cellular therapies 
While autologous cellular therapies is considered the ideal therapeutic option for many conditions 
requiring cellular therapies161, generating autologous cellular therapies and bioengineered tissue for 
every patient would be highly time consuming and unlikely to be logistically or economically viable 
for the foreseeable future. Additionally, if generating primary-derived cellular therapies, such as COs, 
deriving autologous cell lines may not always be possible in cases where the native biliary system is 
significantly damaged (e.g., late stage primary biliary cirrhosis) or missing altogether (e.g., biliary 
atresia).  
Allogeneic primary derived cellular therapies are expected to have similar immunogenicity to their 
tissue of origin but may be less immunogenic than a solid organ transplantation. This is because cellular 
therapies would typically be a purified population of one cell type (for example, cholangiocytes, 
hepatocytes) and so would lack passenger lymphocytes, including APCs. In solid organ transplants, 
these passenger APCs would interact with the recipient’s immune system via the direct alloimmune 
pathway due to their expression of HLA class II and costimulatory molecules, as well as via the 
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semidirect and indirect alloimmune pathways. Cellular therapies, in contrast, would not be able to 
interact with the recipient immune system through the direct pathway as non-professional APCs lack 
co-stimulatory molecules and express HLA class II only under heightened pro-inflammatory conditions. 
Despite this, it is highly unlikely that allogeneic cellular therapies would be able to be transplanted 
without some form of immunosuppression or other attempts to ameliorate their immunogenicity.  
Aside from standard immunosuppressive treatment, one method for reducing immunogenicity of 
cellular therapies that is under investigation is HLA matching of donors and recipients. This has been 
discussed in the context of generating banks of pluripotent stem cell therapies from a wide range of 
donors of varying HLA types, particularly homozygous donors, in order to provide allogeneic, HLA-
matched cells for as many patients as possible162-166. The impact of HLA matching has been investigated 
in the context of iPSC and ESC-derived cellular therapies, with reports indicating so far the HLA 
matching is able to significantly reduce, although not entirely prevent, the immune response to 
allogeneic cellular therapies167-170. While the generation of banks of homozygous cell lines is likely to 
be challenging149, particularly in multi-ethnic populations, genetic engineering strategies can be used to 
knock out heterozygous HLA types, reducing immunogenicity and improving the likelihood of finding 
an HLA match171.  
Another promising option is genetic modification of cellular therapies to remove HLA expression 
completely, particularly HLA class I, which is expressed on all nucleated cell types. This has been 
shown to reduce immunogenicity by preventing or limiting CD8+ T cell mediated cytotoxic 
killing172,173, however HLA I KO cells remain vulnerable to cell killing from natural killer (NK) cells174. 
The impact of NK cells can be ameliorated by the concurrent overexpression of a non-classical HLA 
class I molecule, such as HLA E or G, on HLA class I KO cells175.  
 
 
1.4. Humanised mouse models 
 
1.4.1 Immunodeficient mice 
Clinical translation of cellular therapies is critically dependent upon the ability to assess the human 
immune response they induce. While mouse models are essential for investigating the safety and 
functionality of cellular therapies, as well as contributing towards immunological research in general, 
the differences between mouse and human immune systems and the need to test human-specific cellular 
therapies require the “humanisation” of the mouse immune compartment. Generation of these models 
requires the use of severely immunocompromised mouse strains, onto which human leukocytes can be 
engrafted through a variety of methods outlined below. The first steps towards generation of humanised 
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mice was the discovery of the severe combined immunodeficiency (SCID) mouse strain, which contain 
almost no mature B or T lymphocytes and are unable to reject skin xenografts176. This phenotype is due 
to a mutation of the prkdc gene (encoding protein kinase C) on chromosome 16 which affects the DNA 
repair mechanism essential for VDJ recombination during maturation of B and T cells177. Subsequently, 
RAG1-/-  and RAG2-/- strains were generated178,179 – these strains are homozygous for a mutation in the 
RAG1 and RAG2 genes respectively, preventing VDJ recombination and T and B lymphocyte 
maturation in a similar manner to SCID mice. Backcrossing the non-obese diabetic NOD/ShiLtj (NOD) 
strain with the SCID or RAG1/2-/- strains was an important advance in humanised mouse research as 
NOD/SCID mice had reduced NK cells, reduced macrophage functionality and lacked complement as 
well as the near-complete lack of T and B cells typical of SCID mice180. 
It was not until the development of the NOD/shi-SCID/γ (NOG) strain, however, that engraftment of 
immunodeficient mice with human leukocytes became efficient enough to allow for effective 
humanised mice research. NOG mice lack T, B and NK cells, have reduced macrophage, complement 
and dendritic cell activity and engrafted human haematopoietic stem cells (HSCs) more effectively than 
other immunocompromised strains. NOG mice were generated by crossing NOD/shi-SCID mice with 
γc
-/- mice, which have a mutation in the γ chain of the common cytokine receptor181 (formerly known as 
the IL-2 receptor)182 resulting in an abrogated, non-functional form of the molecule. The common 
cytokine receptor γ-chain (γc) is found within the receptors for the cytokines IL-2, IL-4, IL-7, IL-9, IL-
15 and IL-21. The lack of IL-15 and IL-2 signalling results in an inability to form NK cells183,184, while 
the lack of signalling from IL-2 and multiple other cytokines (e.g. IL-4, IL-7) contributes further to the 
deficiency in B and T cells182. Around the same time, a similar strain, the NOD/LtSz-
Prkdcscid Il2rgtm1Wjl/J (NSG) strain, was developed. NSG mice are similar to NOG mice, with the 
principle difference that their IL-2Rγ chain is completely lacking, rather than simply non-functional 
185. NSG mice are commonly used for the generation of humanised mice as they provides highly 





Figure 1.3: Schematic of the different humanised mouse models 
Figure adapted from Schultz et al. (2012)186 
 
1.4.2 The Hu-SRC-SCID model 
The human SCID repopulating cell (Hu-SRC-SCID) method of reconstitution of the human immune 
compartment involves the engraftment of immunodeficient mice with human haematopoietic stem cells 
(HSCs) after gamma irradiation. Gamma irradiation is necessary to ensure that any residual murine 
leukocytes are eradicated and to provide an adequate biological niche within the bone marrow for the 
engraftment of human HSCs187. Irradiation and engraftment with human HSCs can be carried out either 
on newborn188 or adult189 mice. Following injection of HSCs, multiple lineages of human lymphoid and 
myeloid cells develop over a period of one to three months and can be found in the spleen and bone 
marrow, including B cell, T cells, NK cells dendritic cells and platelets185,188,190 . The level of 
engraftment and the success of multilineage differentiation of human cells is highly variable and is 
dependent on a range of factors such as the route of HSC delivery, the age of the recipient mice, the 
origin of the HSCs and the strain of mice used191. Human B cells at multiple stages of development 
have been found in the spleen and BM of Hu-SRC-SCID mice, including pre-B cells, pro-B cells and 
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early B cells192, however fully mature B-cells are rare192. While these B cells have been shown to 
produce high levels of IgM and IgD antibody, very little IgG production has been demonstrated192,193 
and class switching has been difficult to demonstrate135,194. This is likely due in large part to the lack of 
properly developed germinal centres in the spleen and other secondary lymphoid tissues195, resulting in 
a suboptimal antigen-specific B-cell response. Additionally, the proportions of CD3+ T cells is often 
very low192,196. While mature CD3+ T cells can be found in Hu-SCR-SCID mice and are able to 
proliferate after stimulation, the degree of proliferation and the survival of the T cells is significantly 
lower than that of normal human PBMCs, due to inadequate maturation in the murine thymus135. 
 
1.4.3 The Hu-PBL-SCID model 
This model involves the reconstitution of immunodeficient mice with adult peripheral blood 
mononuclear cells (PBMCs) [lymphocytes], typically by intravenous197 or intraperitoneal198 injection. 
This method of engraftment provides a rapid immune response, resulting in infiltration or rejection of 
engrafted human tissue in as little as seven days197. The Hu-PBL-SCID model has been used to 
demonstrate acute, cell-mediated rejection of multiple cell types, such as islets199, endothelial cells200 
and skin grafts 200,201 and to test the efficacy of Treg treatment for allograft rejection and dysfunction 
202,203.  
 If left for longer than a few weeks, mice reconstituted through the Hu-PBL method will develop 
xenogenic graft-versus-host disease (GVHD) - wherein the allogeneic donor (human) lymphocytes are 
activated by recipient (mouse) antigen and attack the recipient tissue, often fatally204. This occurs in 
response to mouse MHC molecules197,205, a development that can be useful for modelling GVHD but 
acts as a confounding factor for the study of transplant rejection more generally. This limitation can be 
reduced by ensuring that adequate positive and negative controls are used within each experiment, to 
ensure that any rejection seen is above the baseline GVHD response. In contrast to the Hu-SRC model, 
PBMC reconstitution typically results in a significant predominance of CD3+ T cells, with very little 
engraftment of B cells and an approximately even ratio of CD4+ and CD8+ T cells199,206,207. Antigen-
specific activation of T cells has not been adequately demonstrated, likely due to the lack of APCs in 
this model.  
1.4.4 Advances in humanised mice 
Current humanised mouse models have significant limitations in their ability to adequately recapitulate 
the human immune system. Multiple solutions to these remaining limitations are under exploration, 
mostly through the development of additional transgenic strains better capable of supporting human 
haematopoiesis and immune cell engraftment.   
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For the Hu-PBL model, one of the most significant drawbacks is the inevitable development of a strong 
xenogenic GVHD response. Transgenic strains have been developed which lack murine MHC, 
significantly reducing this effect. The first strain to be developed was the NOG-IabnullB2mnull strain208 - 
NOG immunodeficient mice lacking murine MHC class I and II through the knock-out of the Beta-2 
Microglobulin (B2M) molecule essential for MHC class I expression and the I-Ab isoform of murine 
MHC class II. This double KO strain still allows for the engraftment of human PBMCs capable of 
allogeneic rejection of human grafts but levels of GVHD are significantly reduced compared to the 
standard NOG strain. Additionally, these mice are capable of developing antigen-specific human B and 
T cells when challenged with antigen.  
A similar advance was the development of NSG-B2Mnull(IA IE)null and NSG-(KbDb)null(IA)null  mice209, 
two NSG strains lacking both MHC class I and II through different knockout mutations. Both strains 
permit engraftment of adult human leukocytes capable of rejecting allogeneic grafts with minimal 
GVHD209. Due to the lack of the B2M molecule, the NSG-B2Mnull(IA IE)null mice cannot maintain IgG 
antibody at expected levels within the peripheral blood. This is due to the requirement for the neonatal 
Fc receptor to maintain IgG levels within the blood, and expression of the neonatal Fc receptor is 
dependent upon B2M210. This issue does not arise with the NSG-B2Mnull(IA IE)null variant, however.  
For Hu-SRC model there have been several recent developments, including the development of an NSG 
strain expressing human HLA DR1 or HLA DR4 molecules, potentially allowing for a more 
physiologically relevant T cell education within the mouse thymus, with the aim of improving the 
overall T cell response in the Hu-SRC model. Additionally, a variety of transgenic strains expressing 
human cytokines have been developed to promote better differentiation of specific myeloid or 
lymphocyte populations.  To promote myeloid cell and macrophage development, NOG mice 
expressing GM-CSF and IL3 were developed211, along with NSG-SGM3 mice which showed increased 
engraftment of both myeloid and Treg populations212, while IL-15 expressing transgenic mice are able 
to improve the development of NK cells213,214.  
 
1.4.5 Assessment of immunogenicity using humanised mice 
Humanised mice can be used to assess the degree of alloimmune or autoimmune response to human 
cellular or tissue grafts. This assessment can be made through several methods, one of the most common 
being the histological examination of the graft area for signs of graft damage and lymphocytic 
infiltration215,216, often accompanied by a quantitative assessment of the degree of lymphocyte 
infiltration between different experimental groups206,217. In instances where the graft expresses factors 
or causes physiological effects that can be detected or measured in the serum of peripheral blood, such 
as blood sugar levels for islet transplantation in diabetic mice, this is a common method of assessing 
graft survival and function in live mice215,218. In instances where such functional readouts are not 
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available, it is becoming increasingly common to track the survival of grafts in vivo using some form 
of live imaging, often bioluminescent imaging (BLI)175,219-221. This requires the generation of graft cells 
expressing the gene luciferase, typically firefly luciferase. Luciferase constructs can be introduced into 
the cells in a variety of ways, such as electroporation, lipofection and viral transduction, although 
primary-derived cells typically require transduction with lentiviral vectors for efficient construct 
integration222. The luciferase enzyme, when exposed to its substrate, luciferin, catalyses a reaction 
resulting in the emission of visible light. When small animals transplanted with cells containing a 
luciferase construct are given an intraperitoneal injection of 100-200 µl of luciferin, typically at a 
concentration of 20-50µg/ml, the graft cells emit light that can be detected through the skin and muscle 
using a bioluminescent in vivo imager. The light signal can be detected qualitatively, to produce an 
image showing the graft location within the animal’s body, and also quantitatively, to give a 
measurement of photon intensity in a selected region of interest, making this technique useful for 



















1.5 Aims and objectives  
 
The overarching aim of this dissertation was to explore the immunogenicity of cholangiocyte organoids, 
with the view towards eventual clinical translation. I aimed to assess the extent to which COs would be 
rejected within a transplantation setting to determine the necessity of ameliorative measures such as 
immunosuppression, HLA matching or HLA knock-out. I then aimed to explore the viability of using 
HLA matching to reduce the immunogenicity of COs in an alloimmune setting. To characterise the 
immunogenicity of COs I relied on a combination of in vitro and in vivo assessment of antigenicity and 
humanised mouse models. 
Chapter 3: Characterisation and refinement of cholangiocyte organoid culture systems 
The overall aims of the experiments presented in this chapter were to demonstrate the efficacy of the 
CO system for interrogating questions of cholangiocyte cellular therapy immunogenicity, to refine the 
system to improve its suitability for generating cellular therapies and to develop CO lines capable of 
real-time in vivo monitoring. Specifically, the objectives of this chapter were to: 
• Characterise the CO system previously developed by our lab and assess its suitability for 
humanised mouse studies 
• Refine the CO system to allow for generation of CO lines from intrahepatic tissue- to expand 
the available pool of donors for CO lines and to allow sampling of biliary tissue from patients 
with intrahepatic biliary conditions 
• Improve method for generating bioengineered biliary tissue to advance the translation of CO 
therapies closer towards clinical application- this will also allow for assessment of more 
physiologically relevant graft structures in humanised mice 
• Generate CO lines expressing luciferase to allow for tracking of CO grafts in vivo and 
quantitative assessment of graft rejection in humanised mice 
Chapter 4: Assessment of the antigenicity of cholangiocyte cellular therapies 
The aim of this chapter was to characterise the expression of immunogenic markers on COs, specifically 
the expression of HLA class I and II molecules. I aimed to assess how HLA expression changed in 
response to the move from primary cholangiocytes to cultured organoids and the extent to which these 
changes could be reversed by pro-inflammatory stimulation, with the understanding that HLA 
expression would affect CO immunogenicity in an allogeneic transplant setting. To this end, I also 
aimed to characterise CO upregulation of HLA, particularly HLA class II, in a series of physiologically 
relevant models of pro-inflammatory environments, both in vivo and in vitro. This information would 
also help us to assess the necessity for either full or partial HLA-matching for CO cellular therapies.  
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• Assess the expression of HLA molecules on COs compared to primary cholangiocytes 
• Assess the expression of HLA molecules on COs after exposure to IFN-γ 
• Assess the expression of HLA molecules on COs in a range of physiologically relevant pro-
inflammatory environments through co-culture with activated lymphocytes and transplant into 
immunocompetent or humanised mice 
Chapter 5: Assessment of the immunogenicity of cholangiocyte cellular therapies 
In this chapter I aimed to establish two complementary humanised mouse models, a model of splenocyte 
(SpMC) reconstitution and one of haematopoietic stem cell (HSC) reconstitution. I assessed the immune 
response of these two models to allogeneic and autologous CO grafts and established a system of 
bioluminescent imaging (BLI) in live mice to monitor and quantify the rejection of CO grafts. I also 
aimed to compare the immunogenicity of HLA matched and HLA mismatched CO grafts using a 
humanised mouse model. The specific aims of this chapter were to: 
• Establish the SpMC-reconstituted and HSC-reconstituted humanised mouse models 
• Assess the capacity of SpMC-reconstituted and HSC-reconstituted humanised mice to reject 
allogeneic CO grafts 
• Compare the immune response to allogeneic and autologous CO grafts in humanised mice 
• Compare the immunogenicity of HLA-matched and HLA-mismatched allogeneic CO grafts in 













CHAPTER 2. METHODS 
 
2.1 Cell culture methods 
 
2.1.1 Cholangiocyte organoid culture 
 Isolation of primary cells  
All primary cells and tissues (biliary tissue, liver biopsies, splenocytes, blood and bone marrow) were 
isolated from deceased organ donors within Addenbrooke’s Hospital and obtained with full ethical 
approval (Ethical approval reference number: 15/EE/0152) or from human pancreases retrieved for 
transplantation but subsequently declined (ethical approval reference number: 12/EE/0253 and 
16/EE/00227- since 29/07/2016). Tissue from both donation after circulatory death (DCD) and donation 
after brainstem death (DBD) donors were used, although peripheral blood could only be taken from 
DBD donors. All samples were processed in a type 2 laminar flow cabinet in an appropriate category 
two tissue culture facility using sterile instruments.   
 
2.1.1.1 Isolation of cholangiocytes from extrahepatic biliary tissue  
Cholangiocytes were isolated from the common bile duct or gallbladder of deceased organ donors. The 
biliary tissue was excised from either DBD or DCD deceased donors by a transplant surgeon after the 
retrieval of organs for transplantation, and transferred to a sterile 50 ml centrifuge tube containing 
University of Wisconsin (UW) cold storage solution. Alternatively, bile duct tissue was isolated from 
declined pancreases unsuitable for transplant that had been accepted for research. The tissue was kept 
at 4 °C until it could be transferred to the category 2 facility within the Laboratory of Regenerative 
Medicine for processing. Processing of tissue occurred as soon after excision as possible, with a 
maximum cold storage time of approximately ten hours. 
All tissue processing took place in a category 2 biosafety cabinet within a category 2 tissue culture 
facility. The bile duct or gallbladder was incised longitudinally in a 10 cm petri dish filled with 
William’s E+ medium. The tissue was washed gently three times in 50 ml centrifuge tubes of sterile 
PBS to remove any bile. The tissue was returned to the 10 cm petri dish and the lumen was carefully 
scraped using a sterile scalpel to remove the epithelial cells. The tissue was washed repeatedly with 
William’s E+ during this process until it was judged that as many cells as possible had been transferred 
into the media. The presence of biliary cells was confirmed using an Olympus CKX41 microscope. The 
cell suspension was then transferred into a 50 ml centrifuge tube and centrifuged at 444 g for 4 minutes 
at room temperature. The pellet was then washed in 10 ml of William’s E+ medium and any fibrous 
tissue removed using a p1000 pipette before a further centrifugation step. If the cell suspension 
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contained a high number of erythrocytes, an additional red blood cell lysis step was included. The pellet 
was resuspended in 10 ml of ice-cold red blood cell lysis buffer and incubated at 4 °C for 10 minutes. 
The cells were then centrifuged for 4 minutes at 444 g and resuspended in 5 ml of William’s E+ to 
wash. The cell suspension was centrifuged at 444 g for 4 minutes and the cholangiocytes were plated 
in 50 µl droplets in the method described in Section 2.1.6.  
 
2.1.1.2 Isolation of cholangiocytes from intrahepatic biliary tissue 
Intrahepatic cholangiocytes were isolated from liver tissue from deceased organ donors. A fine needle 
biopsy of liver tissue was taken from either DBD or DCD deceased donors by a transplant surgeon after 
the retrieval of organs for transplantation, and transferred to a sterile 15 ml centrifuge tube containing 
William’s E+. The tissue was kept at 4 °C until it could be transferred to the category 2 facility within 
the Laboratory of Regenerative Medicine for processing. Processing occurred as soon after excision as 
possible, with a maximum cold storage time of six hours. 
All tissue processing took place in a category 2 biosafety cabinet within a category 2 tissue culture 
facility. The biopsy was transferred to a sterile, dry 10 cm tissue culture dish using sterile forceps. The 
tissue was dissected into as small pieces as possible (<1 mm3) using a sterile scalpel. The tissue was 
then washed with 1 ml of William’s E+ media with 50 ng/ml of EGF and 10 μM (1 μl/ml) of Y27632 
and collected using a p1000 pipette. The tissue pieces were transferred to a 15 ml centrifuge tube and 
centrifuged at 200g for 3 minutes. The media was removed using a p1000 pipette and the tissue was 
washed with 1 ml of William’s E+ media with 50 ng/ml of EGF and 10 μM (1 μl/ml) of Y27632 and 
centrifuged for a further 3 minutes at 200g. The tissue pieces were then plated in 50 µl droplets in the 
method described in Section 2.1.1.3. 
 
2.1.1.3 Plating of primary-derived cholangiocyte organoids 
Before plating of COs, the required number of 24-well tissue culture plates were pre-heated at 37 °C 
for at least one hour prior to plating- ideally overnight whenever possible. Matrigel was thawed on ice 
for two hours to overnight prior to starting the plating procedure. The CO pellet (or pellet of primary 
cholangiocytes/primary liver pieces) was resuspended in William’s E+ medium supplemented with 
EGF, R-spondin-1, Dickkopf-related protein 1 (DKK-1) and Y27632 at triple the concentration required 
for organoid maintenance. This was done to ensure that the concentration of cytokines was correct after 
the addition of Matrigel. The pellet was resuspended in a volume of this 3X William’s E+ medium 
appropriate for the number of wells being plated. For example, if plating 9 wells, the pellet was 
resuspended in 150 μl of William’s E+ media with 1.5 µg/ml R-spondin, 150 ng/ml EGF, 30 μM (3 
μl/ml) Y27632 and 300 ng/ml DKK-1. 
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The thawed Matrigel stock was mixed thoroughly with a p1000 pipette. The Matrigel was kept on ice 
throughout the entire procedure and was mixed with care to avoid bubbles. Matrigel was added to the 
cell suspension in a 2:1 ratio (66.7% vol/vol) and mixed well. A pre-warmed 24 well cell culture plate 
was transferred to the plate heater and the organoids were plated in 50 µl Matrigel/media domes using 
a p1000 pipette, each in a well of the 24 well plate. The cell suspension was mixed thoroughly before 
plating each dome, to ensure equal distribution of cells between each dome. The Matrigel domes were 
allowed to solidify for 1-2 minutes in the plate heater. Once the domes were confirmed to have 
solidified, the plate was gently inverted and kept in the 37 °C incubator for 30 minutes. This step was 
required to ensure the cell clumps did not attach to the bottom of the plate and was omitted when plating 
dissected liver tissue or EpCAM+ sorted single cells. The 3X William’s E+ media solution was made 
up to a final concentration of 500 ng/ml Rspondin, 50 ng/ml EGF, 10 μM (1 μl/ml) Y27632 and 100 
ng/ml DKK-1 (+/- 50 ng/ml HGF) and 1 ml of this supplemented media was added per organoid dome 
using a 5 ml or 10 ml pipette. Media was added slowly to avoid disrupting the Matrigel domes. The 
organoids were then cultured at 37 °C in a cell culture incubator.  
 
2.1.1.4 Maintenance of primary-derived cholangiocyte organoids 
Media for the COs was changed approximately every 48 hours. William’s E+ medium supplemented 
with 500 ng/ml Rspondin, 50 ng/ml EGF and 100 ng/ml DKK-1 was used for organoid maintenance 
and 1 ml was added to each well of a 24 well plate. In cases of slow-growing or suboptimal CO lines, 
2 μM of FSK was added to the maintenance media. COs were passaged approximately every 5 days. 
Visual inspection of organoids was used to determine when plates were ready for passage, as premature 
passage could lead to a suboptimal number of cells while a delay in passaging could lead to the collapse 
of larger organoids, potentially causing permanent damage to the CO culture. 
 
2.1.1.5. Passaging of cholangiocyte organoids 
Media was aspirated and 500 μl of cell recovery solution was added to each well. The pipette was aimed 
at the centre of the Matrigel dome and the cell recovery solution was ejected forcefully to disrupt the 
surface of the dome. The Matrigel domes were then mechanically dissociated by scraping with a p1000 
pipette. The cells were transferred from each well to a 15 ml centrifuge tube after dissociation. Each 
well was then washed with 500 μl of cell recovery solution- the same 500 μl was carried across to each 
of the wells to minimize the volume of cell recovery solution required for the washes. This final 500 μl 
was then added to the centrifuge tube. The cells were incubated on ice at 4 °C for 30 minutes to fully 
dissolve the Matrigel and then centrifuged at 444 g for 4 minutes at room temperature. The supernatant 
was aspirated and the cells were washed in 1 -7 ml of William’s E+ medium, depending on the size of 
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the pellet. If necessary, the cell suspension was divided at this stage, typically into 4-6 15 ml centrifuge 
tubes and the organoids were plated as described in section 2.1.1.3.  
 
2.1.1.6 Cryopreservation and thawing 
COs were cryopreserved after removal from organoid culture as described in section 2.1.1.5. The 
resulting organoid pellet was washed once in 1 ml of William’s E+ medium and then centrifuged at 
444g for 4 minutes. The pellet was resuspended in 1-6 ml of CellBanker2 depending on the size of the 
pellet. The CO suspension was transferred to 2 ml cryovials at 1 ml per cryovial and the cryovials were 
frozen immediately at -80°C. For long-term cryopreservation, COs were transferred to a liquid nitrogen 
tank.  
When thawing COs, cryovials were removed from the liquid nitrogen tank/-80 °C freezer and 
transferred immediately to dry ice to prevent uncontrolled thawing. CO cryovials were thawed in a 37 
°C water bath and the cells transferred immediately to pre-warmed WE+ medium supplemented with 
10 µM Y27632 and centrifuged at 444 g for 4 minutes. Thawed cells were washed once in 5 ml of pre-
warmed William’s E+ medium and then plated as described in section 2.1.1.3.   
 
2.1.2 LX2 cell culture 
LX2 cells were cultured in 25 cm2 (T25) uncoated tissue culture flasks with 4ml of LX2 medium (see 
the lists of media in appendix table 1). LX2 medium was changed every 48 hours. The cells were 
passaged when the flask reached confluency, approximately every five days. The medium was aspirated 
and the cells were washed in PBS. The PBS was aspirated and 500 µl of trypsin-EDTA (0.05%) was 
added. The cells were incubated at 37°C for approximately 5 minutes, until the cells had lifted from the 
flask surface. The cells were collected in a 15 ml centrifuge tube and washed with 4 ml of LX2 medium. 
The cells were centrifuged for five minutes at 300g and the medium was aspirated. The pellet was 
resuspended in 1 ml of LX2 medium and approximately 100 µl of the cell suspension was added to a 
fresh T25 flask containing 4 ml of LX2 medium. 
 
2.1.3 PBMC/SpMC culture 
2.1.3.1 Isolation of mononuclear cells from primary spleen tissue 
Original method (2015-2016) 
5 cm3 spleen sections were obtained from deceased organ donors and transferred to University of 
Wisconsin (UW) organ preservation solution before processing.  The spleen was stored at 4 °C for up 
to 24 hours before processing. The tissue was mechanically dissociated using a 100 µm steel sieve and 
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washed with Dulbecco's Modified Eagle Medium (DMEM) (Gibco Life Technologies) and 10% foetal 
calf serum (FCS) (Sigma Life Sciences). After dissociation the cells were filtered through a 70 µm filter 
into a 50 ml centrifuge tube. 50 ml Centrifuge tubes were prepared with 17 ml of Lymphoprep™ 
gradient (StemCell Technologies) and 20 ml of the cell suspension was layered on top in each tube. The 
tubes were then centrifuged at 300 g for 20 minutes with the centrifuge brake off. The mononuclear cell 
fraction was isolated and washed in DMEM + 10% FCS. After centrifugation at 300 g for 20 minutes 
with the centrifuge brake on, the cells were resuspended in 10 ml of DMEM+10% FCS and counted 
using a haemocytometer. After a second similar centrifugation step, the cells were cryopreserved in 
FCS + 10% DMSO at a concentration of approximately 1.0 x 108 cells/ml and placed in a Mr. FrostyTM 
Freezing Container (ThermoFischer Scientific) for 24h before being transferred for long-term storage 
in a liquid nitrogen Dewar (at -196 °C). 
 
Updated method (2017 onwards) 
5 cm3 spleen sections were obtained from deceased organ donors and transferred to University of 
Wisconsin (UW) organ preservation solution before processing.  The spleen was stored at 4 °C for up 
to 24 hours before processing. Spleen tissue was cut into small pieces (approximately 5mm3) with a 
scalpel on a sterile, dry 10 cm tissue culture dish. A gentleMACSTM dissociator (Miltenyi Biotec) was 
used to dissociate the tissue to a single cell suspension. Spleen tissue was placed into gentleMACSTM 
“C” Tubes with PBS + 2% FCS and dissociated using a pre-set programme B-0. The resulting cell 
suspension was filtered through a 70 µm cell strainer to remove any fibrous debris and diluted at a 1:1 
ratio with PBS + 2% FCS. LymphoprepTM was used to isolate the lymphocytes from the cell suspension. 
50 ml centrifuge tubes were prepared with 15 ml room-temperature LymphoprepTM in each tube and 20 
ml of the filtered suspension was carefully layered on top. Tubes were centrifuged at 800 g for 25 min 
at 20 °C with no brake. The mononuclear cell layer was collected from each tube using a Pasteur pipette 
and the mononuclear cell fraction from all tubes were combined into one 50 ml centrifuge tube. The 
tube was topped up to 50 ml with PBS + 2% FCS and centrifuged at 300 g for 7 minutes with the break 
on. The supernatant was aspirated and the pellet was resuspended in 10 ml of Red Blood Cell Lysis 
(RBCL) 1x buffer for 10 minutes at 4°C. Cells were then washed and counted using an automated cell 
counter. Based on the cell count, the appropriate volume of cryopreservation medium to resuspend the 
pellet in to obtain a concentration of 5.0 x 107 cells/ml was calculated. The cell suspension was 
centrifuged at 300 g for 7 minutes and then resuspended in the appropriate volume of cryopreservation 
media (FCS + 10% DMSO). The cell suspension was aliquoted into pre-labelled cryovials (1 ml per 
cryovial) and the cryovials were placed into a pre-cooled Nalgene Mr. FrostyTM  freezing container. The 
Mr. FrostyTM container was stored at  -80°C for a minimum of 24 hours  (a maximum of seven days) 
before the cryovials were transferred to a liquid nitrogen dewar for long-term storage. 
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2.1.3.2 Isolation of PBMCs from primary peripheral blood 
Peripheral blood was collected in heparinised 50 ml syringes from DBD donors during surgery with the 
assistance of the anaesthetist. The peripheral blood was then stored at room temperature on a benchtop 
orbital shaker at 150 rpm for up to 12 hours before processing. The peripheral blood was filtered through 
a 70 µm cell strainer and diluted in a 1:1 ratio with PBS + 2% FCS. Mononuclear cells were then 
isolated using LymphoprepTM, processed and cryopreserved as described in section 2.1.3.1. 
 
2.1.3.3 Isolation of mononuclear cells from primary bone marrow 
Bone marrow was collected using a Jamshidi needle from the vertebral bodies of DBD or DCD donors 
and transferred into heparinised 50 ml syringes. The bone marrow was stored at room temperature on a 
benchtop orbital shaker at 150 rpm for up to 12 hours before processing. Bone marrow was filtered 
through a 70 μm filter and then diluted in a 6:1 ratio with PBS + 2% FCS (6 parts bone marrow to 1 
part PBS + 2% FCS). Mononuclear cells were then isolated using LymphoprepTM, processed and 
cryopreserved as described in section 2.1.3.1. 
 
2.1.3.4 Thawing of mononuclear cells 
Thawing media (50% DMEM and 50% FCS) was prepared in advance and warmed to 37 °C in a water 
bath. The required cryovial was removed from liquid nitrogen storage and kept on dry ice before being 
transferred to a 37 °C water bath. The cryovial was held in the water bath and monitored closely until 
almost all of the cell suspension had thawed. The vial was quickly transferred to a pre-prepared category 
2 tissue culture cabinet. The cell suspension was gently added to a 15 ml centrifuge tube containing 10 
ml of pre-warmed thawing media (if more than one cryovial was being thawed at a time, then each vial 
was added to a separate 15 ml centrifuge tube containing 10 ml of thawing media) and the tube was 
centrifuged at 300 g for 7 minutes. The supernatant was aspirated and the pellet resuspended by gently 
flicking. The cell suspension was washed in 5 ml of thawing media to remove any traces of DMSO and 
centrifuged at 300 g for 7 minutes. The pellet was then resuspended in 10 ml of DMEM + 10% FCS 
and 60 µg/ml DNase I. The cell suspension was incubated at 37 °C for 20 minutes, or until all clumping 
was gone. The cell suspension was centrifuged at 300 g for 7 minutes and resuspended in 10 ml of 
DMEM + 10% FCS (without DNase I). The cells were counted using an automated cell counter with 
trypan blue as a live/dead stain. 
 
2.1.3.5 PBMC activation 
PBMCs prepared as described in 2.1.3.4 and resuspended in an appropriate volume of complete RPMI 
media to give a concentration of 1.0 x 106 cells/ml. The cell suspension was aliquoted into wells of a 24 
well plate at a volume of 100 μl (1.0 x 105 cells) per well. CD3/CD28 Dynabeads were resuspended 
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and the required volume (0.5 µl per 105 cells) was transferred to a 1.5 ml Eppendorf. The beads were 
washed in 1 ml of sterile PBS with 0.1% BSA and pelleted using a DynaMag-2 magnet. The PBS 0.1% 
BSA was removed and the beads were resuspended in a volume of RPMI equal to the initial volume 
removed from the Dynabead vial. 0.5 µl of beads were added to each well requiring activation and the 
plate was gently agitated to mix the beads with the cells. The plate was transferred to a humidified 
incubator with 5% CO2 at 37 °C for 24 hours. The beads were removed from the cells using the 
DynaMag magnet 24 hours after activation and the cells were returned to the plate without changing 
the media.  
 
 
2.2 Humanised mouse methods 
2.2.1 Engraftment with HSCs 
Irradiation of NSG mice 
Female NSG mice between the ages of 5-6 weeks were exclusively used for the HSC-reconstitution 
humanised mouse model. The required cages of NSG mice were transferred to the irradiator room. The 
animals were transferred from their cage to the irradiator box in a category 2 biosafety cabinet. The 
time required to produce 2.5 Gy of irradiation was calculated and the animals were placed in the 
irradiator at the second shelf level. The door was shut and the required time was input into the irradiator. 
Irradiation was initiated and, when complete, the animals were removed from the irradiator and 
transferred back to their cage. They were returned to their usual location in the animal facility. The 
animals were reconstituted with SpMCs or CD3-depleted bone marrow no later than 24 hours after 
irradiation. Any animals that had been irradiated but could not be reconstituted (for example, due to a 
lack of available cells) were culled.  
 
Thawing and CD3-depletion of cryopreserved bone marrow lymphocytes 
Cells were thawed as described in section 2.1.3.4 and counted using an automated cell counter. The 
required volume of MACS beads and MACS buffer necessary for MACS cell sorting was calculated 
based on the cell number. Cells were resuspended in 80 μl of MACS buffer per 107 cells and 20 μl of 
MACS beads per 107 cells. The suspension was mixed well and incubated on ice for 15 minutes. During 
the incubation time, the MACS cell sorter was turned on and a column exchange was run to ensure a 
new, sterile set of columns was used. The storage buffer was exchanged for a new bottle of MACS 
running buffer.  At the end of the 15 minute incubation, 10 ml of MACS buffer was added to the cell 
suspension to wash and the cells were centrifuged at 300g for 7 minutes. The supernatant was aspirated 
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and the cell suspension was resuspended in 5 ml of MACS buffer and transferred to a 15 ml centrifuge 
tube. The cell suspension was CD3-depleted using an AutoMACS cell sorter on the “depleteS” 
programme. The cells were counted using an automated cell counter and centrifuged at 300g for 7 
minutes at room temperature. The cells were resuspended in an appropriate volume of sterile saline for 
a concentration of 1.0 x 107 cells per 100 μl. 
 
Tail vein injection of CD3-depleted BM leukocytes 
CD3-depleted bone marrow leukocytes were transported to the animal facility on ice. The controlled 
heating unit was cleaned, transferred to a category 2 biosafety cabinet and set to 37°C for two hours. 
The irradiated NSG mice were transferred to the heating unit while the rest of the equipment was 
prepared (minimum of ten minutes). Individual 1 ml syringes with 30G needles were prepared for each 
animal, to prevent contamination and needle damage from multiple usage.  The cell suspension was 
mixed with a 1 ml syringe with a 30G needle to break up any cell clumps and then the required number 
of syringes were loaded with 100 μl of cell suspension each. All air bubbles were removed from the 
needles and syringes and the syringes were placed on a sterile surface in the biosafety cabinet. A supply 
of sterile tissues was prepared and the tail vein restraint was cleaned and set in the biosafety cabinet. 
The first mouse was transferred to the tail vein restraint and secured in place, with the tail hanging 
outside the restraint and held in place. The 100 μl of cell suspension was injected intravenously into the 
tail vein and the bleeding was stopped using a sterile tissue. The mouse was then transferred back to the 
cage and the process was repeated until all animals were injected.  
 
2.2.2 Engraftment with PBMCs/SpMCs 
IP injection of PBMCs/SpMCs 
PBMCs/SpMCs were thawed and counted as described in section 2.1.3.4. The cells were centrifuged at 
300g for 7 minutes and resuspended in a volume of RPMI media to give a concentration of 1.0 x 107 
cells per 100 μl. The cells were transferred to a small universal tube and transported on ice to the animal 
facility. The required cage of mice were transferred to a category 2 biosafety cabinet. The mice were 
scruffed and injected with 100 μl of the cell suspension though an intraperitoneal injection. The mice 
were then returned to their cage.  
 
2.2.3 Tail vein bleeds 
The controlled heating unit was cleaned using Trigene and the Category 2 biosafety cabinet cleaned 
using Trigene and ethanol. The controlled heating unit was placed in the biosafety cabinet and turned 
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on- set to 37°C for two hours. The mice were transferred into the controlled heating unit from their 
cages and left for 10 minutes. Bleeding tubes were primed with heparin and the required number of 27G 
needles were opened and sterile tissues were prepared. The bleeding stand was cleaned with Trigene 
and placed in the biosafety cabinet. After the ten minutes incubation, mice were removed individually 
from the heating unit by their tail and placed in the bleeding stand with their tail hanging out of the 
tube. One of the two tail veins was located and briefly pierced with the needle. The needle was 
withdrawn and 2-6 drops of blood was collected using a heparinised bleeding tube. Sterile tissue was 
applied to the wound. The mouse was removed from the bleeding stand and pressure was maintained 
with the tissue until bleeding had stopped. The mouse was transferred back to the cage. The bleeding 
tube was capped and the blood mixed with the heparin.  
 
2.2.4 Transplantation of cells under the kidney capsule 
A cell suspension in 100% Matrigel was prepared as described in section 2.1.1.5 and transported to the 
animal facility on ice. The cages of mice for transplantation were transferred to the surgery room and 
the surgical space and equipment was prepared. The cell suspension was loaded into an autoclaved 
Hamilton syringe with a blunt 27 gauge needle and kept on ice, with a layer of autoclaved foil between 
the syringe and the ice to maintain sterility. The surgical technician anaesthetised the first mouse using 
isoflurane at a flow rate of 2% and shaved the area directly above the left kidney (if both kidneys were 
being transplanted then the area above the right kidney was also shaved). The shaved area was cleaned 
and the mouse was given a subcutaneous injection of Temgesic analgesic by the technician and 
transferred to the surgery room where it was placed on the heat mat. 
The animal was turned onto its left side, with the kidney facing directly up, and secured to the isoflurane 
nose cone and the heat mat with surgical tape. The isoflurane was set to 2% and the oxygen flow rate 
was set to 2 L/minute. A 2 ml syringe was placed under the mouse to elevate the kidney and the mouse 
was covered in a sterile drape, leaving the left side exposed. The heat mat was set to 37 °C and the 
internal temperature of the animal was monitored using a rectal probe.  
The magnification of the surgical microscope was set to 6x and the location of the kidney was identified 
through the skin. An incision was made in the skin directly above this area. The incision was made no 
larger than was judged to be necessary for the kidney to fit through, typically approximately 5 mm. The 
magnification was increased to 10x and a second incision was made in the muscle directly above the 
kidney, taking care to avoid nerves and blood vessels. If not immediately obvious, the kidney was 
located using a sterile cotton bud and then gently pushed out through the incision in the muscle and skin 
using a pincer movement with the thumbs and forefingers of both hands. Sterile saline was immediately 
applied to the kidney to prevent it drying.  
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The magnification of the surgical microscope was increased to 16x and a small incision was made in 
the side of the kidney using a 30G needle. This needle was then set aside. The syringe containing the 
cell suspension was taken from the ice box and the blunt Hamilton needle was inserted into the kidney 
through the incision made with the 30G needle. Once the end of the needle was at the kidney capsule, 
approximately 30 μl of the cell suspension was injected into the kidney- great care was taken to ensure 
the suspension was injected directly below the kidney capsule and not into the parenchyma, as this 
would risk causing a pulmonary embolism if the cell suspension entered the bloodstream. The needle 
was withdrawn and placed directly back on ice to prevent the Matrigel from solidifying. 
Simultaneously, a sterile cotton bud was placed onto the exit wound where the needle was withdrawn 
and pressure was applied to stop any bleeding. Once the bleeding had stopped, the kidney was placed 
back into the abdominal cavity using a sterile cotton bud.  
The muscle was sutured using Novosyn 3/0 sutures with uninterrupted sutures (approximately 3 sutures, 
depending on the size of the incision). The skin was closed using interrupted sutures, typically three to 
five sutures depending on the size of the incision. Two skin clips were applied to the skin using an 
automated clip applicator and the surgical technician transferred the mouse to the recovery room. The 
animals were monitored by the technicians every ten minutes after the procedure for an hour, to ensure 
there were no health effects of the procedure or anaesthetic. The animals were then monitored and 
weighed daily for a week after the procedure and the skin clips were removed by the technicians seven 
days after the surgical procedure.  
 
2.2.5 Non-recovery removal of organs/tissue under general anaesthetic 
The surgical bench area was prepared as if for a normal surgical procedure (see section 2.2.4). Animals 
were anaesthetised by the surgical technician using isoflurane at flow rate 2.5% and the abdomen was 
shaved. The animal was placed on its back on the heat mat by the surgical technician and secured to the 
nose cone using surgical tape. A laparotomy was performed and the abdomen was opened using an Alm 
self-retaining retractor.  The surgical microscope was set to 16x magnification and the organs were 
gently moved using a sterile cotton bud until the inferior vena cava (IVC) was located. A 1 ml syringe 
with a 27G needle was inserted into the IVC and as much blood as possible was taken, typically between 
800-1000 μl, depending on the size of the mouse. This blood was then shared between one heparinised 
and one non-heparinised Eppendorf tubes- for flow cytometry and serum samples, respectively. The 
kidneys, spleen and any other required organs were carefully excised using fine surgical scissors and 
transferred to individual labelled universal tubes filled with Hank’s balanced salt solution (HBSS) for 
further processing later. If required for the experiment, the femurs were also removed and transferred 




2.2.6 Bioluminescent live imaging of transplanted mice 
Luciferin was reconstituted with sterile deionised water at a concentration of 20 mg/ml and aliquoted 
into 1 ml aliquots and stored at -20°C until required. 
The animals were transferred to the imaging room and the IVIS imager was initialised using the Living 
Image programme. The IVIS imager stage area was cleaned using ethanol wipes and the anaesthetic 
box was cleaned using Trigene. The waste scavenger, oxygen and anaesthetic systems were set up and 
the oxygen flow rate (pre-set to 2 L/min) was checked. 
The nose cones and dividers were cleaned using ethanol and set up in the IVIS imager. 1 ml syringes 
with 30G needles were set up with the required amount of luciferin for the number of mice to be 
injected- no more than three mice were injected with the same syringe in order to reduce the risk of 
damage to the needle from reuse. Each mouse was injected intraperitoneally with 150 μl of luciferin 
and transferred immediately to the anaesthetic chamber. In instances where more than one cage of mice 
required imaging, each cage was injected and imaged separately.  
A timer was set for ten minutes and the anaesthetic flow rate was set to 2%. Once the animals were 
anaesthetised they were transferred to the anaesthetic nose cones in the IVIS imager and placed with 
their left side facing upwards, making note of the order of the animals by ear notch in cases where repeat 
imaging at another time was required. During the ten minute wait, the Living Image programme was 
set up with the required imaging sequence. Typically, one image was taken using the automatic 
exposure setting and then a series of images were taken at defined exposure times according to the 
requirements of the specific experiment (e.g. 120 seconds, 60 seconds and 30 seconds). The use of an 
automatic exposure time allowed high-quality images to be taken, while setting pre-set exposure times 
allowed images to be comparable across multiple animals and imaging sessions, a requirement of 
quantification. Once the ten minute waiting step was finished, the imager was initialised and the series 
of images obtained. Once this was completed, the animals were immediately transferred back to their 
cages and the anaesthetic flow turned off.  
 
 
2.3 In vitro characterisation methods 
2.3.1 RNA isolation and qPCR 
2.3.1.1 Extraction of RNA from cultured cells 
Cells were lysed using 250 µl of RNA lysis buffer (Sigma) and snap-frozen in dry ice. Samples were 
stored at -80°C until use. RNA extraction was performed with a Sigma GenElute™ Mammalian Total 
43 
 
RNA Miniprep Kit and the yield of RNA was measured by measuring 1.0 µl of the RNA extract on a 
Nanodrop spectrophotometer.  
 
2.3.1.2 Reverse Transcription of RNA samples 
The volume of RNA solution containing 500 ng of RNA was calculated and mixed nuclease-free water 
to a total volume of 11.8 µl. This was added to a 1.5 ml Eppendorf along with 0.5µl of Random Primer 
(Promega, C1181) and 1.0 µl of dNTP mix (Promega, U1511). The tube was briefly centrifuged and 
incubated at 65°C for five minutes and then snap cooled on ice. A master mix was made up for the 
reverse transcription reaction, the volumes for one RNA sample were: 4.0 µl of 5x 1st strand buffer 
(Invitrogen), 2.0 µl DTT (Invitrogen), 0.5 µl of RNase OUT (Invitrogen) and 0.2 µl of Superscript II 
(Invitrogen 18064071). 6.625 µl of this master mix was added per sample and the tube was briefly 
centrifuged. The tube was incubated at room temperature for 10 minutes, then at 42°C for 50 minutes 
and finally at 70°C for 15 minutes. At the end of the reaction, 580 µl of nuclease free water was added 
to make the cDNA solution to a final volume of 600 µl and then stored in the -80°C freezer.  
 
2.3.1.3 Quantitative PCR 
Reagents were thawed on ice and a master mix was made up for each primer pair. HydroxyMethylBilane 
Synthase (HMBS) was used as the housekeeping gene and run on every plate to allow for normalisation 
between plates. The volumes of each reagent per reaction were: 7.5 µl Sensi mix (Bioline); 0.6 µl 
forward primer; 0.6 µl reverse primer and 1.3 µl nuclease free water. Master mixes were kept on ice. 
10 µl of each primer master mix was pippetted into a 96 well non-skirted PCR plate and then 5 µl of 
the appropriate cDNA samples were added, changing pipette tip between each well to avoid cross-
contamination. The plate was briefly centrifuged and then run on the Stratagene Mx-3005P (Agilent) 
with the following programme: first cycle at 95°C for 10 minutes, 40 cycles of 95°C for 30 seconds, 
60°C for 30 seconds and 72°C for 30 seconds and then one cycle at 95°C for one minute. All primers 
were generated by Sigma and are listed in appendix table 2. 
 
2.3.2 Immunofluorescence 
2.3.2.1 Immunofluorescence of cholangiocyte organoids 
William’s E+ culture medium was aspirated and 1 ml of 4 % PFA (vol/vol) was added per well. PFA 
was added gently to the side of the well to not disrupt the Matrigel dome and the plate was incubated at 
4 °C for 20 minutes to fix the cells. The PFA was aspirated with a p1000 pipette to avoid disruption to 
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the Matrigel dome and each well was washed twice for ten minutes per wash using PBS. If required, 
the plate was sealed and kept at 4 °C for up to four weeks until ready for immunofluorescence staining. 
A solution of 10% (vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS was prepared and 1 
ml of this solution was added to each organoid well. The plate was incubated at room temperature for 
one hour to block and permeabilise the COs. The primary antibodies were diluted in a solution of 1% 
(vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS (see appendix table 4 for the dilutions 
of all antibodies used). 500 μl of primary antibody solution was added per CO well and the COs were 
stained overnight at 4 °C. The COs were washed three times with 1% donkey serum and 0.1% TritonX-
100 in PBS. Each wash was 45 minutes. The secondary antibodies were diluted in a solution of 1% 
(vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS (see appendix table 4 for dilutions). 
500 μl of secondary antibody solution was added per CO well and the organoids were stained overnight 
at 4 °C. CO plates were wrapped in foil to prevent exposure of the secondary antibody to light.  Hoechst 
33258 was diluted 1:10,000 (vol/vol) in PBS, the secondary antibody solution was aspirated from the 
CO wells and 1 ml of the Hoecscht 33258 solution was added per well. COs were incubated in this 
Hoecscht 33258 solution for 10 minutes at room temperature. The organoids were then washed three 
times in PBS, each wash for 45 minutes at room temperature. A final 1 ml of PBS was added per CO 
well. The COs were either imaged immediately or the plate was sealed, wrapped in foil and stored at 4 
°C (for no more than three months) until ready for analysis. 
 
2.3.2.2 Immunofluorescence of OCT-embedded cryosections 
Cryosection slides were thawed and during thawing, a barrier pen was used to draw a square around 
each cryosection (typically two or three sections per slide). Approximately 100 μl of 4% 
paraformaldehyde was added to each section and the slides were incubated at 4°C for 20 minutes. The 
slides were transferred back to room temperature and washed twice for five minutes per wash using 
PBS. The sections were blocked for 30 minutes at room temperature using PBS + 0.1% Triton X + 10% 
donkey serum. The primary antibodies were diluted in a solution of 1% (vol/vol) donkey serum and 
0.1% (vol/vol) TritonX-100 in PBS (see appendix table 4 for the dilutions of all antibodies used). 200 
μl of primary antibody solution was added per section and the slides were stained overnight at 4 °C. 
The sections were returned to room temperature and washed three times with 1% donkey serum and 
0.1% TritonX-100 in PBS. Each wash was 5 minutes. The secondary antibodies were diluted in a 
solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS (see appendix table 4 
for dilutions). 200 μl of secondary antibody solution was added per section and the sections were stained 
for one hour at room temperature. Hoechst 33258 was diluted 1:10,000 (vol/vol) in PBS, the secondary 
antibody solution was discarded and 200 μl of the Hoecscht 33258 solution was added per section. 
Sections were incubated in this Hoecscht 33258 solution for 5 minutes at room temperature. Three five 
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minute washes with PBS were then performed. The PBS was discarded and one drop of Fluoromount 
G mounting solution was added per section. The slides were carefully mounted with a coverslip, making 
sure there were no air bubbles on or near the tissue.  
 
2.3.2.3 Imaging and analysis 
Imaging was performed using a Zeiss LSM 700 confocal microscope. ImageJ 1.51h software (Wayne 
Rasband, NIHR, USA, http://Imagej.nih.gov/ij) was used for image processing such as merging of 
different channels, addition of scale bars and analysis such as lymphocyte counting.  
 
2.3.3 Flow cytometry 
2.3.3.1 Flow cytometry of cholangiocyte organoids 
COs were removed from organoid culture as described in section 2.1.1.5. The pellet was resuspended 
in 1 ml of William’s E+ media and centrifuged at 444g for 4 minutes. A solution of Accutase (pre-
warmed to 37 °C) with 4 mg/ml of DNase I and 10 μM Y27632 was prepared. Addition of DNase I was 
necessary to prevent cell clumping and Y27632 was important to reduce cell death during dissociation. 
The supernatant was aspirated and the pellet was resuspend in 1 ml of the Accutase solution. The cells 
were incubated at 37 °C for up to five minutes to produce a single-cell suspension. The cells were 
inspected under a microscope halfway through to check the progress of the dissociation and once a 
single-cell suspension had been obtained, 1 ml of William’s E+ media or PBS 1% BSA (wt/vol) with 4 
mg/ml of DNase I and 10 μM Y27632 was added to the cell suspension with a p1000 pipette. The single 
cell suspension was centrifuged at 444 g for 4 minutes at room temperature and the pellet was 
resuspended in 1 ml of William’s E+ media or PBS 1% BSA (wt/vol) with 4 mg/ml of DNase I and 10 
μM Y27632. The cells were filtered through a 40 μm filter.  
 
2.3.3.2 Staining for cell-surface markers 
A 1 in 20 dilution of FcR block in PBS 1% BSA was prepared. The cells were centrifuged at 444 g for 
4 minutes at room temperature and resuspended in 200 μl ml of diluted FcR block. The cells were 
incubated at room temperature for 30 minutes.  A master mix of all conjugated antibodies was prepared 
in PBS 1% BSA (see appendix table 4 for antibody dilutions). An aliquot of the cell suspension 
(typically at least 1 x 105 cells) was set aside as an unstained control. The cells were centrifuged at 444 
g for 4 minutes at room temperature and the pellet was resuspended in 200 μl of master mix solution 
and incubated at 4 °C for half an hour. The cells were washed three times in PBS 1% BSA (5 minutes 
per wash) and filtered through a 40 μm filter into a FACS tube before analysis.  
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2.3.3.3 Staining for intracellular markers 
The cells were centrifuged at 444 g for 4 minutes at room temperature and the pellet resuspended in 1 
ml of 4% PFA. The cells were incubated at 4 °C for 15 minutes to fix and then 1 ml of PBS 1% BSA 
was added to wash. The cells were centrifuged at 444 g for 4 minutes at room temperature and gently 
resuspended in 1 ml of PBS 1% BSA. This wash step was repeated three times, with each wash lasting 
5 minutes. A 1 in 20 dilution of FcR block in PBS 1% BSA + 0.1% Triton X was prepared. The cells 
were centrifuged at 444 g for 4 minutes at room temperature and resuspended in 200 μl ml of diluted 
FcR block. The cells were incubated at room temperature for 30 minutes. After the blocking step, a 
small aliquot of cells was set aside as a secondary-only control and another as an unstained control. The 
cells were centrifuged at 444 g for 4 minutes at room temperature. A solution of primary antibodies was 
prepared in PBS 1% BSA + 0.1% Triton X and the cells were resuspended in 200 μl of primary antibody 
solution and incubated at room temperature for one hour. The cells were washed three times in PBS 1% 
BSA +0.1% Triton X (5 minutes per wash). A solution of secondary antibodies was prepared in PBS 
1% BSA +0.1% Triton X and the cells (and secondary-only control) were resuspended in 200 μl of 
secondary antibody solution. The cells were incubated at room temperature for an hour and were kept 
in the dark to prevent exposure of the secondary antibody to light. The cells were washed three times 
in PBS 1% BSA +0.1% Triton X (5 minutes per wash) and then resuspended in 200 μl of PBS 1% BSA 
(wt/vol) and filtered through a 40 μm filter before analysing the sample on the flow cytometer. All flow 
cytometric analyses were performed on a FACS Cyan flow cytometer and analysed using FlowJo 
version 10.4.2. 
 
2.3.4 GGT assay 
GGT assays were performed using a MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic 
Assay Kit according to the manufacturer’s instructions.  
 
2.3.5 ALP assay 
Alkaline phosphatase staining was carried out on 4% PFA-fixed CO wells using the BCIP/NBT color 
development substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium, Promega) 
according to the manufacturer’s instructions. 
 
2.3.6 ELISA 
ELISAs for IFN-γ were performed using a Thermo Fisher IFN gamma Human Uncoated ELISA Kit 
and Thermo Fisher uncoated ELISA 96 well plates, according to the manufacturer’s instructions.  
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2.4 Analysis of in vivo samples 
2.4.1 Histology 
2.4.1.1 Preparation of OCT-embedded samples 
The tissue was washed in PBS and an OCT mould was filled with OCT solution. The tissue was gently 
placed in the mould using forceps and arranged in the desired orientation. The OCT mould was gently 
placed in a large box of dry ice until fully frozen and then transferred to -80°C storage until required. 
OCT tissue blocks were sectioned using a Bright OTF5000 cryostat. The tissue was sectioned at a 
thickness of 7.5 μm and collected onto Sigma PolyPrep slides. 
 
2.4.1.2 Preparation of paraffin-embedded samples 
The tissue was washed in PBS and then placed into a universal tube containing 10% formalin. The 
sample was fixed overnight at room temperature on a rocker and then washed twice in PBS for five 
minutes per wash. The tissue was then transferred to a solution of 80% ethanol and 20% deionised water 
and stored at 4°C for up to one week. An automatic tissue processor was used to prepare the sample for 
embedding in paraffin. The paraffin blocks were left at 4°C overnight before being transferred to room 
temperature storage. Paraffin-embedded samples were sectioned using a Leica RM2255 microtome. 
The tissue was sectioned at a thickness of 5 μm and collected onto VWR SuperFrost Plus slides. 
 
2.4.1.3 IF staining of cryosections  
When staining cryosections, unfixed slides were taken from -80 storage and the sections were outlined 
with a barrier pen while the slides were thawing. Immediately after thawing, 100-200 µl of 4% PFA 
was added to each section and the slides were incubated at 4°C for 20 minutes to fix the tissue. The 
slides were returned to room temperature and two five minute washes were performed with PBS. The 
slides were then stained as described in section 3.2.2.1, with each section receiving 200 µl of antibody 
master mix during staining. The slides were incubated overnight in a Sigma Aldrich StainTray to 
prevent drying. After staining, 1 drop of Fluoromount G mounting medium was added per section and 
the slides were mounted with a coverslip and stored at 4°C in the dark until required for imaging. 
 
2.4.1.4 IF staining of paraffin-embedded sections 
Paraffin-embedded sections were deparaffinised through a series of 5 minutes washes: 2 washes with 
xylene, 2 with 100% ethanol, 2 with 90% ethanol, 2 with 80% ethanol, 2 with 70% ethanol and 2 with 
50% ethanol. The slides were then incubated in a beaker of citrate buffer and boiled for 15 - 20 minutes 
in a water bath. The beaker was removed from the water bath and left for ten minutes to cool at room 
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temperature. The slides were then transferred to room temperature PBS and then stained for 
immunofluorescence analysis as described in section 2.4.1.3, without any further fixation or wash steps.  
 
2.4.2 Preparation of murine spleen/bone marrow/peripheral blood samples for flow 
cytometry 
 
2.4.2.1 Preparation of murine spleen samples 
Murine spleen samples were dissociated by filtering through a 40 µm filter into a 50 ml centrifuge tube 
and the filter washed multiple times with RPMI medium to collect as many cells as possible. The cells 
were centrifuged at 300g for 7 minutes at room temperature and the supernatant discarded. The pellet 
was resuspended in 1 ml of cold red cell lysis buffer and incubated at 4°C for ten minutes. 10 ml of 
RPMI medium was added to wash and the tube was centrifuged again at 300g for 7 minutes at room 
temperature. The supernatant was discarded and the pellet resuspended in 200 µl of FACS buffer. The 
cell suspension was transferred to a U-bottomed 96 well plate for further washes and staining as 
described in section 2.3.3.  
 
2.4.2.2 Preparation of murine bone marrow samples 
Bone marrow samples were extracted from the femur bones of culled humanised mice and the marrow 
cells were isolated by repeated flushing of RPMI media through the femur using a 27 gauge needle and 
a 1 ml syringe. The bone marrow was then dissociated into single cells using the 1 ml syringe and 27 
gauge needle and the cell suspension was transferred to a centrifuge tube. The cells were treated with 
red cell lysis buffer as described in section 2.4.2.1 and then transferred to a U-bottomed 96 well plate 
for further processing. 
 
2.4.2.3 Preparation of murine peripheral blood samples 
Peripheral blood samples were transferred either directly to a 96 well plate (if  < 200 µl in volume) or 
to a 15 ml centrifuge tube for larger volumes. The samples were centrifuged at 400g for 4 minutes at 
room temperature and the supernatant discarded. The pellets were resuspended in cold red cell lysis 
buffer- 150 µl for samples in a 96 well plate and 1 ml for samples in a centrifuge tube. Red cell lysis 
was performed as described in section 2.4.2.1. In the case of peripheral blood samples, it was often 





2.5 Gene editing 
2.5.1 Plasmid preparation 
2.5.1.1 Plasmid expansion and extraction 
Plasmids obtained from Addgene as agar stabs and inoculated into 100 ml of sterile LB broth with 100 
µl of ampicillin. The broth was incubated overnight (approximately 16 hours) at 37°C in a shaking 
incubator at 150 rpm. The broth was aliquoted into two 50 ml centrifuge tubes and centrifuged at 1500g 
for 30 minutes. The supernatant was discarded and the plasmids were extracted using a QIAGEN® 
Plasmid Plus Midi Kit according to the manufacturer’s instructions. The plasmid was resuspended in 
200 µl of RNase-free water and the concentration of DNA was measured using a Nanodrop 
spectrophotometer.  
 
2.5.2 Viral packaging 
 
2.5.2.1 Maintenance and passaging of HEK 293T cells 
HEK 293T cells were cultured on 10 cm2 tissue culture dishes in MEF media. The media was changed 
every 48 hours and the cells were passaged approximately every five days, once a confluent monolayer 
had been reached. During passaging, the cells were washed in PBS and incubated in TryplE for 
approximately 3 minutes at 37°C to lift the cells from the plate. The cells were added to a centrifuge 
tube containing equal volume of MEF media to wash and centrifuged at 300g for 3 minutes at room 
temperature. The pellet was resuspended in 1 ml of MEF media. 10 ml of MEF media was added to an 
uncoated 10 cm2  tissue culture dish and 100 μl of HEK 239T cells from the 1 ml suspension was added 
to the 10 cm plate. The plate was gently shaken to distribute the cells evenly, and this was confirmed 
by examination under the microscope. The cells were then returned to the 37°C incubator.  
 
2.5.2.2 Plating of HEK 293T cells in flask 
The cells were removed from the 10 cm plate using tryplE as described in 2.5.2.1 and resuspended in 1 
ml of MEF media. The cells were counted using an automated cell counter (1 in 10 dilution in trypan 
blue) and the volume of the 1 ml suspension containing 1.8 x 107 cells was calculated. 25 ml of MEF 
media was added to an uncoated T175 flask and the calculated volume of HEK 293T cell suspension 
containing 1.8 x 107 cells was added to this flask using a p1000 pipette. The flask was shaken gently to 
ensure an even distribution of cells on the bottom of the flask and incubated overnight at 37° C. The 




2.5.2.3 Preparation of plasmid packaging components 
1.5 ml of RPMI media was added to a 15 ml centrifuge tube and an appropriate volume of each plasmid 
was added to obtain the following amounts: 25 µg of the vector plasmid, 14 µg of the PAX2 helper 
plasmid and 6 µg of the MD2.G envelope plasmid. The tube was briefly vortexed and 68 µl of TurboFect 
reagent was added. The tube was vortexed again and left to sit at room temperature for 20-30 minutes. 
The transfection solution was added to the T175 flask of in a dropwise fashion and the flask gently 
rocked to ensure even distribution of the solution across the entire surface of the flask. The flask was 
returned to the 37°C incubator for 18-24 hours. The media was aspirated from the flask after the 18-24 
hours and the cells were gently washed with 10 ml of sterile PBS. The PBS was aspirated and 25 ml of 
fresh MEF media was added. The flask was returned to the incubator for a further 24-36 hours. 
 
2.5.2.4 Extraction and concentration of packaged virus 
The media containing the viral particles was carefully transferred to a 50 ml centrifuged tube and filtered 
using a 0.45 µm filter. 5 U/ml of DNase I and 1 mM of MgCl2 was added to the supernatant and mixed 
well. The tube was left at room temperature for 20 minutes. 8 ml of Lenti-X concentrator was added 
per 25 ml of supernatant and incubated at 4°C for 45 minutes. The samples was then centrifuged at 
1500g for 45 minutes at 4°C. The supernatant was carefully aspirated and the pellet gently resuspended 
in 250 µl (1000th the original volume of supernatant) of PBS. The viral suspension was quickly aliquoted 
into single-use 20 µl aliquots and stored at -80°C until required.  
 
2.5.3 Viral transduction 
COs were made into a single cell suspension as described in 2.3.3.1. The cells were counted using an 
automated cell counter and resuspended in 1 of WE+ media with EGF, Rspondin, DKK and Y at the 
usual concentrations (Section 2.1.1.3). The cells were transferred to the category 2 tissue culture room. 
A 20 µl aliquot of the required virus was thawed and the full viral aliquot was added to the cell 
suspension, along with 1:1000 of polybrene solution (1 µl). The CO suspension was gently mixed and 
transferred to a single well of a six well plate and incubated at 37°C overnight. The cell suspension was 
transferred to a 15 ml centrifuge tube, washed in 10 ml of WE+ media and centrifuged at 400g for 4 
minutes at room temperature. The cells were then plated in organoid format (typically 6-9 wells) as 
described in section 2.1.1.3. After 24 hours, the CO wells were washed in PBS after 24 hours and 
provided with new media. The cells were washed and the media exchanged again 48 hours after plating, 




CHAPTER 3: CHARACTERISATION AND REFINEMENT OF 
CHOLANGIOCYTE ORGANOID CULTURE SYSTEMS 
 
Statement of Source  
Figures 3.1 - 3.4 and 3.6 – 3.10 and the text for the introduction presented in this chapter are based upon 
my first author publication referenced below125 and has been taken verbatim or slightly modified from 
this source.  
O. C. Tysoe, A. W. Justin, T. Brevini, S. E. Chen, K. T. Mahbubani, A. K. Frank, H. Zedira, E. Melum, 
K. Saeb-Parsy, A. E. Markaki, L. Vallier,  F. Sampaziotis. Isolation and propagation of primary human 





Cholangiopathies comprise a diverse group of disorders characterized by damage to the biliary tree and 
loss of bile ducts resulting in cholestasis, hepatic injury and ultimately liver failure1,27. However, 
treatment options are limited to liver transplantation. Indeed, biliary disease remains the leading 
indication for this intervention in children, with more than 70% of paediatric liver grafts being used to 
treat biliary atresia39. The generation of healthy biliary tissue suitable for replacing or reconstructing 
damaged bile ducts could address the clinical need for alternative therapeutic approaches and reduce 
pressure on the transplant waiting list. 
Sampaziotis et al. developed a system for culturing cholangiocyte organoids derived from primary 
biliary tissue. To achieve expansion of the isolated cholangiocytes, the cells were embedded in Matrigel 
and treated with a combination of EGF, R-Spondin-1 and DKK-1. EGF has been well established to 
promote the proliferation of cells in organoid format105 and had previously been demonstrated to be a 
required factor in the culture of iPSC-derived cholangiocyte organoids223. To support the long-term 
expansion of adult cholangiocytes we used R-spondin-1, a Wnt agonist reported to stimulate organoid 
derivation from multiple adult epithelia110,113,224-227. However, R-spondin promotes the propagation of 
adult stem cells rather than mature epithelial populations by enhancing canonical Wnt signalling228. To 
avoid the amplification of adult stem cells, we introduced DKK-1229, a canonical Wnt/β-catenin 
pathway antagonist230,231. When used in combination with R-spondin, DKK-1 inhibits canonical and 
enhances non-canonical Wnt signalling though the planar cell polarity (PCP) pathway124, which has 
been reported to play a role in cholangiocyte maturation17,232. The combination of EGF, R-Spondin-1 




COs are capable of long-term expansion, retain expression of key cholangiocyte markers and 
functionality and, importantly are able to populate artificial collagen scaffolds and successfully rescue 
in vivo models of extrahepatic biliary injury. These properties demonstrate the system’s potential as a 
source of cholangiocyte cellular therapies for the treatment of cholangiopathies. However, the 
immunogenicity of COs and CO-derived therapeutic products must be determined before CO cellular 
therapies can be used in a clinical setting. 
In order to characterise the immune response to COs, it was first necessary to derive additional CO lines 
from donors for which autologous immune cells (PBMCs, SpMCs and/or bone marrow) could also be 
obtained. These lines were then characterised to ensure they had been derived and maintained 
effectively and were representative of the CO system. In this chapter we describe the characterisation 
of COs derived using our standard CO protocol.  
Furthermore, in collaboration with Dr Fotios Sampaziotis and Teresa Brevini, several refinements were 
made to the CO protocol and to the protocol for developing artificial biliary tissue, in order to expand 
the available sources of CO lines and improve the generation of artificial biliary tissue. The original CO 
protocol developed by Sampaziotis et al. only allowed for derivation of COs from extrahepatic biliary 
tissue (common bile duct and gallbladder), but not intrahepatic tissue. This potential limitation would 
restrict the availability of  CO lines, as it would not permit derivation of lines where the gall bladder or 
extrahepatic bile duct was is not available (including from deceased donors in a research setting and 
from potential live donors or explanted livers from transplant recipients, from which liver biopsies could 
be taken). In order to obtain tissue from these potential donors, I developed a method for the derivation 
of intrahepatic cholangiocyte organoids (ICOs) from liver biopsies, in collaboration with Fotios 
Sampaziotis, which I present in this chapter.  
Additionally, one important application of the CO system in the development of cellular therapies is 
the generation of artificial bile ducts that can replace or repair bile ducts damaged by cholangiopathies 
or surgical complications. The original protocol for the generation of artificial biliary tissue required 
the CO cells to be mixed in with the collagen gel during the densification process, rather than seeded 
onto the lumen of the densified collagen tubular scaffold. As seeding the CO cells onto the scaffold 
surface represents a more physiological approach, we developed a protocol for seeding CO cells directly 
onto the surface of densified collagen scaffolds, including in the lumen of tubular scaffolds. This aspect 
of the project was done in collaboration with Teresa Brevini, under the supervision of Fotios 
Sampaziotis and utilising tubular scaffolds generated by Alexander Justin. 
As a significant proportion of the work for this project requires transplantation of COs in vivo and the 
monitor graft survival, it was necessary to assess the capacity of COs to survive and proliferate in vivo. 
Additionally, it was important to develop a system to allow COs to be easily identified and tracked in 
vivo. I chose to use bioluminescence imaging (BLI) using a construct expressing luciferase and red 
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fluorescent protein (RFP) under an Ef1α promoter. BLI is commonly used for a wide variety of in vivo 
research applications233-236, including assessment of graft survival in transplantation models237-239 and 
has the major advantage of allowing for imaging of live animals on multiple occasions, as well as being 
relatively straightforward to perform compared to other types of imaging such as magnetic resonance 
imaging (MRI) and positron emission tomography (PET)235. In this chapter we characterise the ability 
of COs to survive in vivo and develop a bioluminescent imaging system to allow for live imaging and 





























3.2.1 Cholangiocyte organoids express key cholangiocyte markers and functionality 
 
 
Figure 3.1: qRT–PCR of representative CO lines confirming the expression of the key biliary 
markers  
Sox9, cytokeratin 7 (CK7), cytokeratin 19 (CK19) and gamma glutamyl transpeptidase (GGT) in COs 
compared to freshly isolated primary cholangiocytes (PC). COs express key cholangiocyte markers at 
comparable levels to primary cholangiocytes. n = 4 biological replicates. Centre line, median; box, 
interquartile range (IQR); whiskers, range (minimum to maximum). Values relative to the housekeeping 
gene HMBS.  # P > 0.05 (two-tailed Student’s t-test).  
 
Using our established protocol for the derivation and maintenance of COs124,125, I first focused on 
generating and validating new CO lines. Throughout the duration of this project, I generated 66 CO 
lines from 43 separate donors (appendix table 3) aged between 23 and 77. Neither donor age nor any 
other demographic factor was found to impact on the health of the CO line or success of line derivation. 
Derivation efficiency was typically close to 100%, although different methods of derivation resulted in 
different success rates and variation in the processing of the tissue before derivation could also impact 
derivation success. For example, common bile duct tissue that had not been adequately flushed of bile 
typically resulted in a much lower rate of derivation success (from 95% successful to 40%). I aimed to 
generate as many CO lines as possible with corresponding autologous immune cells available, as well 
as to potentially identify CO lines for which fully and/or partially HLA matched immune cell donors 
were available (see chapter 5 for more details). 
In keeping with our previously reported results124, these CO lines expressed the cholangiocyte markers 
Sox9, cytokeratin 7 (CK7), cytokeratin 19 (CK19) and gamma-glutamly transferase (GGT) at levels 
similar to primary cholangiocytes (no statistically significant difference), as determined by qRT-PCR 
(figure 3.1). Expression of these markers was confirmed via immunofluorescence (figure 3.2), as was 





Figure 3.2: Representative immunofluorescence images demonstrating expression of key biliary 
markers in COs 
Immunofluorescence images demonstrating CK7 (green) CK19 (red), Sox9 (red) and GGT (green) 
expression in COs and the lack of expression of the hepatic marker albumin (red). Scale bar, 50 μm. 






Figure 3.3: COs display typical cholangiocyte functional properties 
(a) COs demonstrate ALP activity. Left- unstained CO control; right- COs stained with ALP assay 
substrate. Scale bars, 100 μm. (b) GGT activity of COs measured in absorbance units (a.u.); n = 3; 
MEFs: mouse embryonic feeders, used as a negative control. Error bars, s.d.; individual data points are 
demonstrated; **P < 0.01, two-tailed Student's t-test.  
 
CO lines display the typical functional properties of large cholangiocytes, such as alkaline phosphatase 
and gamma-glutamly transferase activity (figure 3.3). COs represent a highly purified cholangiocyte 
population. Population purity increases after derivation and plating, with the isolation of primary 
cholangiocytes typically resulting in a purity of >90% (for isolation of extrahepatic cholangiocytes), 
which increases to >99% once in CO culture (figure 3.4). This level of purity remains stable throughout 







Figure 3.4: Flow cytometric quantification of CK7 and CK19 expression in primary 
cholangiocytes and COs 
Representative flow cytometric analyses performed on isolated primary cholangiocytes (left) compared 
to COs after long term culture (20 passages) (right). The population of primary cholangiocytes is >90% 
CK7+/CK19+ while the population of passage 20 COs demonstrates >99% CK7+/CK19+ expression 
(gating strategy demonstrated in appendix figure 1). 
 
3.2.2 Cholangiocyte organoids can be derived from intrahepatic biliary tissue 
In order to capture all possible sources of CO lines, it was important to adapt the existing CO protocol 
to enable derivation of CO lines from intrahepatic as well as extrahepatic biliary tissue. As our main 
source of biliary tissue was from deceased organ donors, I initially attempted two methods of isolating 
cholangiocytes from pieces of whole liver tissue from livers deemed unsuitable for transplantation. The 
first method involved cutting a small piece of liver tissue (approximately 1 cm3) and gently scraping it 
with a scalpel into a tissue culture dish filled with William’s E+ media, with the aim of dissociating the 
tissue into small clumps of cells. These small clumps of cells were then collected, centrifuged and plated 
in organoid format as described in Section 2.1.1.3. The second method involved manual dissociation of 
the liver tissue by sieving through a 100 μm sieve and then collecting the cells and plating as described 
above. While both of these methods resulted in the generation of CO lines (figure 3.5), they were both 
inefficient. In typical CO lines derived from the gallbladder or bile duct, organoids emerge within 48 
hours of initial plating and require passaging within five days, while lines derived by either of these two 
methods were not ready to be passaged until 8-10 days later. Additionally, far fewer organoids 
developed per well compared to extrahepatic CO lines, and several of the organoids showed signs of 
thickening and collapse. While passaging was successful for both methods, the low numbers of 
organoids in passage 0 resulted in a much slower expansion of the CO lines than typical and prevented 




Figure 3.5: Comparison of initial organoid development in passage 0 CO lines using different 
derivation methods 
Brightfield images comparing a representative gallbladder (GB) CO line at passage 0, 24 hours after 
derivation, with two intrahepatic bile duct (IHD) lines derived by either the scraping method or filtering 
method at passage 0, five days after derivation. Scale bar = 200 μm. Multiple organoids can be seen 
proliferating in the P0 GB line, while in the same spatial area, only one organoid has developed in each 
of the two IHD lines, despite a greater length of time elapsing since initial derivation.  
 
Due to the limitations of these two derivation methods, I developed a new protocol for intrahepatic CO 
(ICO) derivation. This new method preferentially involved sampling the liver tissue as a needle biopsy 
rather than excising a whole piece of tissue (although whole tissue pieces could be used in instances 
where it was not possible to take biopsies). The tissue was then finely diced using a scalpel. The tissue 





Figure 3.6: Development of a method for isolation intrahepatic cholangiocyte organoids (ICOs) 
from liver tissue  
(a) Schematic representation of ICOs derivation (b) Representative images of key stages of ICO 
derivation. 1: Dissection of liver tissue. 2: Collection of dissected tissue. 3-4: Dissected tissue before 
(3) and after (4) centrifugation. 5: Representative image of liver tissue after embedding in Matrigel, 
prior to media addition. 1-5: Scale bars, 1 cm. 6: Representative brightfield images of liver tissue 




Figure 3.7: Brightfield images of intrahepatic cholangiocyte organoids 
(a) An intrahepatic organoid emerging from liver tissue at passage 0 (scale bar = 200 μm) and (b) 
brightfield image of an established ICO line at passage 20 displaying typical healthy morphology (scale 
bar = 200 μm).  
 
In this new method, I did not attempt to fully dissociate the liver tissue but instead plated the tissue as 
relatively large (0.5-1.0 mm3) pieces in standard CO conditions (William’s E+ media with EGF, 
Rspondin and DKK-1). After several days (typically between 3-5 days), cholangiocyte organoids began 
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to emerge from the tissue pieces, while all other cell types in the liver tissue did not proliferate (figure 
3.7), as the WE+ media components and additional cytokines (EGF, Rspondin-1, DKK-1) promote the 
survival and proliferation of cholangiocytes while not supporting the survival of other cell types124. The 
ICO lines were typically ready for passaging at 7-10 days after derivation. While this method required 
a similar time to the previous two methods, it typically resulted in a much greater number of organoids 
at passage 0. This enabled the lines to be expanded more rapidly and early passages to be cryopreserved 
due to the greater cell number. Additionally, despite ICO lines deriving from intrahepatic biliary tissue 
rather than extrahepatic, ICOs could be derived and maintained in identical conditions to ECOs, without 
any other requirements. After initial derivation, all CO lines maintained similar characteristics and 
morphology, regardless of tissue of origin or derivation method (figure 3.8). Importantly, established 
ICO lines also expressed key cholangiocyte markers at levels comparable to both freshly isolated 
primary cholangiocytes and extrahepatic CO lines derived from the common bile duct or gallbladder 
(figure 3.9).  
 
Figure 3.8: Representative brightfield images of healthy CO lines derived from all tissue types 
1: bile duct, 2: gallbladder, 3: Endoscopic Retrograde Cholangio-Pancreatography (ERCP) brushings, 





Figure 3.9: qRT–PCR comparison of representative CO lines derived from intrahepatic and 
extrahepatic biliary tissue  
Sox9, cytokeratin 7 (CK7), cytokeratin 19 (CK19), gamma glutamyl transpeptidase (GGT), cystic 
fibrosis transmembrane conductance regulator (CFTR) and Hepatocyte Nuclear Factor-1 Beta 
(HNF1B) in freshly isolated primary cholangiocytes (PC) compared to established (passage 20) CO 
lines derived from intrahepatic ducts (IHD), the common bile duct (CBD) and the gallbladder (GB). 
IHD, CBD and GB CO lines express key cholangiocyte markers at comparable levels to primary 
cholangiocytes. n = 4 biological replicates. Centre line, median; box, interquartile range (IQR); 
whiskers, range (minimum to maximum). Values relative to the housekeeping gene HMBS.  # P > 0.05 
(One-way ANOVA with Dunnett’s multiple comparisons).  





3.2.3: Refinements to the generation of artificial biliary tissue 
 
 
Figure 3.10: Schematic representation of densified collagen tube seeding.  
1: COs are removed from Matrigel and manually dissociated to a single cell suspension. 2: The densified 
collagen tube is cannulated with a small-gauge needle. 3: The cell suspension is loaded into the syringe 
which is then attached to the needle and the cells are seeded in the lumen of the tube. 4: The tube is left 
at 37°C without media for approximately half an hour to ensure adequate attachment of the cells to the 
lumen wall. 5: William’s E+ media is added to the plate to the point of covering the tube.  
 
In our original protocol for generating bioengineered artificial biliary tissue, the CO cells were 
dissociated to small clumps and mixed into the collagen gel during the densification process. This 
ensured that cells were retained within the tubular scaffold but did not adequately reflect a physiological 
biliary system. We refined the protocol to allow for seeding of CO cells directly onto the surface of the 
scaffold (figures 3.10 and 3.11) by delivering the cells in a highly concentrated, low volume suspension 
into the lumen of the scaffold. The scaffold was dried for 30-60 minutes before seeding to encourage 
the cell suspension to adhere to the scaffold walls, and then left without media for a further 30-60 
minutes to allow the cells to attach.  
This refined method was successful in seeding small (200 μm lumen diameter) tubular scaffolds (figure 
3.11) and work is ongoing by Fotios Sampaziotis and Teresa Brevini to adapt the protocol to scaffolds 







Figure 3.11: Successful seeding of CO cells on the luminal surface of a densified collagen tube 
Immunofluorescence images showing expression of key biliary markers (CK19 and CK7) in CO-seeded 
densified collagen tubes. COs seeded on the luminal surface of densified collagen tubes retain 
expression of key cholangiocyte markers (CK19 and CK7) and form an uninterrupted monolayer. Scale 
bar, 100 μm. 
 
3.2.4: COs survive in vivo when transplanted under the kidney capsule 
 
COs were transplanted under the kidney capsule of immunodeficient NSG mice in order to assess the 
survival and proliferation of the cells in vivo. Approximately 1.0 x 106 cells were injected per animal, 
in a suspension of 100% Matrigel, containing the cytokines EGF and Y27632. EGF was chosen as it is 
a cytokine known to promote proliferation of epithelial cells105,124,223 and Y27632 helps prevent 
apoptosis caused by disruption of cell-cell and cell-matrix contact105,240. COs typically survived in vivo 
and formed cystic, duct-like structures under the kidney capsule, often surrounded by a layer of fibrosis 
due to the transplantation. The rate of proliferation and degree of survival of CO lines was highly 
variable and some lines were not able to survive in vivo for even the minimum required time of two 
weeks (table 3.1), while others proliferated rapidly and were able to survive for at least 12 weeks in 
vivo. Eight lines in total were transplanted in vivo over the course of this project, with two lines failing 
to survive in vivo to any extent (appendix figure 2), resulting in a survival rate of 75%. All CO lines 
transplanted thus far have been derived from extrahepatic biliary tissue. CO survival and morphology 
was assessed at the point of culling (variable, according to the experiment) by immunofluorescence on 





Figure 3.12: CO lines survive in vivo under the kidney capsule of NSG mice  
Immunofluorescent images of two different CO lines four weeks after transplantation under the kidney 
capsule in immunodeficient NSG mice. CO lines form duct-like cystic structures and retain expression 
of key cholangiocyte markers such as CK7 and CK19. The degree of CO survival and the rate of 

























Weeks in vivo 
200 (BD) P6 Yes Good 12 
243 (BD) Variable (P6-P10) No - Variable (2-16) 
256 (BD) Variable (P7-P10) Yes Good Variable (2-6) 
261 (BD) P10 No - 4 
286 (GB) P6 Yes Poor 4 
299 (BD) P7 Yes Good 3 
325 (BD) P4 Yes Good 4 
378  (BD) P6 Yes Good 4 
Table 3.1: Variation in survival and proliferation of CO lines in vivo 
Table showing the eight CO lines transplanted in vivo. All lines were of extrahepatic origin, either bile 
duct (BD) or gallbladder (GB).  The criterion for survival was set at the ability to locate living CO cells 
at the site of transplantation at least two weeks post-transplantation. “Good” quality lines are defined 
as lines surviving at least four weeks in vivo, with reliable survival across all transplanted animals and 
formation of duct-like structures. “Poor” quality lines are defined as lines unable to reliably survive 
over four weeks post-transplant, with survival varying between transplanted animals and abnormal graft 
structure.  
 
3.2.5: bioluminescent imaging can be used to monitor CO survival in vivo 
 
In order to enable CO grafts to be monitored in live animals and to quantify changes in graft size during 
experiments, we generated luciferase-expressing CO lines. I initially chose a commercially-available 
construct (available as pre-packaged lentiviral particles) with luciferase and GFP both controlled by a 




Figure 3.13: Plasmid map of the construct used to generate the initial GFP-Luciferase CO lines.  
The luciferase and GFP genes are both controlled by the CMV promoter and joined by a T2A linker.  
 
This construct was transduced into two passage 2 BD lines, 378 and 312, at a multiplicity of infection 
(MOI) of 5 and 10, respectively. Both lines were successfully transduced (figure 3.14), and were sorted 
by flow cytometry on GFP expression at two passages after transduction. Only approximately 1% of 
the population of both CO lines were GFP+ at the time of sorting.  
 
Figure 3.14: Generation of GFP luciferase CO lines 
Fluorescent images of two CO lines (378 and 312) transduced with a GFP luciferase construct, at P0 
after transduction (P3 in total). Scale bar = 150 µm. 
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These lines were transplanted under the kidney capsule of NSG mice (1.0 x 106 cells per mouse) and 
BLI was performed 24 hours after transplant (figures 3.15 and 3.16). Both lines expressed luciferase 
and were able to be detected in vivo. NSG mice were transplanted with the 312 GFP Luc line at different 
cell numbers to determine the sensitivity of the luciferase signal (figure 3.15). Luciferase signal showed 
a broadly linear dose-response curve to the number of cells transplanted. Luminescence was detectable 
at 1.0 x 105 cells, 10 times fewer than was typically transplanted in a standard in vivo experiment, but 
the signal was low, while injection of 1.5 x 106 cells resulted in significant over-saturation. From this I 
determined that the typical cell number of approximately 1.0 x 106 cells per mouse remained the optimal 
choice.  
While both lines could be detected by BLI at 24 hours after transplant, when imaged again at four weeks 
post-transplant, no signal was detectable for either CO line (figure 3.16). Upon culling, the kidneys 
were sectioned and imaged by immunofluorescence and surviving grafts were found (figure 3.17). 
These grafts were proliferative and expressed typical cholangiocyte markers but did not express GFP, 
either as natural fluorescence or when stained with a GFP-specific antibody (figure 3.17). A lack of 
GFP signal was also seen in the two lines in vitro following flow cytometric sorting, with no detectable 




Figure 3.15: Assessment of luciferase sensitivity in vivo 
Luminescence intensity at varying cell concentrations in vivo, one day after transplantation. (a) IVIS 
images of GFP-luciferase COs (line 312) under the kidney capsule at increasing cell numbers. 1: 1.0 x 
105 cells; 2: 2.5 x 105 cells; 3: 5.0 x 105 cells; 4: 1.5 x 106 cells. Imaging exposure time- 120 seconds. 
(b) Dose-response curve of light intensity (105 photons) against CO cell number (106). Values based on 
luminescence readings from imaged mice shown in (a). Luminescent signal increases linearly with 
increasing cell number. Signal is clearly visible at 1.0 x 105 cells, 10 times fewer than typically injected, 





Figure 3.16: Assessment of the long-term expression of luciferase signal in vivo 
NSG mice were transplanted with approximately 1.0 x 106 cells of either the 312 GFP Luciferase or 
378 GFP luciferase line and imaged 24 hours post-transplantation (left) and 30 days post-transplantation 
(right)  with automatic exposure. High levels of luminescence were seen at day 1 post-transplantation 
but luminescent signal was gone from all animals at day 30.   
Figure 3.17: GFP-Luciferase COs survive in vivo at four weeks post-transplantation 
Immunofluorescent images of 378 GFP-Luciferase COs (passage 6) under the kidney capsule at four 
weeks post-transplantation. 378 COs express the cholangiocyte markers CK7 (yellow) and CK19 (not 
shown here) but do not express GFP, either as natural fluorescent signal (green) or via anti-GFP 




Figure 3.18: Flow cytometric analyses of GFP expression in 312 GFP-Luciferase COs compared 
to a wild-type CO control 
(a) GFP expression in 368 wild-type control COs and (b) GFP expression in 312 GFP-luciferase COs. 
Flow cytometry gating: >103 = positive expression < 103  = no expression. No positive expression seen 
in either the WT control or 312 GFP-luciferase lines.  
 
Due to loss of luminescence signal over time in vivo and the complete loss of GFP signal (preventing 
selection of transduced cells as GFP was the only selection marker), I discontinued using the established 
GFP-Luciferase lines and explored a new luciferase construct. Due to time constraints, I selected a 
commercially available plasmid, with two important new criteria for selection: a promoter less likely to 
be silenced in primary-derived cells (either Ef1α or CAG) and an antibiotic resistance gene, to ensure 
availability of two methods of selection. I investigated several constructs (data not shown) and 
eventually chose the LL420 plasmid from Systems Bioscience (figure 3.19). This plasmid contains 
luciferase and RFP under the Ef1α promoter, joined by a T2A linker and has a separate puromycin 
resistance gene under the mPGK promoter. I packaged this plasmid into viral particles in-house using 
HEK 293T cells and successfully transduced the 299 BD line at passage 2 (figure 3.20). The 299 RFP-
Luciferase COs were transduced at an efficiency of 40% (according to RFP expression at P4, two 
passages after transduction). The cells were flow cytometrically sorted by RFP signal at P4 and treated 
with puromycin at 4 ng/ml for seven days at P6 (P1 after flow sorting) (figure 3.21). Due to time 
constraints and logistical challenges at the time, I was unable to assess the proportion of RFP+ cells 
post-sort, however work is ongoing to determine this and to assess the stability of RFP expression in 




Figure 3.19: Plasmid map of the LL420 luciferase construct  
This construct was used to generate the 299 BD Luc-RFP CO line. The luciferase and RFP genes are 
both controlled by the Ef1α promoter and joined by a T2A linker. A puromycin resistance gene is 





Figure 3.20: Transduction of 299 BD COs with the LL420 construct.  
(a) Fluorescent image of 299 BD one passage after transduction (passage 3) showing RFP expression 
in the majority of cells. Lack of expression in the GFP channel confirms the RFP signal is at a level 
above background. (b) Brightfield image of 299 BD one passage after transduction (passage 3) 
demonstrating a healthy, normal morphology after transduction. (c) Overlay of RFP and brightfield 
images of 299 BD two passages after transduction (passage 4) displaying strong RFP expression in 
some cells but low or absent expression in others. (d) Flow cytometry diagram of 299 BD three passages 




Figure 3.21: 299 BD RFP Luciferase COs treated with puromycin after cell sorting by flow 
cytometry  
Brightfield images of 299 BD RFP Luciferase COs treated with 4 ng/ml puromycin at day two of 
puromycin treatment compared to day seven. Scale bar- 200 μm. Cell death (determined through 
morphological changes) can be seen at day two following puromycin treatment but the majority of cells 
remain healthy and proliferative. 
 
Luciferase expression in 299 RFP Luciferase COs was tested in vitro and in vivo (figure 3.22). In vitro 
expression was compared against wild-type 299 COs and 299 COs transduced with a construct 
expressing GFP only. Each condition contained approximately 1.0 x 105 cells and the luciferin substrate 
was added at a concentration of 300 μg/ml, according to the recommendations of the plasmid 
manufacturer.  299 RFP Luciferase COs showed a strong luminescent signal while no signal was seen 
in wild-type or GFP control COs.  
NSG mice were injected with approximately 5.0 x 105 299 RFP Luciferase COs and imaged 24 hours 
after transplantation. A clear luciferase signal was seen in one animal, while the CO graft was less 
visible in the other animal, possibly due to a technical error in the transplantation procedure preventing 
the full volume of cells from being delivered. Furthermore, luciferase activity was observed in 299 RFP 
Luciferase COs in vitro at passage 20, 18 passages after viral transduction (figure 3.23), demonstrating 
that the 299 RFP luciferase CO line is robust and viable long-term and that the luciferase construct is 
not silenced in vitro, even after several months. Work is currently ongoing to quantify the long-term 
luciferase expression in the 299 RFP luciferase CO line, to determine whether the luciferase signal 







Figure 3.22: Luciferase activity in 299 BD RFP Luciferase COs in vitro and in vivo 
(a) IVIS images of 299 BD COs transduced with the Ef1a-Luciferase-RFP LL420 construct compared 
to a 299 BD wild-type control and a 299 BD GFP-only control. (b) Luminescence intensity (photons) 
of the Ef1a-Luciferase-RFP LL420 construct compared to a 299 BD wild-type control and a 299 BD 
GFP-only control. (c) IVIS image of 5.0 x 105 299 BD RFP-Luc COs one day post-transplantation 





Figure 3.23: Luciferase activity persists long-term in vitro in 299 BD RFP Luciferase COs 
IVIS image of 299 BD COs transduced with the Ef1a-Luciferase-RFP LL420 construct at passage 20, 























Refinement of the cholangiocyte organoid protocol and establishment of new cholangiocyte 
organoid lines 
In this chapter, the establishment of new CO lines and the refinements made to the CO protocol were 
described. I have demonstrated that I can successfully isolate and maintain new CO lines in accordance 
with our established extrahepatic CO protocol, with a derivation efficacy of 93% across all tissue types 
and methods of derivation. The most important factor in determining the success of a CO derivation 
appears to be the initial processing of the tissue, before CO derivation.  
This was highlighted by the dramatic decrease in successful CO derivation in common bile ducts which 
have not been adequately flushed of bile compared to those which were thoroughly flushed. This is 
likely due to the toxicity of bile – cholangiocytes are normally protected against the toxic effects of bile, 
however due to the effects of ischaemia and lack of nutrients in an explanted bile duct, the metabolic 
activity of the explanted cholangiocytes is likely to be reduced, making them vulnerable to damage 
from bile. A similar loss of viable cholangiocytes was seen in gallbladders that had not been flushed, 
although due to the overall greater cell numbers in gallbladder compared to bile duct samples, this was 
much less likely to result in derivation failure. As my biliary tissue samples were primarily derived 
from deceased organ donors and were collected during an ongoing retrieval procedure by the transplant 
surgeons, there is a limit on how much control can be exerted over the tissue sampling process. As this 
is the case, it is important to ensure that CO lines are derived from biliary tissue as soon as possible 
after tissue collection.  
I have also demonstrated that the extrahepatic CO protocol can be adapted for intrahepatic CO isolation 
and maintenance. My initial attempts at intrahepatic derivation, while able to produce CO lines, were 
not effective due to the low organoid numbers produced and the resulting slow expansion of the CO 
lines. This was likely due to the highly stressful processing methods required, particularly the filtration 
method, resulting in cholangiocyte cell death due to the disruption of cell-cell contact240-242. 
Additionally, as I initially tried ICO derivation from roughly cuboid pieces of liver, approximately 
1cm3, there was likely a high amount of cell death within the tissue between the time of sampling and 
line derivation due to ischaemia, as the tissue was too large to allow oxygen and nutrients to adequately 
diffuse through it entirely. These factors likely greatly reduced the number of viable cholangiocytes 
within the tissue, meaning that a very small number of organoids were able to survive and proliferate, 
even from a relatively large amount of starting tissue. This highlights again the importance of collecting 
tissue samples for line derivation in the most optimal manner for cell survival, even when the tissue is 
processed as soon after collection as possible.  
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My final method resulted in much more effective CO line derivation, most likely due to two factors: a 
change in the tissue sampling method from whole tissue pieces to core needle biopsies (diameter 2.0 
mm) and a less disruptive form of mechanical dissociation. Dicing the tissue with a scalpel resulted in 
tissue pieces <0.5 mm3, small enough to be plated in organoid format and for media to diffuse through 
the tissue entirely, but large enough that many of the bile ducts within the tissue were left intact. 
Maintaining these tissue pieces in William’s E+ media and our established CO cytokines allowed for 
the survival and proliferation of cholangiocytes while discouraging the survival of all other cell types 
within the tissue. As with our ECO derivation method, this results in a highly pure cholangiocyte 
population within a few passages.  
A limitation of this method of ICO derivation is that it does not allow for the derivation of an ICO line 
from a single cell, which, while not necessary for this project, may be required for some experiments, 
such as tracking the development of mutations after the establishment of an organoid line. Hand-picking 
individual organoids, while possible with this method, is technically challenging and there is no 
guarantee that individual organoids were derived from a single cell, making them unsuitable for 
experiments requiring monoclonal lines. We have developed a separate protocol for isolating 
cholangiocytes as single cells from liver tissue through EpCAM+ sorting via MACS or FACS125, 
however, this derivation method has a very low efficiency (appendix table 3) so we preferentially use 
the whole-tissue derivation method described in this chapter when single cell isolation is not required.  
 
Refinement of the protocol for generating bioengineered biliary tissue 
We have developed a protocol for generating bioengineered artificial bile ducts through seeding the 
luminal surface of a densified collagen construct with COs. The benefit of our new method for the 
generation of bioengineered biliary tissue is that it more accurately reflects the physiology of the native 
bile duct, with a monolayer of biliary epithelium lining the collagen tube rather than cholangiocyte 
organoids being embedded within the collagen walls. This is an improvement on previously published 
protocols for generating bioengineered biliary tissue, which relied either on the use of immortalised cell 
lines or on murine-derived organoids seeded on the outside of tubular scaffolds243,244  
The main limit of the new seeding method is that it is technically challenging to perform and requires a 
high cell numbers due to the high proportion of cell death after the initial seeding. This typically happens 
due to the failure of a proportion of cells to attach to the scaffold combined with the effect of the 
prolonged drying time (30-60 minutes) required for cell adherence. Additionally, it is necessary to leave 
the seeded tube in culture for between 2-6 weeks (depending on the size of the tube and the initial 
number of cells) to allow for the formation of a complete monolayer. Work is ongoing by Teresa Brevini 
and Fotios Sampaziotis to further refine this technique and determine the optimum length of time for 




Assessment of in vivo survival of CO lines 
The survival of CO lines in vivo is essential for their clinical application, and failure to properly assess 
the in vivo survival capacity of particular CO lines can lead to significant experimental challenges (see 
chapter 5). I have demonstrated in this chapter that COs are able to survive and proliferate in vivo under 
the kidney capsule and retain expression of cholangiocyte markers. However, the extent of survival and 
proliferation is line-dependent and several CO lines did not survive after transplantation. There did not 
appear to be any correlation between the age (passage number) of the line and its ability to survive in 
vivo, nor was there any change in CO maintenance or transplantation technique between lines. Equally, 
donor-specific factors did not appear to be the cause, as lines showing poor or no survival (243, 261 
and 286) were not from significantly older or younger donors than lines that engrafted well in vivo, nor 
were there any other noticeable differences between the two donor groups. There was not any notable 
difference in quality and proliferation rate in vitro of successful CO lines (in vivo survival) compared 
to unsuccessful CO lines. However, it is possible that there were differences in line quality which 
undetectable by morphological assessment alone. One strategy to address this would be to assess the 
quality of each CO line intended for transplantation through RT-qPCR assessment of expression of key 
cholangiocyte markers (e.g. CK19, CK7, Sox9, CFTR) compared to CO lines with high viability in 
vivo. Due to the unpredictable nature of CO survival in vivo, it is also important to test the survival of 
all CO lines in vivo in NSG mice before their use in immunogenicity experiments. Additionally, now 
that I have generated luciferase-expressing CO lines (figures 3.20 and 3.21), bioluminescent imaging 
can be used in vivo to track the survival and proliferation of CO grafts post-transplantation.  
 
Generation of luciferase CO lines for in vivo imaging 
In order to better monitor and quantify the survival of COs in vivo, I generated COs expressing the 
enzyme luciferase. This enabled me to perform bioluminescent imaging in live mice and to quantify 
CO graft growth or death during in vivo experiments, technique that is increasingly common in studies 
of allograft survival in humanised mice175,221,239. I used a lentiviral transduction system to introduce the 
luciferase construct into the cells. Lentiviral transduction has the limitations of requiring packaging of 
the transgene plasmid into viral particles and the risk of integration of viral DNA into the genome245 
and there has been recent developments in using other transfection methods such as lipofection and 
electroporation with primary-derived organoids246-249. However, as we had already established a method 
of lentiviral transduction in COs and have effectively generated GFP and RFP COs using this protocol, 
I felt it most efficient to continue using our established method of lentiviral transduction. 
One limitation in the generation of luciferase CO lines is the requirement for the organoids to be 
dissociated into single cells before lentiviral transduction and again before FACS sorting to purify the 
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luciferase-positive population. As cholangiocytes are epithelial cells which naturally form a monolayer 
with tight junctions between cells, dissociation to single cells can result in a noticeable loss in cell 
viability. This is particularly true when the cells must remain in a single-cell suspension for a prolonged 
period of time, as is necessary during viral transduction and FACS sorting. Careful dissociation with an 
appropriate enzymatic dissociation solution (e.g. Accutase) and addition of DNase I during the 
dissociation process and ROCK inhibitor throughout dissociation and transduction/sorting can help 
improve viability but cannot prevent cell death entirely. For this reason, viral transduction and the 
generation of purified luciferase CO lines was limited to only very early passage CO lines (< P3) in 
order to maximise the chance of line survival and proliferation, both in vitro and in vivo.  
An additional limitation of our current transduction method is the use of randomly integrated genetic 
constructs rather than targeting constructs to integrate into a safe genetic harbour such as the AAVS1 
locus250,251. While this has the significant advantage of being quicker and less technically challenging 
than targeted integration, it risks disrupting the endogenous chromatin and potentially integrating into 
an existing gene, which could impact on cell behaviour or lead to malignant transformation252,253. 
Additionally, random integration into the genome increases the risk of the transgene(s) being silenced 
over time254-256. 
 Taken together, these factors greatly increase the risk that expression of the transgene construct - in 
this case, luciferase and RFP - will eventually be lost, either due to out-competition of transduced cells 
by the wild-type population, or transgene silencing. It is likely that the loss of GFP expression and in 
vivo luciferase expression in our initial luciferase lines (378 and 312 GFP luciferase) was due to 
silencing of the CMV promoter, which is previously reported to be at risk of silencing when transduced 
into primary or primary-derived cells257. I attempted to mitigate this risk as much as possible in my 
second attempt at generating luciferase CO lines, through a stringent selection process of both FACS 
sorting and puromycin treatment and by choosing the Ef1a promoter, which is known to be stable and 
provide relatively strong expression in multiple cell types258-261. Work is ongoing to assess the stability 
of luciferase and RFP expression in my 299 RFP luciferase line, as well as to characterise the expression 
of typical CO markers in the 299 RFP luciferase line compared to the WT 299 line, to ensure the 
transduction has not negatively affected the health of the line.  
Preliminary IVIS data demonstrates that the 299 RFP luciferase CO line retains luciferase activity at 
passage 20 (figure 3.23), however this activity has not been normalised to total cell number and so can 
only demonstrate that some degree of luciferase expression remains after long-term culture and cannot 
determine whether the level of luciferase activity has decreased compared to early passage 299 RFP 
luciferase COs. Additional experiments to assess the luciferase activity of 299 RFP luciferase CO line 
at multiple passages normalised to overall cell number is required to be confident that consistent 
luciferase expression is retained long-term. If the random integration strategy is demonstrated to have 
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negatively impacted cellular behaviour or survival, or if reliable long-term luciferase and RFP 
expression cannot be guaranteed, it may be necessary to develop luciferase CO lines using a targeted 

























CHAPTER 4. ASSESSMENT OF THE ANTIGENICITY OF 




HLA class I and II are a group of highly polymorphic cell-surface molecules responsible for presenting 
antigen to cells of the immune system, primarily to T cells262. HLA class I molecules (HLA-A, HLA-B 
and HLA-C) are found on all nucleated cells and present endogenous antigen peptides to cytotoxic 
CD8+ T cells while HLA class II molecules (HLA-DR, HLA-DP and HLA-DQ) are found on the 
surface of antigen presenting cells (APCs) and present antigen from exogenous sources262. HLA class 
II is expressed constitutively on professional APCs- immune cells such as macrophages, dendritic cells 
and B cells- but can also be expressed on non-professional antigen presenting cells such as endothelial 
cells and many epithelial cell types263,264, including cholangiocytes26. Transplantation of solid organs or 
cellular therapies can result in an inflammatory reaction130, during which pro-inflammatory cytokines 
will be upregulated. Exposure of cholangiocyte cellular therapies to this inflammatory environment 
may result in the upregulation of immunogenic markers, including HLA molecules. As HLA is known 
to be the major determinant of immunogenicity in a transplantation setting130, it is important to 
characterise the expression of HLA on COs in order to assess their likelihood of inducing an immune 
response in cases of allogeneic transplantation. 
Interferon-γ (IFN-γ) is a pro-inflammatory cytokine produced by a range of immune cell types, most 
notably T cells and NK cells. IFN-γ is produced during a Th1 immune response, which is characterised 
by a highly pro-inflammatory environment and, in is involved in the clearance of bacterial and viral 
infections, as well as tumour cells265. In the case of transplantation, Th1 T cells are an important 
mediator of allograft rejection130. IFN-γ plays multiple roles during an immune response, most notably 
the activation of macrophages, however it is also responsible for upregulating expression of HLA class 
I and class II. IFN-γ is able to upregulate HLA class I on all nucleated cell types and HLA class II on 
antigen presenting cells and a variety of other cell types266-268, including endothelial269 and epithelial 
cells. HLA upregulation by IFN-γ is mediated by the JAK/STAT signalling pathway, which is initiated 
by the binding of IFN-γ to the dimeric IFN-γ receptor at the cell surface membrane. Phosphorylation of 
STAT1 results in the upregulation of the Interferon Regulatory Factor-1 (IRF-1) which induces HLA 
class I expression270. HLA class II expression is also mediated by the JAK/STAT pathway but requires 
the upregulation of the Class II Transactivator (CIITA)271,272 which then activates HLA class II genes 
directly.  
Exposure of primary cholangiocytes to the pro-inflammatory cytokines IFN-γ, IL-1 and TNF-α has 
been demonstrated to induce increased expression of adhesion molecules273, as well as to increase 
expression of HLA class I and to induce de novo expression of HLA class II molecules26. Expression 
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of HLA class II on healthy intrahepatic cholangiocytes has also been reported274. While this effect has 
been primarily demonstrated in vitro, cholangiocytes from livers with PBC274, PSC, GVHD and 
allograft rejection25 have been shown to express HLA class II275. This has caused speculation that 
cholangiocytes may be able to act as APCs to CD4+ T cells - this may be unlikely, however, as it is still 
not clear whether cholangiocytes can express CD80 and CD86, even under inflammatory conditions. 
Cholangiocytes exposed to pro-inflammatory cytokines in vitro have not been shown to express CD80 
or CD8626,274, although cholangiocytes from patients with PBC have been found to express CD80 and 
CD8624. IFN-γ challenged intrahepatic cholangiocytes have been shown to be capable of presenting 
antigen to CD4+ T cells via HLA class II, however the cholangiocytes were incapable of inducing T-
cell proliferation due to their lack of CD80/CD86276. Cholangiocytes have also been shown to 
constitutively express CD40 in vitro26,277 and CD40 expression is upregulated by exposure to TNF-α 
and IFN-γ26.  
In this chapter I present the results of my assessment of the expression of HLA class I and II molecules 
in COs under both normal and pro-inflammatory conditions. I first investigated the expression of HLA 
in COs compared to primary cholangiocytes through in vitro challenge with IFN-γ. I then assessed the 
expression of HLA class II in COs under a range of more physiologically relevant pro-inflammatory 
conditions, both in vivo through transplantation in xenogenic immunocompetent mice and differing 

















4.2 Results  
4.2.1 COs upregulate HLA class I and II in response to interferon-γ stimulation 
 
 
Figure 4.1: Downregulation of HLA molecules and other immune markers in COs compared to 
primary cholangiocytes 
Bulk RNA-Seq analysis of primary cholangiocytes compared to COs at passage 1, passage 10 and 
passage 20 and embryonic stem cell controls (n=3 biological replicates).  
RNA-Seq data provided by Fotios Sampaziotis. 
 
Our previous characterisation of mRNA expression in COs compared to primary cholangiocytes had 
highlighted that expression of multiple immune markers was significantly downregulated in COs at 
early (P1), mid (P10) and late (P20) passages compared to primary cholangiocytes (figure 4.1). This 
included almost all HLA class I and II molecules. Given the importance of HLA molecules in 
immunogenicity during transplantation, I decided to focus primarily on the expression of HLA and 
related costimulatory molecules in CO culture and pro-inflammatory conditions. I initially tested HLA 
expression after stimulation with two pro-inflammatory cytokines, IFN-γ and IL-6 (appendix figure 3), 
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however, after no noticeable differences in expression of HLA or any other immune genes was seen 
after IL-6 treatment, I  focused on challenging COs with IFN-γ in subsequent experiments.  
COs from three different lines (passages 4-6) were treated with recombinant IFN-γ at a concentration 
of 100ng/ml for 72 hours and then harvested for qPCR (figure 4.2) or fixed for immunofluorescence 
(figure 4.3) along with untreated control COs from the same CO lines and passage number. RT-qPCR 
was performed on the IFN-γ treated and untreated CO samples along with primary cholangiocytes from 
the same donors. Primer functionality was validated using human splenocytes (appendix figure 3). All 
samples were run in technical duplicates. The expression of the HLA genes HLA-A, HLA-B, HLA-C, 
HLA-DR, HLA-DQ and HLA-DP and the costimulatory molecules CD80, CD86 and CD40 was 
quantified relative to the housekeeping gene HMBS. Primary cholangiocytes expressed HLA class I 
(HLA-A, B and C) and HLA-DR (HLA class II) at high levels, although there was high variability of 
expression between different donors. HLA-DQ and HLA-DP were expressed at low levels on primary 
cholangiocytes. Expression of HLA class I was significantly reduced for all three genes following CO 
culture while expression of HLA-DR was lost completely. HLA-DQ and HLA-DP were downregulated 
after CO culture but this decrease was not statistically significant, likely due to the comparatively low 
levels of expression in both the primary and untreated CO groups. Treatment with IFN-γ significantly 
increased expression of HLA class I and HLA-DR. HLA-A was upregulated to levels equivalent to 
primary cholangiocytes while HLA-B, C and DR were expressed at higher levels than in primary 
cholangiocytes. IFN-γ treatment had no effect on HLA-DP expression but was able to significantly 
upregulate HLA-DQ, although to a much lesser degree than HLA-DR and with a large degree of 
variability between lines.  
I also investigated the expression of the co-stimulatory molecules CD80, CD86 and CD40. Primary 
cholangiocytes did not express CD80, while CD86 and CD40 were expressed at very low levels. IFN-
γ treatment did not upregulate CD80 or CD86 and caused a modest but significant upregulation of 
CD40. Due to the low or completely lacking expression of costimulatory molecules on COs, I decided 






Figure 4.2: RT-qPCR expression of immunogenic markers in COs and primary cholangiocytes 
(a) HLA class I (b) HLA class II and (c) co-stimulatory molecules in primary cholangiocytes (PCs) (3 
biological replicates, 2 technical replicates) and interferon-γ-treated COs (3 biological replicates, 2 
technical replicates*) compared against untreated COs (4 biological replicates, 2 technical replicates). 
*One technical replicate excluded from HLA B IFN-γ+ group due to a technical error). Centre line, 
median; box, interquartile range (IQR); whiskers, range (minimum to maximum). Values relative to the 
housekeeping gene HMBS. # P> 0.05; * P< 0.05; ** P< 0.01; *** P< 0.001; ****P<0.0001 (one-way 




Figure 4.3: HLA expression in COs after IFN-γ treatment 
Immunofluorescent images of HLA class I and class II expression in a representative CO line after 
treatment with 100ng/ml interferon-γ for 72 hours compared to untreated CO controls. Scale bar = 
50μm. Untreated COs express HLA class I but not HLA class II while IFN-γ-treated COs express both 
HLA class I and II. 
 
IFN-γ treated and untreated COs from the same experiment, as described in figure 4.2, were fixed for 
immunofluorescence and stained with pan HLA class I and II antibodies (figure 4.3). The untreated 
COs expressed HLA class I but not HLA class II while the IFN-γ treated COs expressed both HLA 




Figure 4.4: Flow cytometry histograms of HLA class I and class II expression in COs and primary 
cholangiocytes 
(a) HLA class I expression and (b) HLA class II expression in primary cholangiocytes (green) compared 
to control COs (blue) and IFN-γ-treated COs (red) and an unstained control (yellow). Flow cytometry 
gating: >103 = positive expression < 103  = no expression. All populations shown are EpCAM+ (see 
appendix figure 4 for gating strategy). HLA class I expression is high in primary cholangiocytes and 
reduced in unchallenged COs. IFN-γ treatment restores HLA class I expression to levels equivalent to 
primary cholangiocytes. HLA class II is moderately expressed in primary cholangiocytes but not 
expressed in COs. IFN-γ treatment upregulated HLA class II expression to levels above primary 
cholangiocytes. 
 
To confirm the RT-qPCR and IF results, primary cholangiocytes were fixed using 4% PFA as described 
in section (2.3.3.1) and stored at 4°C while an established CO line was challenged with IFN-γ as 
described for figures 2.2 and 2.3. The IFN-γ treated COs and matching untreated CO controls were 
fixed with 4% PFA and all samples were stained with EpCAM and pan-HLA class I and II antibodies 
and run concurrently on the flow cytometer. EpCAM staining was included in order to ensure the purity 
of the primary cholangiocyte population, as EpCAM is expressed on cholangiocytes but not leukocytes 
or other potentially contaminating cell types in the primary cholangiocyte population. In agreement 
with my RT-qPCR and IF data, HLA class I was expressed at high levels on primary cholangiocytes 
while untreated COs all expressed HLA class I but at lower levels than primary cholangiocytes. 
Treatment with IFN-γ restored HLA class I levels to equivalent to primary cholangiocytes. HLA class 
II was partially expressed on primary cholangiocytes and expression was lost on untreated COs. IFN-γ 
treatment upregulated HLA class II to levels above primary cholangiocytes.  
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These results were confirmed by using a total of four different CO lines and primary cholangiocyte 
samples (figure 4.5), all of which show consistent patterns of HLA class I and II protein expression in 
primary cholangiocytes and IFN-γ treated and untreated COs. Primary cholangiocytes consistently 
express HLA class I at levels near 100% of cells examined, while HLA class II expression was more 
variable across donors, being expressed by an average of 30% of all CO cells (figure 4.5a). Untreated 
COs express HLA class I at variable levels (figure 4.5b), with a mean expression of 82% of cells, while 
IFN-γ treatment upregulates expression to a mean expression of 98% of cells (not statistically 
significant). HLA class II was not expressed on untreated COs and IFN-γ treatment significantly 
upregulated HLA class II expression to a mean of 92.3% of cells.  
 
Figure 4.5: Graphs demonstrating HLA class I and II expression in multiple CO lines 
(a) A graph showing the percentage of primary cholangiocytes expressing HLA class I and II as 
measured by flow cytometry (n= 4 biological replicates). Primary cholangiocytes consistently express 
high levels of HLA class I, while HLA class II expression is consistently lower and shows greater 
variability between donors. (b) A graph showing the percentage of IFN-γ-treated (100ng/ml, 72 hours) 
and untreated COs (multiple passages, all >P1) expressing HLA class I as measured by flow cytometry 
(n=5 biological replicates). Both IFN-γ-treated and untreated COs express high levels of HLA class I 
although untreated COs show greater variability between lines. (c) A graph showing the percentage of 
IFN-γ-treated and untreated COs (multiple passages, all >P1) expressing HLA class II as measured by 
flow cytometry (n=5 biological replicates). Untreated COs do not express HLA class II while IFN-γ-
treated COs express HLA class II at high levels. # P> 0.05; **** P<0.0001 (two-tailed Student’s t-test). 
 
4.2.2 COs upregulate HLA class II under inflammatory conditions in vivo 
 
After characterising the expression of HLA class I and II in COs after exposure to high levels of IFN-
γ, I assessed HLA class II expression under more physiological pro-inflammatory conditions. This is 
important not only to confirm the relevance of the in vitro IFN-γ challenge experiments but also to 
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assess the level of HLA class II expression likely to be expected when transplanting CO cellular 
therapies or bioengineered biliary tissue using COs. To address, this, I transplanted 1.0 x 106 COs from 
established human CO lines under the kidney capsule of 5 different models:  fully immunocompetent 
C57BL/6 mice (figures 2.6. and 2.7), allogeneic SpMC-reconstituted humanised mice (figure 4.8), 
allogeneic HSC-reconstituted humanised mice (figure 4.9), autologous SpMC-reconstituted humanised 
mice (figure 4.9) and autologous HSC-reconstituted mice (figure 4.10).  All CO lines used within this 
experiment had previously been demonstrated to survive for a minimum of two weeks and a maximum 
of at least twelve weeks in naïve NSG mice. Work is currently ongoing to assess HLA class II levels 
on CO grafts in non-humanised NSG mice.  
 
 
Figure 4.6: HLA class II expression in COs after xenogenic transplantation 
Immunofluorescent images of COs transplanted under the kidney capsule of an immunocompetent 
C57BL/6 mouse stained with cytokeratin 19 (red) and HLA-DR (green). Image taken three days after 
transplantation. Scale bar = 50μm. COs upregulate HLA-DR in immunocompetent B6 mice.  
 
 
Figure 4.7: COs express HLA-DP after xenogenic transplantation 
Immunofluorescent images of COs transplanted under the kidney capsule of an immunocompetent 
Cb57BL/6 mouse stained with cytokeratin 19 (red) and HLA-DP (green). Image taken three days after 
transplantation. Scale bar = 50μm. COs upregulate HLA-DP in immunocompetent B6 mice.  
 
HLA-DR was clearly upregulated in fully immunocompetent C57BL/6 mice (figure 4.6), as was HLA-
DP (figure 4.7). The level of HLA-DR expression in different humanised mouse models, however, is 
less clear. COs transplanted into allogeneic SpMC-reconstituted NSG mice show levels of HLA-DR 
staining above that of background (figure 4.8), however the staining is patchy and does not perfectly 
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match the graft, unlike the HLA-DR and HLA-DP staining seen in Black6 mice. HLA-DR staining on 
autologous SpMC-reconstituted (figure 4.10) and allogeneic HSC-reconstituted (figure 4.9) was even 
less pronounced, and likely represent background staining, while autologous HSC-reconstituted grafts 
showed no HLA-DR expression (figure 4.11). In confirmation of our earlier in vitro data showing 
consistent expression of HLA class I even without inflammatory stimulation, COs transplanted into 
non-humanised NSG mice clearly expressed HLA class I (figure 4.12).  
 
Figure 4.8: HLA-DR expression in allogeneic SpMC-reconstituted NSG mice 
Immunofluorescent images of COs transplanted under the kidney capsule of an allogeneic SpMC-
reconstituted NSG mouse, stained with cytokeratin 19 (red) and HLA-DR (green). Image taken 12 
weeks after CO transplantation. Scale bar = 50μm. 
 
Figure 4.9: HLA-DR expression in allogeneic HSC-reconstituted NSG mice 
Immunofluorescent images of COs transplanted under the kidney capsule of an allogeneic HSC-
reconstituted stained with cytokeratin 19 (red) and HLA-DR (green). Image taken four weeks after CO 
transplantation. Scale bar = 50μm. 
 
Figure 4.10: HLA-DR expression in autologous SpMC-reconstituted NSG mice 
Immunofluorescent images of COs transplanted under the kidney capsule of an autologous SpMC-
reconstituted NSG mouse, stained with cytokeratin 19 (red) and HLA-DR (green). Image taken two 




Figure 4.11: HLA-DR expression in autologous HSC-reconstituted NSG mice 
Immunofluorescent images of COs transplanted under the kidney capsule of an autologous HSC-
reconstituted NSG mouse, stained with cytokeratin 19 (red) and HLA-DR (green). Image taken four 
weeks after CO transplantation. Scale bar = 50μm. 
 
 
Figure 4.12: HLA class I expression in immunodeficient NSG mice 
Immunofluorescent images of COs transplanted under the kidney capsule of a non-reconstituted NSG 
mouse, stained with the human-specific nuclear marker Ku80 (red) and pan-HLA class I (green). Image 
















4.2.3 Activated PBMCs upregulate HLA class II expression on COs 
 
 
Figure 4.13: Schematic representation of the experimental design for the CO/PBMC co-culture 
experiment 
Experimental design for the co-culture of COs and PBMCs showing the different co-culture groups in 
a 24 well plate. 1: 1.0 x 105 COs/1.0 x 105 PBMCs without activation; 2: 1.0 x 105 PBMCs with 
activation only; 3: 1.0 x 105 COs/1.0 x 105 PBMCs with activation; 4: 1.0 x 105 COs/2.0 x 105 PBMCs 
with activation; 5: 1.0 x 105 COs only.  
 
I aimed to establish an in vitro system to model the interaction between activated lymphocytes and COs 
in order to determine whether the pro-inflammatory environment resulting from lymphocyte activation 
(in particular, the production of IFN-γ) was sufficient to cause HLA class II upregulation on COs. This 
system was established both in order to determine the extent of HLA upregulation on COs under more 
physiologically relevant concentrations of IFN-γ (in contrast to the super-physiological concentrations 
used in the IFN-γ challenge experiments described in figures 4.3 – 4.5), and in order to model the effect 
of a pro-inflammatory, cell-mediated alloimmune response on a CO allograft. 
  SpMCs were thawed from a liquid nitrogen cryobank as described in section 2.1.3.4 and plated in 
complete RPMI media a 24 well plate as shown in figure 4.13. SpMCs in groups 2, 3 and 4 were 
activated using CD3/CD28 dynabeads as described in section 2.1.3.5 and the plate was incubated at 
37°C for 24 hours, at which point 100 μl of the supernatant was taken for ELISA and frozen at -20°C 
and COs were added to wells 1, 3, 4 and 5. The co-culture was incubated for 72 hours. A further 100 μl 
of supernatant was taken for ELISA and the cells were processed for flow cytometry and stained with 
7AAD, CD45 (expressed on SpMCs but not on COs), EpCAM (expressed on COs, but not on SpMCs), 
pan-HLA class I and pan-HLA class II. All CO groups were from the same line (378 BD, passage 6) 
and all SpMC groups were from one donor (donor 312) which was allogeneic and fully HLA-
mismatched with the CO line (as the CO lines and SpMCs are all from deceased organ donors, records 
of the HLA types were available for all donors).  
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HLA class I was expressed on 97% of COs in groups 1 (COs + non-activated SpMCs) and 5 (COs only) 
and this remained high at 99% on groups 3 (1:1 COs + activated PBMCs) and 4 (1:2 COs + activated 
SpMCs), however, this increase was not statistically significant (figure 4.14).  
Expression of HLA class II, however, was impacted by SpMC co-culture. HLA class II expression on 
COs in group 5 (COs only) was close to 0 while COs in group 1 (COs + non-activated SpMCs) were at 
approximately 1% and group 3 (1:1 COs + activated SpMCs) approximately 3.5% (figure 4.14). The 
mean HLA class II expression in group 4 COs (1:2 COs + activated PBMCs) was 8%. Only this group 
showed a statistically significant increase in HLA class II expression (p < 0.01), however the overall 
trend showed a small but consistent increase in class II expression appearing to correlate with the 
presence of PBMCs, particularly activated PBMCs.  
 
 
Figure 4.14: COs upregulate HLA class II after exposure to activated PBMCs 
Percentage of HLA class II (left) and HLA class I (right) expressing CO cells, as measured by flow 
cytometry after 72 hours of co-culture with activated PBMCs. EpCAM+ cells shown only. ECO only- 
COs in suspension culture without any PBMCs; No activation- COs in a 1:1 co-culture with non-
activated PBMCs; Low PBMC activation- COs in a 1:1 co-culture with activated PBMCs; High PBMC 
activation—COs in a 1:2 co-culture with activated PBMCs. (n = 3 biological replicates). **P < 0.01, 
one-way ANOVA with Tukey’s multiple comparisons.  
 
I assessed the levels of IFN-γ in the supernatant of each condition (with the exception of condition 5, 
COs only), at both 24 hours after activation and at 72 hours of co-culture (a total of 96 hours after 
activation) using ELISA (figure 4.15). Due to a technical error in the standard curve of the ELISA, it 
was not possible to calculate the absolute concentrations of IFN-γ in each group and the values given 
are in relative units. A non-substrate negative control and a positive control (recombinant IFN-γ at a 
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known dilution) was used to validate the values found in the non-standard samples. As expected, 
condition 1 (COs + non-activated PBMCs) did not express high levels of IFN-γ, either at 24 or 96 hours 
after the start of the experiment. All conditions with activated PBMCs resulted in low levels of IFN-γ 
at 24 hours, increasing significantly (P < 0.0001 for all groups) after a further 72 hours incubation. 
There was no significant difference between any of the conditions at 24 hours, except between C1 and 
C4 (P < 0.05). Out of all the conditions containing activated PBMCs, IFN-γ levels were highest in C4, 
which was significantly higher than both C2 and C3 (P < 0.0001) and lowest in C3, which was 
significantly lower than C2 and C4 (P < 0.0001).  
 
 
Figure 4.15: IFN-γ levels in CO/PBMC co-culture conditions, before and after co-culture 
Levels of IFN-γ (relative units) as measured by ELISA in all co-culture conditions containing PBMCs. 
Samples taken for ELISA at 24 hours after activation and 96 hours after activation. (n = 3 biological 
replicates). **** P < 0.0001 one-way ANOVA with Tukey’s multiple comparisons. C2, C3 and C4 24 









HLA expression in vitro after IFN-γ challenge 
HLA class I and HLA class II was expressed on primary cholangiocytes and was shown to be 
downregulated following in vitro culture compared to primary cholangiocytes. This downregulation 
may be due to the lack of normal immune signalling from pro-inflammatory cytokines and other 
immune mediators that would be present in vivo, as well as the lack of exposure to bile and other 
antigens. Challenge with IFN-γ induced expression of HLA class I and II (HLA-DR and DQ but not 
HLA-DP) in COs to levels higher than primary cholangiocytes, which agrees with established reports 
that IFN-γ upregulates HLA class I and causes expression of HLA class II on many cell types, including 
intrahepatic cholangiocytes26,266-268. My RT-qPCR analyses showed that the HLA class II HLA-DR was 
most significantly upregulated both in primary tissue and in COs after IFN-γ challenge. This is in 
keeping with the established research on HLA class II expression in non-APC cell types, which also 
shows a dominance of HLA-DR expression over HLA-DP or DQ266,268,269. 
This is the first time, to my knowledge, that the immune profile of extrahepatic cholangiocytes, either 
cultured or primary, and their response to inflammatory cytokines has been studied. My cytokine 
challenge experiments also have the advantage of being performed on a novel cholangiocyte culture 
system that encourages the formation of ductal organoids. This represents a more physiologically 
relevant culture system than the monolayer systems used in previous studies. This cytokine challenge 
method is limited as it only exposes the cells to one pro-inflammatory cytokine at a time, in a 
concentration that is not reflective of physiological conditions. It is nonetheless an informative 
approach, as it allows preliminary comparison of the immune profile of COs with their primary cell 
type. My in vitro IFN-γ challenge experiments provide an initial starting point for investigation of the 
alloimmune response to cellular therapies as they provide an indication of how a pro-inflammatory 
environment can change the cells’ phenotype and inform design of more complex in vitro or in vivo 
studies.  
A limitation of my characterisation of HLA expression on primary cholangiocytes is that the primary 
tissue is isolated from deceased organ donors, both DBD and DCD, and it is highly likely that these 
donors will be undergoing a systemic inflammatory process, potentially resulting in upregulation of 
HLA class I and II to levels not typically seen within healthy individuals. Expression of HLA class II 
has been reported on primary cholangiocytes, however this finding is not consistent and reports differ 
on whether healthy primary cholangiocytes typically express HLA class II24,26,275. It is therefore possible 
that the present finding that HLA class II is upregulated on primary cholangiocytes is influenced by the 
systemic inflammation in the tissue donors. Due to the requirement to match the primary cholangiocyte 
donors with their corresponding CO lines (all of which were derived from deceased donors) whenever 
possible, it was not possible to avoid this limitation in this current study. However, I plan to gain access 
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to primary biliary tissue from living donors (e.g. patients undergoing a cholestectomy) and to compare 
the expression of HLA class I and II in these samples to the primary cholangiocyte samples from 
deceased donors to confirm the validity of my initial finding.   
An additional limitation of my primary cholangiocyte data is that there was no reasonable way to purify 
the primary cholangiocyte samples when collecting RNA for RT-qPCR analysis, as MACS or FACS 
sorting would have detrimentally impacted the viability and yield of the cholangiocyte population. 
While flow cytometric analysis of the extrahepatic primary cholangiocyte populations demonstrates 
that my isolation method yields a >90% pure cholangiocyte population, the remaining <10% are 
comprised mostly of PBMCs (data not shown), which typically express high levels of HLA class I and 
II and other immune markers, and so may impact on the RT-qPCR results seen for the primary 
cholangiocytes. My flow cytometric analyses on EpCAM+ gated primary cholangiocytes demonstrated 
that primary cholangiocytes do express HLA class II, validating the RT-qPCR data. However, it cannot 
confirm whether the relative quantification of HLA class II expression shown by RT-qPCR is accurate, 
or if the values are artificially elevated by lymphocyte contamination in the primary RNA samples.  
A limitation of my IFN-γ challenge experiments is that the concentration of IFN-γ used is super-
physiological and the degree of upregulation of HLA class I and II seen in these in vitro experiments 
may not reflect the phhysiological levels of HLA expression seen in vivo in a pro-inflammatory 
environment. To address this limitation, I tested HLA expression in vivo under a variety of pro-
inflammatory conditions. I focussed in particular on HLA class II expression as this was not detected 
in COs under normal culture conditions, whereas COs consistently expressed HLA class I, both in vitro 
and in vivo when transplanted into non-humanised NSG mice.  
 
HLA class II expression in vivo 
I demonstrated that COs transplanted into immunocompetent mice were able to significantly upregulate 
HLA class II, likely due to the highly pro-inflammatory response that occurs during xenogenic graft 
rejection. Interestingly, in addition to upregulation of HLA-DR  (consistent with in vitro IFN-γ 
challenge data), I detected upregulation of HLA-DP in vivo; This was not detected in the in vitro IFN-
γ challenge assays, suggesting that other factor(s) may influence the expression of HLA-DP. My earliest 
cytokine challenge experiments with the cytokines IFN-γ, TNF-α, IL-6 and TGF-β (data not shown) 
did not detected cytokines other than IFN-γ as able to induce HLA class II expression on COs. However, 
it may be that a combination of cytokines present during an in vivo immune response is required to 
upregulate HLA-DP expression, rather than any single factor, as previously shown in other cell types 
for HLA class II expression overall278. Additionally, HLA-DP is known to have allelic variation leading 
to either high or low HLA-DP expression, which is correlated with greater or lesser susceptibility to 
conditions such as GVHD and Hepatitis B. It is possible that the CO line in these in vivo experiments 
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in immunocompetent mice carried the allelic variant of HLA-DP responsible for higher expression and 
as such was able to express HLA-DP upon exposure to IFN-γ while other CO lines carried the allele for 
low expression and so did not express HLA-DP even after exposure to high levels of IFN-γ. In order to 
test this possibility, further in vivo experiments should be complemented by RT-qPCR analyses of HLA 
expression in the specific CO lines used in vivo after in vitro IFN-γ challenge.   
HLA class II expression on CO grafts in humanised mice was less definitive. While allogeneic 
humanised mice appear to show some HLA class II staining above the level of background, the staining 
is patchy and variable, while autologous humanised mice do not appear to express HLA class II. Work 
is ongoing to confirm if this potential expression in allogeneic humanised mice is consistent. Alternative 
methods may be needed to assess HLA class II expression, such as flow cytometry, which is able to 
give a quantitative assessment of varying expression levels. Quantitative assessment of marker 
expression would also allow for a more complete assessment of HLA class I expression, which is 
present on COs transplanted into naïve immunocompromised NSG mice (figure 4.12) but may be 
upregulated in humanised and immunocompetent mice, which is not readily established through 
qualitative assessment methods such as immunofluorescence.  
A lack of HLA class II expression on grafts in humanised mice is not surprising, as it is well established 
that the humanised mouse model, either HSC or PBMC/SpMC-reconstituted, does not fully recapitulate 
all features of the immunocompetent human immune system135 (see chapter 5) and so the pro-
inflammatory response may not be as strong or as complete as that seen in a xenogenic model or an 
immunocompetent human. In addition to assessing the expression of HLA class II on the CO allograft, 
determining the extent of the systemic pro-inflammatory response post-transplantation through serum 
ELISAs for pro-inflammatory cytokines such as IFN-γ and IL-6 would also be informative. Comparison 
of the serum levels of pro-inflammatory cytokines of each mouse model (immunocompetent, SpMC-
humanised, HSC-humanised and immunodeficient) with CO transplantation, Matrigel-only 
transplantation and no transplantation would determine the extent to which CO allografts are able to 
induce a pro-inflammatory response above the baseline level of inflammation induced by 
transplantation alone.  
 
HLA class II expression after co-culture with activated lymphocytes 
My initial co-culture experiment with COs and PBMCs demonstrated no statistically significant 
increase in HLA class I expression between any of the conditions. This is in keeping with my earlier 
flow cytometric data, which showed that several CO lines express HLA class I on close to 100% of 
cells. While IFN-γ stimulation can increase the overall intensity of HLA class I expression (figure 4.3), 
it will not greatly increase the proportion of cells expressing HLA class I, as that is already very close 
to the maximum.  
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Expression of HLA class II, however, did increase in a manner that appeared to be dose-dependent upon 
the number and activation status of the PBMCs in co-culture. While only the difference in the 
percentage of HLA class II-expressing cells was statistically significant between conditions 3 (1:1 COs 
+ activated PBMCs) and 4 (1:2 CO + activated PBMCs), the overall trend appeared to be that the 
presence of activated PBMCs caused an increase in HLA class II expression compared to non-activated 
PBMCs, which in turn caused an increase in HLA class II expression compared to no PBMCs.  
I also measured the levels of IFN-γ in the supernatant of the different conditions, both at the start of co-
culture (24 hours after activation) and after 72 hours of co-culture (96 hours of co-culture). COs were 
added 24 hours after activation to ensure that all PBMCs were activated at the beginning of co-culture 
and co-culture was maintained for 72 hours to match the 72 hour time course of my earlier IFN-γ 
challenge experiments (figures 2.2-2.5) and to ensure that the COs had sufficient time to fully upregulate 
HLA class I and II. IFN-γ levels were measured both to confirm that the PBMCs had been successfully 
activated and to investigate whether or not any observed upregulation of HLA class II on COs correlated 
to an increased quantity of IFN-γ produced by the PBMCs.  
My IFN-γ ELISA showed that all conditions containing activated PBMCs had significantly (P < 0.0001) 
increased levels of IFN-γ at 96 hours post-activation compared to 24 hours, confirming that activation 
had been successful. Levels of IFN-γ at 96 hours were highest in condition 4, which was also the 
condition that showed the greatest upregulation of HLA class II on COs.  This finding complements a 
previous report269 showing that epithelial cells exposed to the supernatant of activated PBMCs were 
able to upregulate HLA class II due to the IFN-γ released by the activated PBMCs. The correlation 
between HLA class II expression and IFN-γ levels at 96 hours was not exact, however, as C2 (activated 
PBMCs only) had significantly (P < 0.0001) higher levels of IFN-γ than C3 (1:1 COs + activated 
PBMCs). Further work is needed to validate and investigate this finding, however one potential 
explanation could be that the levels of IFN-γ in the supernatant of C3 wells is lower as some proportion 
of the IFN-γ has bound to IFN-γ receptors on the COs. 
This was only a preliminary experiment, however, and requires repeating to confirm the results shown 
here. This work is currently ongoing. Further experimental groups of higher PBMC numbers (e.g. 1:4 
COs:PBMCs and 1:8 COs:PBMCs) will be added to confirm the apparent dose-dependent relationship 
between activated PBMC ratio and CO HLA class II expression. Additionally, a CO-only group treated 
with recombinant IFN-γ will be added to the experiment as a positive control and to compare the 
percentage of HLA class II expression seen after PBMC co-culture with the levels shown by our earlier 
IFN-γ challenge assays. The activation status of the PBMCs will be confirmed through flow cytometric 
analysis of activation markers such as CD25 as well as IFN-γ production. Additionally, a limitation of 
this initial experimental set up was that the PBMCs were added without determining the proportion of 
T cells to other PBMC cell types. Only T cells are able to be stimulated by CD3/CD28 activation beads 
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and to resultantly produce IFN-γ, so if some groups contained greater proportions of other PBMC types 
(e.g. B cells), this could have affected the results. For that reason, future co-culture experiments will 
assess the proportion of T cells to other PBMCs in each condition, and, if judged necessary, remove 
other cell types through MACS sorting.  
These results demonstrate the COs are capable of upregulating HLA class II (specifically, HLA-DR 
and possibly HLA-DP), not only after super-physiological stimulation with IFN-γ but also after 
exposure to physiologically relevant pro-inflammatory environments. This suggests that COs or CO-
derived therapies would upregulate HLA class II after transplantation into an immunocompetent patient. 
This would be likely to exacerbate the immune response against a CO allograft as the recipient’s 
immune system would respond to both the HLA class I and class II molecules presented on the CO 
graft. The high levels of both HLA class I and II on COs exposed to a pro-inflammatory setting suggests 
that immunosuppression is likely to be required after transplantation, and that HLA matching at HLA-




























Thorough assessment of the immunogenicity of potential cellular therapies is essential before these 
therapies can be utilised in a clinical setting. Due to the logistical and financial challenges of generating 
autologous cellular therapies for each patient, it is highly likely that future cellular therapies will 
originate from allogeneic donors. Therefore it is important to assess the extent to which an allogeneic 
human immune system would respond to a transplanted cellular therapy, and whether interventions to 
ameliorate immunogenicity, such as immunosuppression, HLA matching or gene editing to remove 
HLA, would be effective. 
 Humanised mouse models are an important tool for studying the immunogenicity of cellular therapies 
in the context of a human immune system. Humanised mice are defined as severely immunodeficient 
mice that have been reconstituted with human immune cells, either haematopoietic stem cells or adult 
leukocytes, to recapitulate key features of the human immune system135. There are currently three types 
of humanised mouse model: the Hu-BLT model, which reconstitutes mice with foetal bone marrow, 
liver and thymus; the Hu-SRC model, which reconstitutes mice with HSCs from adult or neonatal 
donors and the Hu-PBL model, which reconstitutes mice with human peripheral blood leukocytes from 
adult donors135. SpMCs can also be used in place of peripheral blood leukocytes in this model.  
Within the Saeb-Parsy group, we utilise Hu-SRC and Hu-PBL mice (described from this point on as 
HSC-reconstituted and SpMC-reconstituted) to assess the immunogenicity of cellular therapies as these 
two models allow for concurrent derivation of organoid lines from autologous donor tissue to serve as 
autologous controls. These models are complementary to each other, with both having strengths and 
limitations. The SpMC-reconstituted model elicits a strong CD3+ T cell response that can effectively 
reject allogeneic grafts, however successful engraftment inevitably leads to a strong GVHD response 
that can confound interpretation of the immune response135. Additionally, the engraftment of immune 
cells other than T cells is not well supported in this model, with B cells surviving only in the spleen and 
other cell types such as macrophages and NK cells not surviving at all205,279.  
Conversely, the HSC-reconstituted model can support the engraftment of a wider variety of human 
immune cells, including B cells, NK cells and macrophages and rarely develops GVHD within the time 
frame of a typical experiment279, as the human T cells are educated on murine thymic epithelial cells. 
However, many of the cell types produced in this model are immature or not fully functional135. This 
reduced functionality is due to a variety of factors, mainly stemming from the inability of the murine 
environment to support the differentiation of human leukocytes and the lack of adequate lymphoid 
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structures within immunodeficient mice. Many cytokines required for the survival and differentiation 
of human HSCs, such as GM-CSF (required for myeloid cell differentiation) and IL-15 (required for 
NK cell differentiation), are not compatible between human and murine cells, reducing the ability of 
such cell types to adequately differentiate and mature within an HSC-reconstituted humanised mouse 
system. Dendritic cells (DCs) are among the leukocyte subtypes that fail to adequately mature within 
humanised mice and this impacts on the functionality of the adaptive immune system, as DCs are 
required for effective antigen presentation to CD4+ T cells and costimulatory activation of B cells 
through CD40L. The lack of human HLA molecules on thymic epithelial cells can also reduce the 
effectiveness of the T cell response as human T cells are incapable of recognising and mounting a 
response to HLA-restricted human antigens. Furthermore, immunodeficient mouse strains such as NSG 
and NOG mice lack adequately developed secondary lymphoid structures such as lymph nodes and 
splenic germinal centres, which are important for T cell maturation, B cell class switching and the 
development of antigen-specific antibodies.  
Additionally, the ability of this model to reject allogeneic grafts is variable and highly dependent on the 
strain of immunocompetent mouse used, the age of the mice at reconstitution and the source of the 
reconstituting human HSCs135,280,281. Only the most immunodeficient strains available, such as NSG or 
NOG mice are capable of adequate reconstitution with human HSCs, with younger mice (particularly 
neonates) and females tending to engraft more effectively. Additionally, human HSCs from cord blood 
or foetal tissue are typically more effective than adult HSCs from sources such as bone marrow.  
It is likely that allogeneic cellular therapies will elicit an immune response in patients, necessitating 
interventions to prevent graft rejection. Immunosuppression is highly effective in preventing graft 
rejection in solid organ transplantation, however long-term immunosuppression can have significant 
negative side-effects158-160 and so alternative strategies are also being explored for cellular therapies. 
One promising option is the generation of gene-edited “universal” cellular therapies that do not express 
HLA class I, and this option is being widely explored172,175,282,283. Gene editing, however, is likely to be 
costly, time-consuming and carries the potential risk of off-target effects and other safety 
implications284,285.  
Another strategy is the generation of banks of cellular therapies to allow for HLA matching of donor 
and recipient. HLA matching is known to be effective at improving graft survival of the majority of 
solid organs after allogeneic transplantation, and several studies have suggested that HLA matching 
may reduce the immunogenicity of allogeneic cellular therapies167,168,170, although this is still 
uncertain286. Therefore HLA-matching is a potential strategy for reducing the immunogenicity of 
allogeneic CO grafts. The role of HLA matching in liver transplantation is controversial- HLA matching 
is generally considered to not affect liver transplantation outcomes154,155, however multiple reports 
suggest that HLA matching may increase the likelihood of developing operational tolerance287-289. 
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Additionally, others have found an association between HLA class I mismatch and the development of 
vanishing bile duct syndrome290, or shown HLA-A matching to be positively associated with ten-year 
graft survival291.  
In this chapter, I present the results of my assessment of the immunogenicity of CO grafts in SpMC-
reconstituted and HSC-reconstituted humanised mice. I assess the capacity of the SpMC-reconstituted 
and HSC-reconstituted humanised mouse models to reject allogeneic grafts and compare the response 
to autologous and allogeneic CO grafts in both models. I describe the refinements I have made to the 
humanised mouse models through the use of bioluminescent imaging (BLI) and present preliminary 
data on the impact of HLA-matching on the immune response to allogeneic CO grafts in an HSC-























5.2.1 Development of the SpMC-reconstituted humanised mouse model 
 
 
Figure 5.1: Schematic representation of the initial SpMC-reconstituted humanised mouse model 
Schematic demonstrating the timetable and key steps of the initial SpMC-reconstituted humanised 
mouse model. Steps in order (left to right): transplantation of organoids under the kidney capsule of 
naïve NSG mice; reconstitution with adult SpMCs (splenocytes) via intraperitoneal (IP) injection; 
weekly monitoring of engraftment; final cull and harvesting of the graft and immune tissues.  
 
Three NSG mice were transplanted with 1.0 x 106 COs from donor 200 under the capsule of the left 
kidney and reconstituted 10 weeks later with 1.0 x 107 allogeneic splenocytes (SpMCs) from donor 150 
via intraperitoneal (IP) injection (figure 5.1). Three non-humanised NSG mice were simultaneously 
transplanted with 1.0 x 106 COs from donor 200 and culled at ten weeks after transplantation. Tail bleeds 
were performed every week on the SpMC-reconstituted mice and the PBMCs analysed by flow 
cytometry to monitor engraftment with human leukocytes (figure 5.2).  The SpMC-reconstituted mice 
showed rapid engraftment with human leukocytes after the first week, with only minor variation in 
engraftment between individual animals. The human CD45+ cell engraftment was almost entirely 
composed of CD3+ T cells, with almost no CD19+ B cell presence in the peripheral blood (figure 5.3). 
The majority of T cells in the peripheral blood were CD4+, although proportions of CD4+ and CD8+ 
T cells varied slightly at each time point. The mice were culled at 3.5 weeks when the proportion of 
human CD45+ cells in the peripheral blood reached 60%. Peripheral blood and spleen were taken for 
flow cytometric analysis and the kidneys, both the CO-transplanted left kidney and the control right 
kidney, were taken for cryosectioning and immunofluorescence imaging, along with the kidneys from 





Figure 5.2: Human CD45+ cell engraftment in SpMC-reconstituted mice 
Timecourse of the engraftment of human CD45+ cells in the peripheral blood of NSG mice as a 
proportion of all live CD45+ cells, as measured by flow cytometry. N = 3 biological replicates. Flow 






Figure 5.3: Human CD45+ subtype engraftment in SpMC-reconstituted mice 
Timecourse of the engraftment of human CD4+ and CD8+ T cells and CD19+ B cells in the peripheral 
blood of NSG mice. T cells and B cells measured as a proportion of all live human CD45+ cells, as 
measured by flow cytometry. N = 3 biological replicates. Flow cytometric gating strategy shown in 
appendix figure 5. 
 
The spleens of the SpMC-reconstituted humanised mouse showed a mean proportion of 30% live human 
CD45+ leukocytes (figure 5.4), although there was variability between animals. The spleens also 
showed engraftment with human CD19+ B cells (40% of all splenic human CD45+ cells) and CD4+ 
and CD8+ T cells (figure 5.4). As in the peripheral blood, the proportion of CD4+ T cells was greater 
than CD8+ T cells, although the difference between the two subtypes was less in the spleen than the 






Figure 5.4: Engraftment of human leukocytes in the spleen of SpMC-reconstituted mice 
(a) Proportion of human CD45+ cells compared to murine CD45+ cells in the spleen of SpMC-
reconstituted mice, as measured by flow cytometry. (b) Proportion of human CD4+ and CD8+ T cells 
and CD19+ B cells as a percentage of all live human CD45+ cells in the spleen, as measured by flow 
cytometry. Splenic engraftment measured at the experimental endpoint (3.5 weeks after reconstitution). 
N=3 biological replicates. Flow cytometric gating strategy shown in appendix figure 5. 
 
The kidneys were cryosectioned at 7µm thickness until the graft area was located. The cryosections 
were initially stained for the human-specific markers Ku80 and HLA class I (figure 5.5). COs in the 
non-humanised control were shown to have formed large, duct-like structures under the kidney capsule, 
with CO cells arranged in a single-cell cystic structure around a lumen. In contrast, COs in the SpMC-
humanised mice showed a collapsed, irregular graft structure, with thickened cells and a high density 
of infiltrating cells expressing the human-specific marker Ku80 but not the cholangiocyte marker CK7 
(figure 5.5). Further immunofluorescent imaging confirmed these infiltrating human cells to be human 
CD45+ leukocytes (figure 5.6). These images also confirmed that the disordered graft structure seen in 




Figure 5.5: Graft infiltration in SpMC-reconstituted mice 
Immunofluorescence images demonstrating CO grafts from line 200 under the kidney capsule of non-
humanised (top) and SpMC-humanised (bottom) NSG mice. The CO graft in the non-humanised mouse 
is stained for two human-specific markers, HLA class I (green) and Ku80 (red) and the CO graft forms 
cystic duct-like structures. The CO graft in the SpMC-reconstituted mouse is stained for the 
cholangiocyte marker CK7 (green) and Ku80 (red) and is surrounded by CK7-/Ku80+ cells. The CO 






Figure 5.6: Leukocyte infiltration into CO grafts in SpMC-reconstituted mice 
Immunofluorescence images of a non-humanised CO graft (top) showing CK19 expression (green) but 
no CD45+ leukocytes (red) compared to an  SpMC-reconstituted CO graft (middle and bottom) showing 
CK19+ CO cells (red) surrounded by CD45+ leukocytes (green). Scale bar (top and bottom rows) = 
50µm. Scale bar (middle row) = 100µm.  
 
After this preliminary experiment, I continued to investigate the immunogenicity of COs using the 
SpMC model, following the experimental parameters outlined in figure 5.1. However, SpMCs from 
donor 150 were no longer available and alternative SpMC donors failed to engraft to any extent, even 
after a significantly longer engraftment time course (data not shown). As a result, and in order to reduce 
the time required for each reconstitution experiment, I modified the design of the SpMC-reconstituted 
humanised mouse experiments. The animals were reconstituted with 1.0 x 107 SpMCs and the SpMC 
engraftment monitored through weekly tail bleeds until a threshold of approximately 5% live human 
CD45+ cells in the peripheral blood was reached, at which point the mice were transplanted under the 
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left kidney capsule with 1.0 x 106 COs. The mice were culled two weeks after transplantation with COs 
(figure 5.7).  
 
Figure 5.7: Schematic representation of the modified SpMC-reconstituted humanised mouse 
model 
Schematic demonstrating the timetable and key steps of the modified SpMC-reconstituted humanised 
mouse model. Steps in order (left to right): reconstitution with adult SpMCs (splenocytes) via 
intraperitoneal (IP) injection; weekly monitoring of engraftment; transplantation of organoids under the 
kidney capsule of naïve NSG mice; final cull and harvesting of the graft and immune tissues.  
 
I aimed to investigate the immunogenicity of allogeneic COs compared to autologous COs through the 
use of the SpMC-reconstituted humanised mouse model and bilateral transplantation of two different 









Figure 5.8: Schematic representation of the experimental design for the bilateral SpMC-
reconstituted humanised mouse experiment 
Five mice were reconstituted with SpMCs from donor 325 (brown) and five with SpMCs from donor 
286 (blue). Three mice of each group were transplanted under the left kidney with 325 COs (brown dot) 
and under the right kidney with 286 COs (blue dot). Two mice of each group were transplanted under 
the left kidney with primary islets (yellow dot) and Matrigel only (green dot). Four non-humanised 
NSG mice were transplanted under the left kidney with 325 COs (brown dot) and under the right kidney 
with 286 COs (blue dot) and two non-humanised NSG mice were transplanted under the left kidney 
with primary islets (yellow dot) and Matrigel only (green dot).  
 
I selected donors 325 and 286 as these were donors for which both CO lines and a high number of 
SpMCs were available. Additionally, both donors had previously been shown to survive in vivo (table 
3.1) and had been used in an HSC-reconstituted humanised mouse experiment conducted earlier 
(discussed later in this chapter). SpMC engraftment of donor 325 was rapid, while donor 286 entirely 
failed to engraft (figure 5.9). The reason for this failure is unclear, however one possible explanation is 
that immune cells from donor 286 were cryopreserved for longer and were derived from an older donor, 






Figure 5.9: Human CD45+ cell engraftment in SpMC-reconstituted mice 
Timecourse of the engraftment of human CD45+ cells in the peripheral blood of SpMC-reconstituted 
NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. (a) Engraftment 
timecourse of SpMCs from donor 325. (b) Engraftment timecourse of SpMCs from donor 286. N = 5 
biological replicates per donor. Flow cytometric gating strategy shown in appendix figure 5. 
 
The mice were transplanted one week after SpMC reconstitution with the CO lines 325 BD and 286 GB 
as shown in figure 5.8, along with the positive (primary islets) and negative (Matrigel only) control 
SpMC-reconstituted mice and non-humanised controls. All mice were culled two weeks after 
transplantation and the kidneys were harvested for cryosectioning and immunofluorescence imaging. 
Processing and analysis of the samples from this experiment is still ongoing and the majority of control 
SpMC-reconstituted kidney samples and non-humanised kidney samples have not yet been analysed. 
Initial analysis of the SpMC-reconstituted/CO engrafted kidney samples reconstituted with SpMC 
donor 325 shows infiltration of CD45+ leukocytes into the graft area of both allogeneic and autologous 
(figure 5.10) grafts. Autologous 325 BD grafts can be seen under the kidney capsule, forming cystic 
duct-like structures containing CD45+ cells while no surviving 286 GB cells can be found in the graft 
area of the allogeneic right kidney graft. Importantly, however, no surviving 286 GB cells could also 
be found under the kidney capsule of a non-humanised NSG mouse (data not shown), although analysis 
of all samples is still ongoing. One possible explanation for the lack of survival of 286 GB cells is that 
the 286 CO line was cryopreserved for longer than the 325 CO line and underwent a greater number of 
freeze-thaw events, which could have damaged the quality of the CO line. Infiltration of CD45+ 




Figure 5.10: Leukocyte infiltration in autologous and allogeneic CO grafts  
Immunofluorescence images of CO grafts in autologous (top) and allogeneic (bottom) SpMC-
reconstituted humanised mice three weeks after SpMC-reconstitution and two weeks after CO 
transplantation, showing CD45+ leukocyte infiltration into the CO graft area. CO grafts stained for CK7 
(red). No remaining evidence of CO graft survival in allogeneic SpMC-reconstituted mice. Autologous 
CO grafts from line 325, allogeneic grafts from line 286. Both allogeneic and autologous humanised 
mice reconstituted with SpMCs from donor 325. Scale bar = 100μm. 
 
 
Figure 5.11: Leukocyte infiltration into a positive control primary islet graft 
Immunofluorescent images of SpMC-reconstituted humanised mice engrafted with SpMCs from donor 
325 and allogeneic primary human islets showing CD45+ leukocyte infiltration (green) into 









5.2.2: Differential graft infiltration of allogeneic vs autologous grafts in HSC-reconstituted 
humanised mice 
 
The aim of our first HSC-reconstituted humanised mouse experiment was to investigate the 
immunogenicity of allogeneic and autologous CO grafts and to determine the extent to which allogeneic 
CO grafts would be rejected in an HSC-reconstituted humanised mouse model. Twelve female mice 
were irradiated with 2.4Gy of gamma irradiation and reconstituted six hours later with 1.0 x 107 CD3-
depleted bone marrow cells - six mice were reconstituted with donor 256 and four with donor 261 (I 
was unable to reconstitute more than four mice with donor 261 due to a lack of adequate bone marrow 
cells). The mice were from two separate cages, one 5.5 weeks old and one 6.5 weeks old. The 
engraftment of human CD45+ cells was monitored by bi-weekly tail bleeds, starting 8 weeks after 
reconstitution and ending at 17 weeks, when the animals were transplanted with COs. One 261-
reconstituted humanised mouse had to be culled soon after HSC reconstitution for health reasons. 
Engraftment of human CD45+ cells in the peripheral blood was variable across mice (figure 5.12).  
 
Figure 5.12: Leukocyte engraftment timecourse in HSC-reconstituted humanised mice 
Timecourse of the engraftment of human CD45+ cells in the peripheral blood of HSC-reconstituted 
NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. Each line represents 
engraftment in an individual animal. Engraftment monitored from 8 weeks after reconstitution to 17 
weeks, at which point the animals were transplanted with CO grafts.  
 
In order to ensure that both CO lines were tested in both an allogeneic and autologous humanised 
immune system, four 256-reconstituted humanised mice were transplanted with COs from line 256 (256 
autologous) and four with COs from line 261 (261 allogeneic). Two 261-reconstituted humanised mice 
were transplanted with COs from line 261 (261 autologous) and one 261-reconstituted humanised 
mouse was transplanted with COs from line 256 (256 allogeneic). The mice were culled four weeks 
after transplantation, a total of 21 weeks after HSC reconstitution. At the time of the final cull, the 261-
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reconstituted humanised mice were noticeably less well engrafted than the 256-reconstituted humanised 
mice, with two out of the three 261 animals showing less than 5% human CD45+ cells in the spleen, 
compared to a mean engraftment of 40% human CD45+ cells in the spleens of 256-reconstituted 
humanised mice (figure 5.13). 
 
Figure 5.13: Leukocyte engraftment in the spleen of HSC-reconstituted humanised mice 
Engraftment of human leukocytes in the spleen of HSC-reconstituted humanised mice at the end of the 
experimental time course, 21 weeks after initial HSC reconstitution, as measured by flow cytometry. 
(a) Engraftment of live human CD45+ leukocytes as a percentage of all live CD45+ cells in the spleen 
of HSC-reconstituted humanised mice reconstituted with HSCs from either donor 256 or donor 261. 
 
 
Figure 5.14: Lack of survival of 261 CO grafts 
Immunofluorescent image demonstrating the lack of survival of 261 CO grafts. No specific CK19 (red) 
staining was seen. Some infiltrating CD45+ (green) cells were seen in proximity to the graft area. Scale 
= 100 µm.   
 
No survival was seen of any 261 CO grafts, in either the allogeneic, autologous or non-humanised mice, 
although evidence of graft death could be seen, along with infiltrating leukocytes in the allogeneic graft 
areas (figure 5.14). 256 CO grafts showed good survival within all conditions (figure 5.15) and there 
was no noticeable difference in graft structure or size in the allogeneic, autologous or non-humanised 
grafts. CD45+ staining was seen in both allogeneic and autologous grafts (figure 5.15), but a greater 
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degree of lymphocyte infiltration was seen in allogeneic grafts. This difference was significant (P < 
0.05) although there was a high level of variation was seen between different areas of the CO grafts 
(figure 5.16). When the number of infiltrating leukocytes was normalised to the percentage of human 
leukocytes in the peripheral blood at the point of transplantation (infiltrating leukocytes/percentage 
peripheral blood leukocytes), the difference in leukocyte infiltration between allogeneic and autologous 
grafts became more pronounced (P < 0.01) (Figure 5.16).  
 
Figure 5.15: Graft infiltration into CO grafts in HSC-reconstituted humanised mice  
Immunofluorescent images showing CD45+ leukocyte (green) infiltration into CK19+ CO grafts (red) 
in autologous (top) and allogeneic (middle) HSC-reconstituted mice. Allogeneic and autologous grafts 
compared to CO grafts in non-humanised NSG mice (bottom). All CO grafts are from line 256. 
Autologous HSCs are from donor 256 and allogeneic HSCs from donor 261. All grafts shown four 






Figure 5.16: Allogeneic grafts show higher numbers of infiltrating leukocytes than autologous 
grafts in HSC-reconstituted humanised mice 
(a) Numbers of infiltrating leukocytes in CD45/CK19 stained cryosections of CO grafts taken from 
autologous (n=2 biological replicates) and allogeneic (n= 1 biological replicate) HSC-reconstituted 
humanised mice. Representative cryosections of the graft area containing live CK19+ CO cells were 
randomly sampled from throughout the extent of the graft and imaged at 10x magnification, with the 
CO graft in the centre of the image. Surrounding/infiltrating CD45+ leukocytes were counted using 
Image J. P < 0.05 (Student’s T-test). (b) Numbers of infiltrating leukocytes from the same CD45/CK19 
cryosections after normalisation to the total percentage of human CD45+ cells in the peripheral blood 
at 17 weeks post-engraftment (immediately before CO transplantation). P < 0.01 (Welch’s T-test).  
 
5.2.3: CO line quality is the greatest indicator of survival in HSC-humanised mice  
 
Fourteen NSG mice were irradiated at 2.4Gy and reconstituted with 1.0 x 107 CD3-depleted bone 
marrow cells from donor 286. The time course of engraftment in the peripheral blood was monitored 
from week 12 to week 18, at which point the mice were transplanted with COs under the kidney capsule 
(figure 5.17). Two mice were culled before transplantation for health reasons (weight loss <20% of 
initial weight). Four mice were transplanted with 1.0 x 106 COs from line 286 GB, four mice were 
transplanted with 1.0 x 106 COs from line 325 BD and four mice were transplanted with 600 IEQ 
primary islets from an allogeneic donor.  Animals were sorted into groups for transplantation in a 
manner that ensured that each group had an approximately even distribution of well-engrafted, 
moderately engrafted and poorly engrafted animals. One animal from the 286 autologous group was 
culled after transplantation due to health reasons. Two non-humanised mice were transplanted with 325 
BD COs, two non-humanised mice were transplanted with 286 GB COs and two non-humanised mice 




Figure 5.17: Leukocyte engraftment timecourse in HSC-reconstituted humanised mice (donor 
286) 
 Timecourse of the engraftment of human CD45+ cells in the peripheral blood of HSC-reconstituted 
humanised NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. Each 
line represents engraftment in an individual animal. All animals engrafted with CD3-depleted BM cells 
from donor 286. Engraftment monitored from 12 weeks after reconstitution to 18 weeks, at which point 
the animals were transplanted with CO grafts.  
 
 The animals were culled at 2 weeks after transplantation and tissue taken for analysis. Engraftment 
levels of human CD45+ cells and CD19+/CD20+ B cells in the spleen and peripheral blood was highly 
variable between individual animals, with no difference in engraftment levels between autologous, 
allogeneic or islet positive control groups (figure 5.18).  
Survival was seen in both 325 allogeneic and 286 autologous grafts (figure 5.19), however the degree 
of graft survival and the formation of typical duct-like structures was much greater in the 325 BD grafts. 
325 BD grafts showed a greater degree of survival and proliferation than any other CO line transplanted 
in vivo, while the 286 CO line showed much poorer engraftment than typical. A greater degree of 
CD45+ cell infiltration was seen into the allogeneic 325 CO grafts, however. Analysis of these samples 
is ongoing, including of the islet positive control samples, and lymphocyte counting has not yet been 
conducted to determine whether the higher numbers of leukocytes observed in the 325 allogeneic grafts 




Figure 5.18: Leukocyte engraftment in the spleen and peripheral blood of HSC-reconstituted 
humanised mice  
(a) Engraftment of live human CD45+ leukocytes as a percentage of all live CD45+ cells in the spleen 
of HSC-reconstituted humanised mice transplanted with either allogeneic COs, autologous COs or 
positive control allogeneic primary islets. (b) Engraftment of live human CD45+ leukocytes as a 
percentage of all live CD45+ cells in the peripheral blood of HSC-reconstituted humanised mice 
transplanted with either allogeneic COs, autologous COs or positive control allogeneic primary islets. 
(c) Engraftment of live human CD19+/CD20+ B cells as a percentage of all live human CD45+ 
leukocytes in the spleen of HSC-reconstituted humanised mice transplanted with either allogeneic COs, 
autologous COs or positive control allogeneic primary islets. (d) Engraftment of live human 
CD19+/CD20+ B cells as a percentage of all live human CD45+ leukocytes in the peripheral blood of 
HSC-reconstituted humanised mice transplanted with either allogeneic COs, autologous COs or positive 
control allogeneic primary islets. Engraftment percentages measured by flow cytometry. Flow 
cytometric gating strategy shown in appendix figure 5. Each data point represents an individual mouse. 







Figure 5.19: Leukocyte infiltration and graft survival in HSC-reconstituted humanised mice  
Immunofluorescent images of allogeneic (top) and autologous (bottom) CK19+ CO grafts (red) under 
the kidney capsule of HSC-reconstituted mice engrafted with HSCs from donor 286, showing 
infiltration of CD45+ leukocytes (green). Autologous COs are from line 286 and allogeneic COs are 
from line 325. Grafts shown at 2 weeks after transplantation (20 weeks after HSC-reconstitution). Scale 
bar = 100µm.  
 
5.2.3: Humanised mice as a method for comparing the immunogenicity of HLA-matched 
and HLA-mismatched cellular therapies 
 
Following these pilot experiments, I aimed to investigate the immunogenicity of HLA-matched CO 
lines compared to HLA-mismatched CO lines using the HSC-reconstituted humanised mouse model. 
As the CO lines, bone marrow and splenocyte samples are all from deceased organ donors, records of 
the HLA types were available for all donors. I used standard kidney transplantation matching criteria to 
determine the criteria for a “complete” HLA match- defined as matching on both alleles for HLA A, B 
and DR. I defined a “partial” HLA match as matching only on HLA A and B, ignoring HLA-DR and 
any other HLA class II molecules.  
I identified one CO line, 299 BD, as being a complete HLA match for one bone marrow/SpMC donor, 
donor 263 (table 5.1). This donor had 5.0 x 108 bone marrow cells and 1.0 x 109 SpMCs available at the 
time of identification - enough for one group of HSC-reconstituted humanised mice and several groups 
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of SpMC-reconstituted humanised mice. Additionally, I identified one donor, 354, as being a partial 
match (HLA A and B) for the 299 BD line. No bone marrow was available from this donor, but 8.0 x 
108 SpMCs were available for use, making it suitable for SpMC-reconstituted humanised mouse 
experiments. There were multiple available candidates for a complete HLA mismatch donor for the 299 
BD line but I initially chose donor 235 due to the high numbers of both bone marrow cells (9.0 x 108) 
and SpMCs (1.2 x 109).  
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Table 5.1: Donors identified as HLA matches/mismatches for CO line 299 
A table showing the details of donors identified to be a complete (HLA A, B and DR) HLA match, 
partial (HLA A and B) HLA match or complete HLA mismatch for the BD CO donor 299. The table 
includes: donor ID, HLA A, B and DR type and numbers of available SpMCs and bone marrow (BM) 
cells at the time of donor identification. 
 
Once I had identified suitable HLA matched and mismatched lines, I set up an HSC-reconstitution 
humanised mouse experiment to investigate the immune response to a fully HLA matched and fully 
HLA mismatched CO graft. I was not able to include an autologous group or a partially mismatched 
group in this experiment due to lack of bone marrow cells for donors 299 and 354. I irradiated ten 
female NSG mice with 2.4Gy of gamma irradiation and reconstituted eight mice each with 1.0 x 107 
CD3-depleted bone marrow cells from donor 325 (complete mismatch) and two with 1.0 x 107 CD3-
depleted bone marrow cells from donor 263 (complete HLA match). I had initially aimed to reconstitute 
up to eight animals in each donor group, however due to a technical error in the CD3-depletion process, 
the majority of the 263 bone marrow cells were lost and I was left with only enough cells to reconstitute 




Figure 5.20: Leukocyte engraftment timecourse in HSC-reconstituted humanised mice 
Timecourse of the engraftment of human CD45+ cells in the peripheral blood of HSC-reconstituted 
NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. Mice were engrafted 
with HSCs from donor 263 (green) or 235 (red). Each line represents engraftment in an individual 
animal. Engraftment monitored from 9 weeks after reconstitution to 21 weeks, one week after 
transplantation with CO or positive control grafts.  
 
I monitored the time course of leukocyte engraftment from week nine to week 21, one week after 
transplantation. Engraftment remained mostly stable after week 18 for 325-reconstituted mice, with 
engraftment in 263-reconstituted mice increasing slightly from week 18 onwards (figure 5.20). The two 
animals reconstituted with donor 263 showed slightly higher peripheral blood engraftment overall than 
the animals reconstituted with donor 235, possibly due to the noticeably higher proportion of CD3+ 
cells in the 263-reconstituted animals (figure 5.21). All animals except two (both donor 235) showed 




Figure 5.21: T cell engraftment timecourse in HSC-reconstituted humanised mice 
Engraftment of CD3+ T-cells as a proportion of all human CD45+ leukocytes in the peripheral blood 
of NSG mice engrafted with HSCs from donors 263 (green) or 235 (red) from 15 weeks post-
reconstitution to 21 weeks post-reconstitution. CD3+ T cell proportion measured by flow cytometry. 
Flow cytometric gating strategy shown in appendix figure 5. 
 
As discussed in chapter 3, I decided to use bioluminescent imaging in this humanised mouse experiment 
(and all future humanised mouse experiments, wherever possible) to aid with tracking and 
quantification of the transplanted CO or positive control grafts. During the engraftment time course, I 
transduced the 299 BD line with a suitable luciferase construct, a process outlined in chapter 3. Once I 
was confident that I had created a suitable construct and had successfully generated the 299-RFP-Luc 
CO line, the next step was to identify a suitable positive control and transduce it with the Ef1α-RFP-
Luciferase construct. I had previously used primary human islets as a positive control, however due to 
their very poor rate of survival after transplantation, even in non-humanised NSG mice, I elected to use 
a different cell type for this experiment. The three criteria for selection were: good survival in vivo for 
at least 3-4 weeks; high immunogenicity; ability to be transduced with the luciferase construct. I 
selected three potential options that met at least one of these criterion: primary endothelial cells, which 
can express high levels of HLA class I and II after IFN-γ treatment; HEK 293T (Human Embryonic 
Kidney) 293T, an immortalised cell line), which are easily transduced and likely to have good in vivo 
survival due to being an immortalised cell line; and LX2 cells, an immortalised human hepatic stellate 
cell line, which have moderate levels of HLA expression, are an immortalised cell line and are able to 




Figure 5.22: Testing of luciferase expression in three potential positive control cell types 
(a) Luciferase expression (luminescence) in LX2-RFP-Luc cells (1) compared to a wild-type control 
(2). Both wells received 7.5µl/ml (150µg) luciferin substrate. (b) Luciferase expression (luminescence) 
in HEK-293T-RFP-Luc cells receiving 15µl/ml (300µg) of luciferin (1), HEK-293T-RFP-Luc cells 
receiving 7.5µl/ml (150µg) of luciferin (2) and wild-type HEK-293T cells receiving 7.5µl/ml (150µg) 
of luciferin (3). (c) Luciferase expression (luminescence) in primary endothelial cells transduced with 
the Ef1α-luciferase-RFP construct receiving 7.5µl/ml luciferin. All images taken with automatic 
exposure.  
 
I was unable to transduce the primary endothelial cells with my luciferase construct, ruling it out of 
consideration (figure 5.22), while transduction was successful in both HEK 293T cells and LX2 cells. 
I then tested the ability of both cell types to upregulate HLA class I and II, in order to make the positive 
control graft as immunogenic as possible. I treated both cell types with increasing concentrations of 
IFN-γ (all super-physiological levels) for 72 hours and then performed flow cytometry to test the levels 
of HLA class I and II with and without IFN-γ treatment.  
 
 
Figure 5.23: Testing HLA upregulation in HEK 293T cells 
Flow cytometric analyses of HLA class I (left) and HLA class II (right) expression in HEK 293T cells. 
HLA expression in untreated HEK 293T cells (blue) compared to expression after 72 hours treatment 
with 100ng/ml (orange), 200ng/ml (light green), 400ng/ml (dark green) and 800ng/ml (purple) 




Figure 5.24: Testing HLA upregulation in LX2 cells 
Flow cytometric analyses of HLA class I (left) and HLA class II (right) expression in LX2 cells. HLA 
expression in untreated LX2 cells (blue) compared to expression after 72 hours treatment with 100ng/ml 
(orange), 200ng/ml (light green), 400ng/ml (dark green) and 800ng/ml (purple) recombinant IFN-γ and 
to an unstained control (red).  
 
HEK 293T cells were unable to upregulate HLA class II at any concentration of IFN-γ and IFN-γ 
treatment was only able to upregulate HLA class I to a very minor extent (figure 5.23). Conversely, 
LX2 cells upregulated HLA class II to a high level after IFN-γ treatment and showed a noticeable 
increase in HLA class I expression after IFN-γ treatment, from an already high baseline expression 
(figure 5.24). Based on this, I opted to use LX2-RFP-Luc cells as positive controls.  
Four 235-reconstituted mice and two 263-reconstituted mice were transplanted at week 20 with 299-
RFP-Luc COs, as were five non-humanised NSG mice. Two 235-reconstituted mice were transplanted 
at week 21 with LX2-RFP-Luc cells, and a further two mice were transplanted with 299-RFP-Luc COs. 
Four non-humanised NSG mice were transplanted with LX2-RFP-Luc cells. The two groups were 
transplanted a week apart due to the positive control cells not being ready for transplantation until week 
21. Four mice had initially been intended to receive LX2-RFP-Luc cells, however, due to technical 
reasons, two of the four initial 235-reconstituted mice transplanted with 299-RFP-Luc COs did not 
receive adequate CO cell numbers, so we decided to transplant a further two mice with COs instead of 
LX2 cells.  
I imaged each group of mice 24 hours after transplantation, and again at 7 and 14 days after 
transplantation, and at the final cull, 21 days after transplantation (figure 5.25). Similar technical issues 
led to three of the five non-humanised NSG mice receiving low cell numbers, limiting the ability to 




Figure 5.25: Bioluminescent images of CO grafts after transplantation in HLA-matched and 
mismatched humanised mice 
Bioluminescent images of 299-RFP-Luc CO grafts transplanted into non-humanised NSG mice; HLA-
matched (donor 263) HSC-reconstituted humanised mice; or HLA-mismatched (donor 235) HSC-
reconstituted humanised mice at day 1, day 7, day 14 and day 21 post-transplantation. Day 21 images 
were taken post-mortem. All images taken with automatic exposure.  
 
All groups showed a large decrease in luminescence over time, both visibly (figure 5.25) and through 
quantification of luminescence (figure 5.26), with luminescence in all groups decreasing to between 105 
and 104 photons, a level similar to background. Normalising luminescence to the values shown at day 
1 (24 hours after transplantation) to remove the variability between initial cell numbers showed a similar 
trend (figure 5.27). One animal in the 299 non-humanised group, however, did show a visible CO graft 
at D21, while no animals in any other group showed any sign of graft survival through BLI (figure 
5.25). Due to the low number of animals in each group, particularly the HLA matched group and the 




Figure 5.26: Time course of luminescence of CO and LX2 grafts after transplantation in HSC-
reconstituted humanised mice 
Luminescence measurements (107 photons) of 299-RFP-Luc and LX2-RFP-Luc grafts transplanted 
under the kidney capsule of HSC-reconstituted humanised mice or non-humanised controls. (a) 299-
RFP-Luc COs transplanted into fully HLA-mismatched humanised mice (donor 235) (n=3). (b) 299-
RFP-Luc COs transplanted into fully HLA-matched humanised mice (donor 263) (n=2). (c) 299-RFP-
Luc COs transplanted into non-humanised NSG mice (n=2). (d) LX2-RFP-Luc positive control cells 
transplanted into fully HLA-mismatched humanised mice (donor 235) (n=2). (e) LX2-RFP-Luc positive 
control cells transplanted into non-humanised NSG mice (n=3). BLI performed at 24 hours, 7 days, 14 
days and 21 days after transplantation. Imaging on D21 was performed post-mortem. Exposure time for 
all images= 7 seconds. Each data point represents an individual animal. Animals with BLI 
measurements below the threshold of visible detection on D1 were excluded from analysis. No 






Figure 5.27: Time course of luminescence of CO and LX2 grafts after transplantation in HSC-
reconstituted humanised mice normalised to D1 
Luminescence measurements (107 photons) of 299-RFP-Luc and LX2-RFP-Luc grafts transplanted 
under the kidney capsule of HSC-reconstituted humanised mice or non-humanised controls normalised 
to luminescence at D1. (a) 299-RFP-Luc COs transplanted into fully HLA-mismatched humanised mice 
(donor 235) (n=3). (b) 299-RFP-Luc COs transplanted into fully HLA-matched humanised mice (donor 
263) (n=2). (c) 299-RFP-Luc COs transplanted into non-humanised NSG mice (n=2). (d) LX2-RFP-
Luc positive control cells transplanted into fully HLA-mismatched humanised mice (donor 235) (n=2). 
(e) LX2-RFP-Luc positive control cells transplanted into non-humanised NSG mice (n=3). BLI 
performed at 24 hours, 7 days, 14 days and 21 days after transplantation. Imaging on D21 was 
performed post-mortem. Exposure time for all images= 7 seconds. Each data point represents an 
individual animal.  
 
Hisological analysis of the kidney samples from this experiment is ongoing, however preliminary 
immunofluorescence results show a greater degree of human leukocyte (CD45+) infiltration into the 
HLA matched CO graft area compared to the HLA mismatched CO graft (figure 5.28). As only one 
HLA matched and one HLA mismatched graft have currently been analysed, quantification of the 
leukocyte infiltration and comparison between the two groups is not yet possible. Leukocyte infiltration 
is seen in both the matched and micmatched grafts, however, with many CD45+ cells in direct contact 
with or very close to the CO graft, with no CD45+ leukocytes observed in the surrounding kidney 
parenchyma. Additionally, preliminary immunofluorescence assessment of the leukocyte subtypes 
within the HLA matched graft demonstrates a high proportion of CD4+ lymphocytes among the 
infiltrating leukocytes (figure 5.29). Further histological analysis is ongoing to identify other leukocyte 
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subtypes and to quantify and compare the proportion of different leukocyte subtypes within HLA 
matched and mismatched grafts.  
 
 
Figure 5.28: Leukocyte infiltration and graft survival in HLA matched compared to HLA 
mismatched HSC-reconstituted humanised mice  
Immunofluorescent images of allogeneic CK19+ CO grafts (red) under the kidney capsule of HSC-
reconstituted mice engrafted with HSCs from donor 263 (top, HLA matched) and donor 235 (bottom, 
HLA mismatched) showing infiltration of CD45+ leukocytes (green). All CO grafts were from CO line 
299 RFP (passage 9). Grafts shown at 3 weeks after transplantation (20 weeks after HSC-




Figure 5.29: Infilatration of CD45+ and CD45+/CD4+ leukocytes into an HLA matched HSC-
reconstituted graft 
Immunofluorescent images of allogeneic CK19+ CO grafts (unstained cystic structures) under the 
kidney capsule of an HLA matched HSC-reconstituted mice engrafted with HSCs from donor 263 
showing infiltration of CD45+ leukocytes (green) and CD4+ T cells (red). Graft shown at 3 weeks after 






5.2.4: Investigation of the immunogenicity of HLA matched and mismatched CO grafts 
using the SpMC-reconstituted humanised mouse model 
Investigation of the immunogenicity of CO grafts with and without HLA matching is ongoing, and the 
next step is to use the SpMC-reconstituted humanised model to address this question. As shown in table 
5.1, high numbers of SpMCs are available for not only complete HLA-matched and complete HLA-
mismatched donors but also for the autologous 299 donor and a partial HLA-match donor, allowing a 
more extensive future investigation into the role of HLA matching on CO immunogenicity (figure 5.30). 
 
 
Figure 5.30: Schematic representation of the planned SpMC-reconstituted humanised mouse 
experiment to investigate the role of HLA matching in CO immunogenicity 
2.4Gy-irradiated NSG mice will be reconstituted with 1.0 x 107 SpMCs from one of the four key donors 
(autologous, fully HLA-matched, fully HLA-mismatched and partially HLA-matched). Each group will 
contain a minimum of four animals to allow for statistical analysis. All mice will be transplanted under 
the left kidney capsule with 1.0 x 106 299-RFP-Luc COs. In addition, at least four non-humanised NSG 
mice will be transplanted under the left kidney capsule with 1.0 x 106 299-RFP-Luc COs. LXs-RFP-
Luc will be transplanted under the right kidney capsule as a positive control to test humanisation 
efficacy.  
 
As shown in previous SpMC-reconstituted humanised mouse experiments, engraftment of SpMCs can 
be highly variable across donors, so in order to ensure I could generate adequately humanised mice 
from all key SpMC donors, I first tested the engraftment of the four donors identified in table 5.1 (299, 
263, 235 and 354). In order to improve the reliability of engraftment, I first irradiated the NSG mice 
and then reconstituted two mice with SpMCs from each donor (eight mice in total). The purpose of this 
experiment was only to test the engraftment of each SpMC donor, and so no CO grafts (or grafts of any 
other cell type) were transplanted into these animals at any point throughout the experiment. The 
engraftment of each donor was monitored weekly through tail bleeds and flow cytometry (figure 5.31). 
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Donor 354 and 263 engrafted rapidly, and one animal from each group had to be culled before the 
planned experimental endpoint of nine weeks, due to very high (>60%) peripheral blood engraftment. 
The second animal reconstituted with donor 263 showed a decrease in engraftment after five weeks, 
however this is unlikely to affect any humanised mouse experiments as the experimental time course 
after CO transplantation is unlikely to last longer than four weeks. Donor 299 showed only modest 
engraftment in one animal, with a much slower rate of engraftment than donors 354 or 263, however 
peripheral blood engraftment at the end of the experiment was >5%, a sufficient level of humanisation. 
 
 
Figure 5.31: Testing reconstitution capacity of SpMCs from key donors 
Timecourse of the engraftment of live human CD45+ cells in the peripheral blood of SpMC-
reconstituted NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. Each 
line represents an individual animal, reconstituted with 1.0 x 107 SpMCs from one of four key SpMC 
donors. Donor 263 (green) - complete HLA match for the 299 BD CO line. Donor 354 (orange) – partial 
HLA-mismatch (HLA A and B) for the 299 BD CO line. Donor 235 (pink) – complete HLA-mismatch 
for the 299 BD CO line. 299 (blue) – autologous SpMCs for the 299 BD CO line. N = 2 biological 
replicate for each donor.  
 
Donor 235, the complete HLA-mismatch for 299 BD, showed no engraftment in either animal. As 
discussed above, however, there were multiple options for complete HLA-mismatch donors available, 
many of which had high numbers of SpMCs. I selected three of these donors with the highest numbers 
of SpMCs and tested their engraftment capacity in NSG mice, using the same method as outlined above. 
All donors showed rapid engraftment, in particular donor 283 (figure 5.32). Donor 318 showed the 
steadiest rate of engraftment, however this was not consistent between both animals in the group, unlike 
the animals engrafted with donors 283 and 322. As with donor 263, engraftment levels of donors 283 
and 322 dropped rapidly after 16 days. Due to logistical reasons, these animals were all culled at 3.5 
weeks post-reconstitution, so further investigation is required to determine whether the loss of 
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engraftment seen in these donors would continue or remain stable at approximately 5-10%, as seen in 
figure 5.32. However, these two SpMC-reconstitution time courses demonstrate that donors 263, 254 
and 299 are suitable for SpMC-reconstituted humanised mouse experiments and that multiple promising 
options are available for a fully HLA-mismatched SpMC donor. 
 
Figure 5.32: Testing reconstitution capacity of SpMCs from HLA-mismatched donors 
Timecourse of the engraftment of live human CD45+ cells in the peripheral blood of SpMC-
reconstituted NSG mice as a proportion of all live CD45+ cells, as measured by flow cytometry. Each 
line represents an individual animal, reconstituted with 1.0 x 107 SpMCs from one of three SpMC 
donors identified as being complete HLA-mismatches for the 299 BD CO line. N = 2 biological replicate 


















Assessment of the SpMC-reconstituted humanised mouse model 
The early SpMC-reconstituted humanised mouse experiments suggested that I could effectively 
reconstitute NSG mice with SpMCs and produce a humanised mouse model capable of a strong immune 
response against allogeneic CO grafts, as evidenced by the high level of leukocyte infiltration around 
the CO graft compared to very minimal infiltration in the surrounding murine tissue. I adapted the 
SpMC-reconstitution method from a similar model of PBMC-reconstitution used by others218 – our 
group had previously tried to generate SpMC and PBMC-reconstituted humanised mice through IV 
injection of 1.0 x 106 cells but had been unsuccessful. I demonstrated that reconstitution through IP 
injection of a higher cell number (1.0 x 107) produced a high level of engraftment. As this IP injection 
method was demonstrated to be successful, further attempts to engraft via IV injection were 
discontinued. The engraftment in the peripheral blood was largely of CD4+ and CD8+ T cells, which 
is consistent with established reports of the Hu-PBL model279 . However, I did also observe some 
engraftment of human CD19+ B cells in the mouse spleen. 
I observed both a high level of human CD45+ cell infiltration into the CO graft area and a noticeable 
change in the graft structure compared to non-humanised controls. The CO grafts lost the typical duct-
like structures and became highly disordered, including a thickening of individual cells and loss of the 
cuboidal, monolayer structure. This was also seen in the CO grafts transplanted into immunocompetent 
C57BL/6 mice (figures 4.6 and 4.7), suggesting that this is a common consequence of a strong 
xenogenic or alloimmune response, and could be a result of the pro-inflammatory environment seen 
during a strong immune response130. The very dense infiltration of human leukocytes into the graft area, 
combined with the high levels of human T cells in the peripheral blood and the enlarged spleens 
(appendix figure 6) suggests that the response to the CO graft may have been at least partially due to 
GVHD292. The development of GVHD is a well-known limitation of the Hu-PBL model279,293 and can 
complicate interpretation of data relating to rejection of the CO graft observed in this experiment. 
However, no human CD45+ lymphocyte infiltration was observed in the right kidney, which was not 
transplanted, suggesting that the infiltration and rejection of the CO graft was at least partially antigen-
specific and not just a systemic GVHD response.  
Another possibility is that the inflammation and injury caused by the CO transplantation procedure 
could have led the human leukocytes to home to the CO graft, making the infiltration a response to 
inflammation and damage generally, rather than a specific alloimmune response. However, this is 
unlikely as the transplantation was performed ten weeks previous to the SpMC reconstitution, at which 
point the impact of the transplantation injury would have disappeared. The design of later SpMC-
reconstituted humanised mouse experiments was altered such that the SpMC reconstitution occurred 
before CO transplantation, in order to ensure that the CO grafts were transplanted into a model already 
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capable of mounting an immune response, and so this initial inflammation (which would also occur in 
the case of CO transplantation into a human patient) was taken into account. This was done in order to 
ensure that the immune response seen in these experiments was as physiologically accurate as possible, 
however it did reintroduce the possibility that the immune response seen could be simply a result of 
transplant-related inflammation and not a true alloimmune response. In order to account for this, 
Matrigel-only negative controls were included in SpMC-reconstituted humanised mouse experiments 
wherever possible. Assessment of these Matrigel-only control grafts is ongoing and will provide further 
clarity on this aspect of the immune response, as they will provide a site of similar tissue damage and 
inflammation without the possibility of an antigen-specific allograft response.  
My initial SpMC-reconstituted experiment was a preliminary test to assess the ability to use the SpMC-
reconstituted humanised mouse model and as such suffers from several major limitations. The main 
limitation is the lack of adequate controls; while non-humanised controls were used, there was no 
positive or negative controls to determine the extent of the model to reject allogeneic grafts, nor was 
there an autologous control to confirm that the infiltration seen was a result of a genuine and specific 
alloimmune response. Additionally, the low numbers of animals used in each group makes quantitative 
comparison of the humanised and non-humanised groups challenging. A further limitation was the 
inability to consistently compare the graft size at the point of transplantation to the graft at the end of 
the experiment. While cell death and/or cell proliferation can be assessed in grafts using TUNEL and 
Ki67 staining respectively (this work is in progress), it was not possible to quantify the level of graft 
loss, either within individual grafts or between grafts. Therefore, while the lymphocyte infiltration and 
graft deformity point strongly to immune rejection, I was unable to adequately assess the proportion of 
graft loss due to the immune response. This limitation is currently being addressed through the use of 
luciferase-expressing CO lines and BLI  in humanised mice (discussed further below).  
My later SpMC-reconstituted humanised mouse experiments aimed to address several of the limitations 
outlined above, through the use of a “crossover” experimental design, where two SpMC donors and 
their corresponding CO lines were used, with both CO lines receiving autologous and allogeneic 
reconstitution. The aim of this experimental design was to ensure that differences in both donor SpMC 
engraftment capacity and CO line proliferation were controlled for in the assessment of 
immunogenicity. I selected two CO lines that had previously been shown to survive in vivo. However, 
there was no assessment of the capacity for SpMC engraftment of either donor before the start of the 
experiment, and the SpMCs from donor 286 did not show any engraftment over the 20-day time course 
of the experiment. This, coupled with the unexpected lack of survival of the 286 CO line in vivo in 
either humanised or non-humanised animals, limit interpretation of the data as as it rendered the entire 
allogeneic arm of the experiment ineffective. The 325 CO graft was able to survive in vivo but there 
was no 286 SpMC engraftment to produce an immune response, while there was effective 325 SpMC 
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engraftment in 325-reconstituted mice but no survival of the 286 CO graft, for reasons unrelated to any 
alloimmune response.  
Human CD45+ infiltration was observed in the 325 autologous CO grafts, primarily clustering within 
the lumen of the duct-like structures (figure 5.10). This suggests that the immune response in SpMC-
reconstituted humanised mice, while not simply a result of systemic GVHD, is also not a specific 
alloimmune response, as leukocytes are infiltrating autologous grafts. This could be due to the 
inflammatory environment as a result of the CO transplantation procedure, which involves damage to 
the kidney parenchyma through the use of Hamilton needles. Additionally, this SpMC-reconstituted 
humanised mouse experiment was performed by first reconstituting the mice with SpMCs and then 
transplanting COs once the immune engraftment was underway, meaning that human leukocytes would 
be present at the time of transplantation injury. However, another possibility is that these infiltrating 
leukocytes are Tregs, which are known to home to areas of inflammation and to help to maintain graft 
tolerance294. The lack of an adequate allogeneic group in this experiment prevented the comparison of 
the graft infiltration in autologous compared to allogeneic grafts. Further assessment of the graft area is 
required, including TUNEL staining to detect CO cell apoptosis and immunofluorescence staining to 
determine the subtype of the infiltrating leukocytes.  In addition, BLI in future SpMC-reconstituted 
humanised mice experiments will help to clarify the role of infiltrating leukocytes in autologous grafts 
as it will be able to determine if autologous graft loss is occurring and, if so, how the rate of graft loss 
compares to both non-humanised and allogeneic grafts. A further adjustment to the current SpMC-
reconstituted humanised model that is planned for future experiments is the use of NSG-
(KbDb)null(IA)null  mice, which do not express MHC class I or II on any cells, preventing the development 
of GVHD.  
 
Assessment of the HSC-reconstituted humanised mouse model 
My first HSC-reconstituted experiment demonstrated reasonable engraftment of HSCs from donors 256 
and 261, however, as with the SpMC-reconstituted experiment described above, the 261 CO line did 
not survive in any conditions, including non-humanised NSG mice, preventing adequate analysis of any 
261 CO grafts. Combined with the initial low number of 261 HSC-reconstituted mice at the start of the 
experiment and the loss of one of the 261 HSC-reconstituted mice engrafted with allogeneic 256 COs 
due to health concerns, the ability of this experiment to quantitatively assess the allogeneic immune 
response was significantly limited. Additionally, while levels of human CD45+ engraftment were 
roughly equivalent in the peripheral blood between 256-reconstituted and 261-reconstituted animals, 
the splenic engraftment of 261-reconstituted mice was much lower than that of 256-reconstituted mice, 
in all but one animal (figure 5.13).  
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There was no noticeable difference in the size of the allogeneic 256 CO grafts compared to either the 
autologous or non-humanised grafts (figure 5.15), nor was there any structural deformity observed in 
the allogeneic graft, as was seen in both SpMC-reconstituted and xenogenic CO grafts. There was a 
significantly greater number of infiltrating leukocytes observed in the allogeneic 256 graft compared to 
the autologous grafts (figure 5.16), and this difference persisted after normalisation to the overall 
systemic humanisation of each experimental animal (as measured by the percentage of human CD45+ 
cells in the peripheral blood). Indeed, the difference between allogeneic and autologous grafts became 
more pronounced after normalisation, as the allogeneic graft originated from a 261-reconstituted animal 
which had very low levels of peripheral blood humanisation and yet high levels of graft infiltration, 
while the autologous grafts originated from 256-reconstituted animals, which had much higher levels 
of peripheral blood humanisation but low levels of graft infiltration despite this fact. The limitations of 
the experimental groups outlined above, however, means that this conclusion required validation from 
further experiments.  
The ambiguity of the immune response against allogeneic and autologous grafts was replicated in the 
second HSC-reconstituted humanised mouse experiment. In this experiment, I reconstituted NSG mice 
with only one HSC donor in order to simplify the experiment and to allow for greater numbers of 
animals in each group. I also aimed to include a positive control group using primary islets, which were 
chosen due to their successful use as positive controls by other groups in humanised mouse 
experiments218. While there was a noticeably greater level of human CD45+ cell infiltration into the 
allogeneic 325 CO grafts, there was no evidence of graft loss or damage in the allogeneic grafts. The 
325 allogeneic graft showed evidence of being highly proliferative and healthy, forming large, regular, 
duct-like structures. The 325 allogeneic grafts were larger than any CO graft observed previously or 
since, from any CO line, including the initial line 200 CO non-humanised grafts that had remained in 
vivo for ten weeks (figure 5.5) - eight weeks longer than the 325 CO grafts. In contrast, while the 
autologous 286 CO grafts showed lower levels of infiltrating leukocytes compared to the allogeneic 
grafts, the grafts themselves were noticeably less robust. While the 286 CO grafts did survive in vivo, 
they were much smaller in size than the 325 grafts and showed a much less ordered structure. Due to 
the low numbers of infiltrating leukocytes, this was unlikely to be due to an autoimmune response but 
instead due to the inherently poor in vivo survival capability of the 286 CO line. This assessment is 
supported by the fact that the 286 line was entirely unable to survive in the later 235/286 SpMC-
reconstituted humanised mouse experiment (figure 5.10), even in non-humanised controls where there 
was no possibility of immune rejection.  
In general, the immune response was notably less in all HSC-reconstituted humanised mice than in 
SpMC-reconstituted humanised mice, both in terms of the levels of peripheral blood engraftment, the 
extent of human lymphocyte infiltration into the graft area and any effect on graft morphology and 
survival. This is likely partially due to the lack of a GVHD response in the HSC-reconstituted model, 
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however, there are also multiple limitations of the HSC-reconstituted humanised model itself that likely 
contributed to the sub-optimal immune response observed in this experiment. These limitations include 
the lack of mature T cells due to improper thymic education, the inability of B cells to undergo class 
switching and the subsequent lack of IgG, and the lack of fully developed lymph nodes and splenic 
germinal centres in immunodeficient mouse strains135 
The humanised mouse models I used utilised young adult (5-6 weeks) NSG mice rather than neonates 
as the use of neonates was found to result in a high rate of accidental death within our group and so was 
abandoned. This has led to a much greater rate of survival for the animals in the experiments, however 
the engraftment of older mice may not be as effective as with neonates280,295. Equally, while HSCs from 
cord blood donors can provide better engraftment296, due to the experimental requirement for autologous 
controls wherever possible, I used HSCs from adult donors. This enabled me to better experimental 
design, however it does mean the immune engraftment may be less effective. Our group previously 
attempted to improve efficacy of our HSC-reconstituted model using HLA II DR4 transgenic mice but 
this was shown to be ineffective and showed no improvement in humanisation, either overall or of any 
specific cell type (personal communication). 
 
The impact of HLA matching on the immunogenicity of CO allografts 
I aimed to investigate whether HLA matching could reduce the immunogenicity of CO grafts, using 
humanised mouse models. Reports have indicated that iPSC-derived cellular therapies show reduced 
immunogenicity and graft rejection when transplanted into non-human primates168,170, although this 
finding remains controversial286, however this is the first time, to our knowledge that the question of 
HLA matching has been addressed with primary-derived cellular therapies in a humanised mouse 
model. While the importance of HLA matching in liver transplantation remains unclear, with the 
majority of reports suggesting that it has no impact on patient or graft survival outcomes154,155, the 
question of whether or not cholangiocyte cellular therapies are improved by HLA matching is worth 
investigating as it is likely that a purified CO graft or bioengineered biliary tissue would elicit a different 
immune response than a solid organ liver graft. In solid organ transplantation, the liver is the organ 
most likely to achieve operational tolerance288 – the absence of graft rejection after an allogeneic 
transplant without the requirement for immunosuppressive treatment297. While the exact causes of this 
tolerising effect is unclear, it is unlikely to be seen in a purified cholangiocyte cellular therapy allograft 
or bioengineered extrahepatic bile duct as liver tolerance is likely the result of factors specific to the 
anatomy and physiology of the liver as a whole, such as the presence of tolerising APCs such as Kupffer 
cells, sinusoidal endothelial cells and dendritic cells130 and the ability of hepatocytes to express 
tolerance-inducing ligands such as Programmed Death 1 ligand (PD-L1) and Fas ligand (FasL), which 
induce apoptosis in autoreactive and alloreactive T cells298. These factors would not be present in a CO-
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derived cellular therapy, increasing the likelihood that other methods to reduce immunogenicity, such 
as HLA-matching, may be required. 
In accordance with the current practice for kidney transplantation299,300, I defined a complete HLA 
match as matching on both alleles for HLA A, B and DR. While it is typically thought that HLA 
matching for cellular therapies would likely involve the use of homozygous HLA donors163, due to 
generating our CO lines from deceased organ donors, I did not have ready access to such homozygous 
donors. Equally, using gene editing techniques to generate homozygous HLA CO lines, as has been 
reported for other cellular therapies171, was beyond the scope of this project. I instead relied on 
identifying a complete HLA match within our banks of CO lines and SpMC/HSC donors, which I was 
able to do by virtue of having generated over sixty CO lines and banked immune cells from over 300 
donors (immune cells were banked primarily by the Cambridge Biorepository for Translational 
Medicine, with assistance from myself and other members of the Saeb-Parsy group).  
Assessment of the role of HLA matching in CO immunogenicity is still ongoing and will require further 
in vitro and in vivo experiments. I conducted a first set of experiments by an HSC-reconstituted 
humanised mouse model. As I had only identified one fully HLA matched CO line and HSC donor pair 
(299 and 263 respectively), I was unable to perform a crossover experiment of the kind described in 
figures 5.12 - 5.16 and so the experimental set up was vulnerable to potential quality issues with the 
263 HSCs and 299 CO lines in terms of humanisation and in vivo graft survival. Additionally, while 
HSC engraftment can vary between donors, it is not possible to test the quality of an HSC donor before 
the start of an experiment due to the long timecourse of humanisation and the typically low numbers of 
available HSCs for each donor. I elected to use HSCs from donor 235 as a fully mismatched donor due 
to the relatively high number of available HSCs (table 5.1).  
While both donors engrafted well in the majority of animals (figure 5.20) the 263 HSC-reconstituted 
mice showed higher levels of peripheral blood engraftment than the 235 HSC-reconstituted mice, likely 
in part due to the higher, and steadily increasing, proportion of CD3+ T cells in the peripheral blood of 
the 263 HSC-reconstituted mice (figure 5.21), which could be an indicator of the beginning of a GVHD 
response. This discrepancy between the engraftment of the HLA-matched and HLA-mismatched donors 
is problematic, as it represents a potential confounding factor in the comparison of the immunogenicity 
of both groups. However, the analysis of the engraftment in the peripheral blood, spleen and bone 
marrow at the experimental endpoint is still ongoing and it remains to be seen if this difference between 
donors will be consistent across all immune compartments. While this experiment cannot be repeated 
due both to logistical considerations and the lack of any further 263 HSCs, one potential way in which 
the difference between 263 and 235 engraftment could be controlled for would be to repeat the fully 




A major difference to the design of this experiment compared to previous HSC-reconstituted and 
SpMC-reconstituted humanised mouse experiments was the use of BLI to assess the degree of graft 
survival across different groups. I had previously assessed immunogenicity through lymphocyte 
infiltration into the CO graft area alone. While graft infiltration is an important aspect of an immune 
response and an indicator of rejection, it is not able to provide information on the extent of graft loss or 
growth in vivo, which is essential for a complete understanding of the immunogenicity of a cellular 
therapy. Additionally, the method of assessing lymphocytic infiltration into the graft required the 
cryosectioning of the entire graft area, the immunostaining of multiple randomly-selected sections from 
different areas of the graft and the manual counting of all leukocytes in the graft area of the chosen 
sections using the Image J programme. This method is susceptible to bias in the selection and counting 
process, and, importantly, is highly time consuming, making the completion of graft infiltration 
assessment for a humanised mouse experiment very challenging within the timeframe of this project. 
To address these limitations, I incorporated BLI of CO grafts in vivo to compare the survival of grafts 
between groups in both a qualitative and quantitative manner, while supporting these data with a 
qualitative assessment of lymphocyte infiltration into the CO grafts.  
Despite the advantages of BLI outlined above, there are several limitations to the technique, particularly 
as I was only able to establish a BLI system and reliable luciferase CO lines immediately before the 
point at which those lines had to be transplanted into HSC-reconstituted humanised mice. The 
limitations of the 299-RFP-Luc CO line specifically, including uncertainty as to the stability of the 
Ef1α-RFP-Luciferase construct and the efficacy of our line purification, are detailed in the discussion 
of chapter 3. In addition, while I have begun assessment of the sensitivity of BLI in terms of detecting 
low cell numbers under the kidney capsule (figure 3.15), this work is still ongoing and the ability of the 
system to detect small changes in graft size and to detect grafts of small overall size is uncertain. 
Furthermore, throughout this HSC-reconstituted humanised mouse experiment, I was limited in the 
number of occasions animals could be imaged (up to three times in live mice), which prevented me 
from extending the time course of the experiment or from performing BLI more than once a week. I am 
currently in the process of amending this aspect of our project licence to ensure that this limitation will 
not affect any future humanised mouse experiments.  
During the time course of our experiment I observed a large decrease in the CO graft size both 
qualitatively (figure 5.25) and quantitatively (figures 5.26 and 5.27) in all animals across all groups, 
regardless of humanisation status or HLA matching. I have observed histological evidence of a similar 
loss of initial graft mass in previous lines transplanted in vivo, including in lines that survived well 
overall. This suggests that this early loss of cells after transplantation is an unavoidable aspect of 
transplantation for all CO grafts, regardless of immune response, likely due to the stress caused to the 
cells during the preparation for transplantation and the transplantation process itself. In experiments in 
which graft survival is assessed immediately after transplantation and for a short duration (3 weeks), 
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this initial loss of cells across all groups significantly limits the ability to assess the impact of the 
immune response on graft size. This limitation is likely to be most significant in the HSC-reconstituted 
humanised mouse model, however, which shows a less substantial immune response than the SpMC-
reconstituted humanised mouse model, and so any effects of immune rejection are likely to be more 
subtle. Due to the nature of the HSC-reconstituted humanised mouse model, which provides a window 
of between 8-4 weeks of optimal engraftment (16-24 weeks after reconstitution) for transplantation 
experiments, it is not possible to first transplant the CO grafts and wait until after the initial graft loss 
has passed and the graft begins to proliferate again to the point of BLI detection before humanising the 
mice. However this strategy could potentially be used in SpMC-reconstituted humanised mice, as 
demonstrated in the initial SpMC-reconstituted humanised mouse experiments.  
At the final imaging time point, I observed that CO grafts were not detectable in any animals of any of 
the groups with the exception of one non-humanised NSG mouse transplanted with 299-RFP-Luc COs 
(figure 5.25). There was no difference in the extent or rate of graft loss in the HLA-matched and HLA-
mismatched groups. While it is promising that one animal in the non-humanised group retained a visible 
CO graft, it cannot be decisively concluded that this was due to the lack of humanisation, or that the 
loss of the grafts in other groups was due to immune rejection. This is due to the fact that only one 
animal in the non-humanised group retained a visible graft and that animal had initially received a 
higher number of cells than most other animals (as determined by quantification of luminescence at the 
D1 time point). Additionally, it is not certain that grafts have been truly lost in all other animals without 
histological assessment, which is still in progress.  
The preliminary data shown by BLI suggest that there is no difference between the immune response 
to HLA-matched and HLA-mismatched CO grafts. This is in agreement with a recent report286 showing 
that both HLA-matched and HLA-mismatched iPSC-derived neurons are rejected in non-human 
primates. However, histological analysis is needed to confirm these findings. Additionally, the HLA-
matched (donor 263) humanised mice showed a noticeably higher proportion of CD3+ T cells in the 
peripheral blood compared to the HLA-mismatched (donor 235) humanised mice (figure 5.21) and a 
higher level of CD45+ cell engraftment overall (figure 5.20) and it is possible that the apparent 
equivalence of the immune response to HLA matched and mismatched grafts is largely due to the more 
robust humanisation in the HLA-matched humanised mice. 
Preliminary histological assessment of one HLA matched and one HLA mismatched graft (figure 5.28) 
demonstrate graft survival in both instances, despite the lack of visible luciferase signal in these animals 
at and after 14 days post-transplantation. This suggests either that the luciferase construct was silenced 
in vivo or that the luciferase signal fell below the level of detection due to CO cell death between D1 
and D14 post-transplantation. Silencing of the luciferase construct is unlikely as The 299 RFP CO line 
has been demonstrated to retain luciferase expression at passage 20 in vitro, 18 passages after viral 
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transduction with the Ef1α-luciferase-RFP construct (figure 3.23). It is possible, however, that the in 
vivo environment results in construct silencing despite persistent in vitro expression. 
Immunofluorescence staining for luciferase protein will be required to determine whether the construct 
has been silenced in vivo.  
The CO graft in the HLA matched kidney sections was noticeably larger than the graft in the HLA 
mismatched sections (figure 5.28), which could indicate that HLA matching promotes overall graft 
survival. However, due to a technical error, a greater number of CO cells was transplanted into the HLA 
matched animals compared to the HLA mismatched animals, and so the larger size of HLA matched 
grafts at the point of the final cull could be due either partially or entirely to the higher number of cells 
delivered at transplantation. Due to the loss of luciferase signal in both the HLA matched and 
mismatched groups at D14 post-transplantation, it is not possible to accurately determine whether or 
not the extent of graft survival at the final cull relative to the initial graft size is greater in HLA matched 
grafts compared to HLA mismatched grafts.  
Human leukocyte infiltration in and around the CO graft appears to be greater in HLA matched sections 
compared to HLA mismatched sections (figure 5.28), however this is likely at least partially due to the 
overall greater degree of humanisation, particularly the greater degree of CD3+ leukocyte engraftment, 
within the HLA matched animals (figure 5.21). Once histological analysis of all kidney grafts is 
completed, quantification of leukocyte infiltration normalised to overall human leukocyte engraftment 
at the point of the final cull will be required to accurately determine the comparable degree of leukocyte 
infiltration into HLA matched and mismatched grafts.  
Preliminary immunofluorescence staining of an HLA matched graft demonstrated a high proportion of 
CD4+ lymphocytes in the graft area (figure 5.29). Immunofluorescence staining for other lymphocyte 
subtypes is still being optimised so it is not currently possible to determine whether these CD4+ 
lymphocytes are T effector cells or T helper cells, and so not currently possible to determine whether 
this CD4+ infiltration represents an immunogenic or immunomodulatory response. Further 
immunofluorescence staining for markers such as CD8, granzyme B, FoxP3 and CD25, combined with 
TUNEL staining on CO cells for evidence of apoptosis, will be required to assess the nature of this 
immune response. Additionally, histological analysis of the HLA mismatched grafts is also required, to 
determine whether the proportions of leukocyte subtypes and apoptotic cells differ between HLA 
matched and mismatched grafts, and so to determine whether the nature of the immune response is the 
same or different between these two groups.  
I have begun preparation for further humanised mouse experiments to assess HLA matching in CO 
grafts, this time using the SpMC-reconstituted humanised mouse model. I have confirmed that SpMCs 
from all key donors are able to adequately engraft in NSG mice (figures 5.31 and 5.32), although, due 
to variation in the rate of engraftment, adjustments may need to be made to the timing of SpMC 
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reconstitution or CO transplantation to ensure that all groups are equally engrafted at the time of the 
experiment. Further preliminary experiments will be needed to address the limitations discussed above 
before this SpMC-reconstitution experiment can be conducted, including a thorough assessment of the 
capacity of the BLI system to assess graft survival under different conditions and a determination of the 
stability of our luciferase construct over time. Once these concerns have been addressed, however, it is 
hoped that the planned SpMC-reconstitution experiment, combined with the ongoing analysis of my 
recent HSC-reconstitution experiment, will provide definitive insight into the role of HLA matching on 






















CHAPTER 6: FUTURE WORK AND CONCLUSIONS 
 
6.1 Future work 
 
6.1.1 Refinement of the method for generating bioengineered biliary tissue 
I have demonstrated that COs can be used to generate bioengineered biliary tissue in the form of 
artificial bile ducts capable of rescuing a model of extrahepatic biliary injury. I further demonstrated 
that this procedure can be further refined to produce more physiologically relevant constructs with COs 
seeded in the lumen of the collagen construct. The next step for this project is to refine the seeding 
process to improve the survival rate of seeded cells and to characterise the length of time needed in 
culture before full confluence is reached. Additionally, work is ongoing by Fotios Sampaziotis and 
Teresa Brevini to develop human-sized bioengineered bile ducts. These larger constructs are being 
generated using COs seeded on either densified collagen scaffolds125 or decellularised301,302 porcine bile 
ducts and are currently being tested in vivo in large animal models to determine the efficacy of the 
construct to rescue a model of biliary injury and the survival of the graft itself. Additionally, work is 
ongoing to investigate the impact of incorporating elastin303 and other extracellular matrix components 
into our densified collagen scaffolds.  
Additionally, a future application of the murine-sized seeded bile duct constructs is to assess the 
immunogenicity of COs in a more physiologically relevant niche - while the current model involves the 
transplantation of COs as a cell suspension under the kidney capsule, many future CO-based therapies 
would involve the transplantation of a bioengineered extrahepatic bile duct and so it is important to 
investigate the immunogenicity of COs in an extrahepatic biliary niche.  
 
6.1.2 Refinement of the method for in vivo bioluminescent imaging 
In response to the challenges encountered with monitoring and assessing the survival of the CO grafts 
in vivo in both humanised and non-humanised mice, I have developed CO lines expressing luciferase 
to enable bioluminescent live imaging in vivo and the quantification of CO graft size by the 
measurement of luminescence. BLI is increasingly becoming an essential tool in humanised mouse 
studies of graft rejection173,175,221 and so fully establishing the BLI system for use in future experiments 
is an important priority. While I have successfully generated luciferase lines capable of BLI monitoring 
in vivo, and utilised these lines in a humanised mouse experiment, some unanswered questions still 
remain before this system can be fully effective. I generated the luciferase CO lines using a construct 
with an Ef1α promoter, known to produce stable expression of integrated constructs. However, I have 
not yet tested the long-term stability of the luciferase constructs in COs either in vitro or in vivo. 
Moreover, I have not yet assessed whether or not the random integration method used to deliver the 
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construct has any negative effects on the transduced COs. This will be done by a combination of in vitro 
analysis of cholangiocyte marker expression and function and in vivo comparison of the survival of 
luciferase CO lines and WT lines. It is also important to assess the sensitivity of BLI detection in vivo, 
as it is possible that any differences in CO graft survival detected in future humanised mouse 
experiments (for example, between fully and partially HLA-matched lines) may be subtle and it is 
critical to better understand the extent to which the BLI system is capable of detecting such differences.  
 
6.1.3 Continued assessment of HLA class II expression in COs under inflammatory 
conditions 
I have assessed the expression of HLA class I and II on COs under a range of different pro-inflammatory 
conditions, including exposure to super-physiological levels of IFN-γ in vitro, in vitro co-culture with 
activated leukocytes and transplantation in vivo in immunocompetent and humanised mice. While the 
effect of in vitro cytokine challenge with recombinant IFN-γ has been well-established throughout this 
dissertation, the assessment of the impact of lymphocyte co-culture and an in vivo inflammatory 
environment is preliminary and requires further investigation. I aim to confirm the findings of these 
preliminary experiments and to expand upon them, for example through assessing HLA class II 
expression in non-humanised NSG mice, quantifying HLA class II expression on CO grafts through 
flow cytometry and extending in vitro co-culture experiments with activated lymphocytes through the 
addition of further experimental conditions and controls. Additionally, while I have extensively 
assessed the impact of IFN-γ on COs, it is important to investigate the expression of HLA and other 
immunogenic markers on COs after exposure to other pro-inflammatory cytokines such as TNF-α, IL-
1 and IL-6. It would also be useful to investigate combinations of two or more pro-inflammatory 
cytokines on CO antigenicity, particularly as I have already demonstrated that COs are not capable of 
expressing HLA-DP after stimulation with purified IFN-γ but that HLA-DP can be upregulated on COs 
during a strong xenogenic immune response in vivo.  
 
6.1.4 Refinement of the SpMC humanised mouse model 
One of the major limitations of the SpMC-reconstituted humanised mouse model is the inevitable 
development of GVHD279 following successful engraftment. While this does not prevent the assessment 
of allograft rejection using this model304, it can limit the timeframe available for experiments and can 
potentially complicate the interpretation of experimental data without the use of adequate autologous 
and negative controls. To address this problem, several strains of NSG mice lacking murine MHC class 
I and II have been generated and have been shown to limit the development of GVHD in an 
SpMC/PBMC-reconstituted humanised mouse model, while still allowing for alloimmune rejection of 
human grafts209. Our group has recently acquired the NSG-(KbDb)null(IA)null strain and the engraftment 
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capacity of these mice is currently being tested by several group members. I plan to assess the capacity 
of these mice to reject allogeneic CO grafts after SpMC reconstitution and, if the results are favourable, 
continue to use this strain in all future SpMC-reconstituted humanised mouse experiments, including 
the assessment of HLA-matched and mismatched CO grafts.  
 
6.1.5 Further assessment of the role of HLA matching in CO immunogenicity 
I have presented the preliminary results of HSC-reconstituted humanised mouse experiments to 
investigate the immunogenicity of HLA-matched compared to HLA-mismatched CO grafts. The 
analysis of this experiment is still ongoing, so the first step is the completion of this work. I will assess 
the humanisation at the point of the final cull in the peripheral blood, spleen and bone marrow and 
compare the engraftment between the two groups of HSC reconstituted mice (HLA-matched and 
mismatched). I will also analyse the CO grafts through histological analysis, including assessment of 
graft morphology, lymphocyte infiltration and CO cell apoptosis or proliferation.  
I will also assess the survival of fully HLA-matched, partially HLA-matched and fully HLA-
mismatched CO grafts using the SpMC-reconstituted humanised mouse model. Solid organ transplants 
are, when applicable, typically matched on both HLA class I (A and B) and HLA class II (DR). 
However,  a purified population of one non-haematopoietic cell type (such as cholangiocytes) may not 
express HLA class II under normal circumstances: Matching for HLA class II may, therefore, not be as 
important as in solid organ transplantation, where there donor passenger HLA class II-expressing 
antigen presenting eclls are expected to be transferred to the recipient in the transplanted organ. My 
investigation into the antigenicity of COs suggests that they may express HLA class II after 
transplantation into immunocompetent recipients, however the impact of this has not yet been fully 
assessed in a humanised mouse experiment.  
An important method of investigating immunogenicity is the use of lymphocyte co-culture assays, 
where the cells of interest are exposed to allogeneic lymphocytes and the degree of lymphocyte 
activation and cytotoxic cell killing are monitored. I plan to use this method to complement the in vivo 
humanised mouse studies, to investigate the ability of COs to activate allogeneic T cells. I will 
investigate the ability of COs to activate T cells through the direct alloimmune pathway by co-culture 
of T cells and COs alone, and through the indirect pathway by co-culture of COs with T cells and 
professional antigen presenting cells. I will compare the activation of T cells by HLA-matched, partially 
matched and mismatched CO lines. Additionally, I will investigate the ability of cytotoxic CD8+ T cells 




6.1.6 Amelioration of CO immunogenicity through gene editing 
In this dissertation, I have focused on assessing the immunogenicity of WT COs, or on the use of HLA 
matching to ameliorate immunogenicity. However, this is only one possible mechanism for producing 
cellular therapies with reduced immunogenicity. Another promising option is the development of 
“universal” cellular therapies through genetic engineering by removing or silencing HLA expression, 
particularly HLA class I expression, on allogeneic cells283,305. While the complete knock-out of HLA 
class I can lead to graft detection and cytotoxic killing by NK cells, human ESCs have recently been 
edited using CRISPR technology to lack all expression of HLA-A, B and C while overexpressing HLA-
E175. This strategy enabled the cells to evade immune detection by cytotoxic T cells, anti-HLA 
antibodies and NK cells. I aim to generate similar “universal” COs in collaboration with the Ghevaert 
group, using a CRISPR/Cas nickase system306. The Ghevaert group have already generated HLA class 
I KO iPSCs from six iPSC lines using this method. These iPSC lines can be successfully differentiated 
into multiple cell types and the differentiated cells can survive in vivo. Furthermore, these cells retain 
HLA class I KO status at all times, including after stimulation with IFN-γ. I will initially generate HLA 
class I KO COs without HLA-E overexpression, and assess their antigenicity and immunogenicity both 
in vitro through lymphocyte co-culture and cytokine challenge and in vivo through the use of HSC-
reconstituted and SpMC-reconstituted humanised mice. I will additionally assess the impact of NK cell 
cytotoxicity on HLA I KO COs using in vitro co-culture assays and humanised mice. If these HLA I 
KO COs are found to be vulnerable to NK cell cytotoxic killing then I will additionally generate HLA 
I/HLA E overexpression COs and assess their ability to evade detection by both cytotoxic T cells and 















The key outputs of my experimental work are summarised below: 
• Refining the existing method for deriving and culturing COs by aiding in the development of a 
protocol for deriving COs from intrahepatic bile ducts 
• Refining the existing method for the generation of bioengineered biliary tissue by aiding in the 
development of a protocol for seeding COs on the luminal surface of densified collagen tubular 
scaffolds 
• Demonstrating and quantifying the ability of COs to upregulate HLA class II molecules upon 
exposure to a range of in vivo and in vitro pro-inflammatory environments 
• Comparing the expression of HLA molecules on primary cholangiocytes and COs across 
multiple donors 
• Generating a bank of over 60 CO lines from over 40 unique, HLA-matched donors and 
identifying HLA-matched immune cell donors 
• Generating luciferase-expressing COs and demonstrating their utility in monitoring CO grafts 
in vivo, including in humanised mouse models. The use of BLI in live mice also allows for a 
reduction in the total number of animals required for timecourse experiments, in keeping with 
the principles of the 3Rs (Replacement, Reduction and Refinement) of humane animal research.  
• Demonstrating that COs can induce an immune response in an allogeneic SpMC-reconstituted 
humanised mouse model 
• Comparing the immune response to allogeneic and autologous COs in two complementary 
humanised mouse models 
• Generating preliminary results of the comparison of the immunogenicity of HLA-matched and 
HLA-mismatched CO grafts 
In conclusion, the results and methods presented here have provided new tools for the development of 
cholangiocyte cellular therapies and the assessment of their immunogenicity, as well as advancing our 
knowledge in the fields of both the transplant of cellular therapies and humanised mouse models. These 
results have laid the groundwork for exciting future experiments, both currently ongoing and in the 






CHAPTER 7. APPENDIX 
 
 
Appendix Figure 1: Gating strategy for flow cytometric analyses of cholangiocytes 
 
Representative flow cytometry plots showing gating strategy for CK7+/CK19+ flow cytometric 
analyses, gating on: 1: exclusion of debris; 2: exclusion of doublets; 3: secondary-only control to 




Appendix Figure 2: Lack of survival of CO line 261 BD 
Immunofluorescence image showing a lack of survival of the 261 BD line 4 weeks after transplantation. 
CK19 (red) and CK7 (green) show background staining but no specific staining of surviving cells. Scale 







Appendix Figure 3: Expression of immunogenic markers in primary cholangiocytes and COs 
after cytokine challenge 
RT-qPCR analyses showing expression of immunogenic markers in primary cholangiocytes, control 
(untreated) COs, IFN-γ treated COs, IL-6 treated COs and splenocytes as a positive control. Values 
relative to the housekeeping gene HMBS. IFN-γ and IL-6 treatment for 72 hours at 100 ng/ml.  
 
 
Appendix Figure 4: Gating strategy for CO and primary cholangiocytes HLA expression 
Representative flow cytometry plots showing gating strategy for flow cytometric analyses of HLA 




Appendix Figure 5: Gating strategy for flow cytometric analyses of lymphocyte populations in 
humanised mice from peripheral blood, bone marrow and spleen 
Representative flow cytometry plots showing gating strategy for flow cytometric analyses of leukocytes 
from humanised mice, gating on: (1) exclusion of debris; (2) exclusion of doublets; (3) live cells. Panel 




Appendix Figure 6: Enlarged spleen of a SpMC-reconstituted humanised mouse 
Image of the spleen of a non-humanised NSG mouse (left) compared to an SpMC-reconstituted 
humanised mouse (right) after 3.5 weeks of engraftment with human SpMCs (peripheral blood 






Appendix Table 1: List of all media used in cell cuture 
 
 
Media Ingredients Company Amount/Dilution 
LX2 media High glucose DMEM,  
GlutaMAX™ 
Supplement 
Life Technologies (10566-016) 490 ml 
Fetal Bovine Serum 
(FBS) 
GE Life Sciences 
(SH30070.03) 
50 ml 
Pen/Strep Life Technologies (15140122) 5 ml 
MEF media Advanced DMEM F12 Thermo Fisher Scientific 
(12634010) 
450 ml 
Fetal Bovine Serum 
(FBS) 
GE Life Sciences 
(SH30070.03) 
50 ml 
Pen/Strep Life Technologies (15140122) 5 ml 
Β-mercaptoethanol Sigma Aldrich (M6250-10ML) 3.5 µl 
Complete RPMI RPMI 1640 Medium, 
GlutaMAX™ 
Supplement 
Life Technologies (61870-010) 500 ml 
Fetal Bovine Serum 
(FCS) 
GE Life Sciences 
(SH30070.03) 
50 ml 
Pen/Strep Life Technologies (15140122) 5 ml 
William’s E  William’s E Gibco, Life Technologies 443 ml 
Nicotinamide Sigma Aldrich 10mM (12.5 ml) 
Sodium Bicarbonate Sigma Aldrich 17mM (8.5 ml) 
Sodium Pyruvate Invitrogen 6.3mM (3.15 ml) 
Glucose Sigma Aldrich 14mM (7 ml) 
HEPES Invitrogen 20mM (10 ml) 
ITS+ BD Biosciences 5 ml 
Pen/Strep Life Technologies (15140122) 5 ml 
Dexamethasone R&D Systems 0.1µM (5µl) 
Glutamine Life Technologies (25030) 2mM (5.3 ml) 
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Gene Forward primer sequence Reverse primer sequence 
HMBS GGAGCCATGTCTGGTAACGG CCACGCGAATCACTCTCATCT 
CK7 GATTGCTGGCCTTCGGGGT TCATCACAGAGATATTCACGGCTC 
CK19 ACGACCATCCAGGACCTGCGG TCCCACTTGGCCCCTCAGCGTA 
Sox9 CTCTGGAGACTTCTGAACGAGAG CCTTGAAGATGGCGTTGGGG 
GGT GTGAGAGCAGTTGGCTGTGC GTTGAACTCTGCTGTGGGGC 
HLA-A TCACAGACTGACCGAGTGGA ATGGTGTGAGAACCGGCCT 
HLA-B CGAGGCCGGGTCTCACA TAGGCTCTCCGCTGCTCC 
HLA-E 
ACTCTAAGGCTGAGTGGAGC AAGACACATAGGGGAGGCGT 
HLA-DMA TCCAGAGGGTTTCCTATCGC ACAGGGACGGAATGATGCTG 
HLA-DMB AGCTGGCCACTCTAGTTACAC AGGAATGAGGTCCCCCAAGT 







CD40 CACCCTTGGACAAGCTGTGA GATAAAGACCAGCACCAAGAGG 
CD80 GGGGAAATGTCGCCTCTCTG GTGGATTTAGTTTCACAGCTTGC 












1          241 BD 76 M DCD AB+ Y 
2          241 GB 76 M DCD AB+ Y 
3         241 IHD (tissue) 76 M DCD AB+ Y 
4 241 IHD (EpCAM) 76 M  DCD  AB+  N 
5 242 BD 50 M DCD O+ Y 
6 242 IHD 50 M DCD O+ Y 
7 243 BD 37 M DCD O- Y 
8 243 GB 37 M DCD O- Y 
9 247 BD 27 F DBD O- N 
10 256 BD 56 M DBD B+ Y 
11 261 BD 77 M DCD A+ Y 
12 261 GB 77 M DCD A+ Y 
13 261 IHD  77 M DCD A+ Y 
14 263 GB 51 F DCD A+ Y 
15 274 GB 68 M DCD A Y 
16 274 IHD 68 M DCD A Y 
17 275 GB 63 M DCD O+ Y 
18 275 BD 63 M DCD O+ Y 
19 275 IHD (EpCAM) 63 M DCD O+ Y 
20 283 GB 73 M DCD AB+ Y 
21 283 BD 73 M DCD AB+ Y 
22 283 IHD 73 M DCD AB+ Y 
23 286 BD 54 M DCD AB+ Y 
24 286 GB 54 M DCD AB+ Y 
25 292 BD 57 M DBD A+ Y 
26 292 GB 57 M DBD A+ Y 
27 292 IHD (EpCAM) 57 M DBD A+ Y 
28 295 GB 79 F DBD O+ Y 
29 299 BD 46 M DBD O+ Y 
30 302 IHD (tissue) 44 M DCD B+ Y 
31 302 BD 44 M DCD B+ Y 
32 310 BD 51 M DBD O+ Y 
33 312 BD 77 F DCD O+ Y 
34 313 BD 35 F DCD O- Y 
35 325 BD 44 F DCD O+ Y 
36 325 GB 44 F DCD O+ Y 
37 328 GB 52 F DCD B+ Y 
38 337 GB 25 F DCD A+ Y 
39 339 GB 73 F DCD A+ Y 
40 343 GB 70 F DBD A+ Y 
41 351 BD 43 F DBD A+ Y 
42 356 GB 41 F DCD O+ Y 
43 356 BD (not flushed) 41 F DCD O+ N 
44 362 GB 60 M DCD A+ Y 
45 367 GB 70 M DCD O+ Y 
46 368 GB 58 M DCD AB+ Y 
47 368 BD (not flushed) 58 M DCD AB+ N 
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48 376 GB 55 M DCD A+ Y 
49 378 BD 49 M DCD O+ Y 
50 382 BD (not flushed) 60 F DBD O+ Y 
51 385 BD 31 M DBD O+ Y 
52 386 BD (not flushed) 75 F DCD O+ N 
53 386 GB 75 F DCD O+ Y 
54 386 IHD (tissue) 75 F DCD O+ Y 
55 390 BD (not flushed) 68 F DCD O+ Y 
56 390 GB 68 F DCD O+ Y 
57 390 IHD 68 F DCD O+ Y 
58 PBC-1a IHD (biopsy) 23 F N/A AB+ Y 
59 PBC-1b IHD (biopsy) 23 F N/A AB+ Y 
60 PSC-1C BD (ERCP) 44 M N/A O+ Y 
61 PSC-2a IHD (biopsy) 38 M N/A O+ Y 
62 PSC-2b IHD (biopsy) 42 M N/A O+ Y 
63 PSC-2c BD (ERCP) 42 M N/A O+ Y 
64 400 BD 57 M DBD B+ Y 
65 402 BD 63 F DBD O+ Y 
66 405 BD 58 F DBD O+ Y 
67 410 IHD - - N/A - Y 
68 414 GB 52 M DCD O- Y 
        
69 415 IHD - - N/A - Y 
70 422 BD 50 M DBD O+ Y 
71 440 BD 48 M DCD A+ Y 
 
Appendix Table 3: List of all CO donors isolated between September 2016 and August 2019 
Table showing key details of all CO lines derived between September 2016 and August 2019: 
anonymised donor ID number; tissue type (bile duct (BD), gallbladder (GB) or intrahepatic ducts 
(IHD)); age; sex; donor type (if applicable) (donation after brain death (DBD) or donation after cardiac 




Appendix table 4: List of all antibodies used in immunofluorescence and flow cytometry analyses 
 
I have included the published version of my first-author publication as an appendix to this thesis. 
Material from:  
O. C. Tysoe, A. W. Justin, T. Brevini, S. E. Chen, K. T. Mahbubani, A. K. Frank, H. Zedira, E. Melum, 
K. Saeb-Parsy, A. E. Markaki, L. Vallier,  F. Sampaziotis. Isolation and propagation of primary human 
cholangiocyte organoids for the generation of bioengineered biliary tissue. Nat Protocols 
Published 2019 
Publisher: Springer Nature Limited 
Antibody Company Product Number Dilution 
Albumin Bethyl Laboratories A80-129A 1:100 
CK19 Abcam ab7754 1:100 
CK7 Abcam ab68459 1:100 
MHC Class I Abcam Ab23755 1:1000 
MHC Class II Abcam ab157210 1:200 
Human CD45 Abcam ab10558 1:100 
Human CD45 BD Biosciences 555480 1:100 
Ku80 Takara Y40400 1:50 
PerCP-7AAD eBiosciences 00-6993-50 1:50 
FITC-hCD45 MACS Miltenyi 51401276779 1:40 
PE-Cy7-mCD45.1 Biolegend 110730 1:40 
APC-CD19 eBiosciences 17-0199-41 1:50 
PE-Cy7-CD3 Biolegend 300316 1:50 
PE-CD4 Biolegend 317410 1:40 
APC-Cy7-CD8 BD Pharminogen 557834 1:40 
PE-EpCAM Biolegend 324205 1:40 
PE/Cy7-HLA I Biolegend 311430 1:100 
APC-HLA II MACS Miltenyi 130-104-824 1:300 
PerCP-mCD45.1 BD Biosciences 561047 1:100 
PE-CD19 BD Biosciences 555413 1:50 
PE Dazzle-CD20 Biolegend 302348 1:200 
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Isolation and propagation of primary human
cholangiocyte organoids for the generation of
bioengineered biliary tissue
Olivia C. Tysoe1,2,12, Alexander W. Justin3,12, Teresa Brevini1,4,12, Si Emma Chen1,
Krishnaa T. Mahbubani2, Anna K. Frank 5,6,7, Hajer Zedira1, Espen Melum5,6,8,9,
Kourosh Saeb-Parsy2,13, Athina E. Markaki3,13, Ludovic Vallier1,2,13* and
Fotios Sampaziotis 1,2,10,11,13*
Pediatric liver transplantation is often required as a consequence of biliary disorders because of the lack of alternative
treatments for repairing or replacing damaged bile ducts. To address the lack of availability of pediatric livers suitable for
transplantation, we developed a protocol for generating bioengineered biliary tissue suitable for biliary reconstruction.
Our platform allows the derivation of cholangiocyte organoids (COs) expressing key biliary markers and retaining
functions of primary extra- or intrahepatic duct cholangiocytes within 2 weeks of isolation. COs are subsequently seeded
on polyglycolic acid (PGA) scaffolds or densified collagen constructs for 4 weeks to generate bioengineered tissue
retaining biliary characteristics. Expertise in organoid culture and tissue engineering is desirable for optimal results. COs
correspond to mature functional cholangiocytes, differentiating our method from alternative organoid systems currently
available that propagate adult stem cells. Consequently, COs provide a unique platform for studies in biliary physiology
and pathophysiology, and the resulting bioengineered tissue has broad applications for regenerative medicine and
cholangiopathies.
Introduction
Cholangiopathies comprise a diverse group of disorders characterized by damage to the biliary tree
and loss of bile ducts resulting in cholestasis, hepatic injury and ultimately liver failure1,2. However,
treatment options are limited to liver transplantation. Indeed, biliary disease remains the leading
indication for this intervention in children, with >70% of pediatric liver grafts being used to treat
biliary atresia3. The generation of healthy biliary tissue suitable for replacing or reconstructing
damaged bile ducts could address the clinical need for alternative therapeutic approaches and reduce
pressure on the transplant waiting list. However, progress in this area has been hampered by chal-
lenges in the long-term culture and large-scale expansion of primary cholangiocytes. Here, we
describe a protocol for the fabrication of functional bioengineered biliary tissue, using biocompatible
and biodegradable scaffolds and a method for the isolation and propagation of primary cholangio-
cytes in organoid format.
Development of the protocol
To generate bioengineered biliary tissue suitable for surgical manipulation and biliary reconstruction,
we decided to combine primary biliary epithelium with appropriate matrices.
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Development of the protocol for CO culture
First, we developed a culture protocol for the propagation and large-scale expansion of primary adult,
functional cholangiocytes4. Because biliary reconstruction is predominantly performed on the
common bile duct (CBD), we initially focused on the isolation of CBD cholangiocytes, using excised
bile ducts from deceased organ donors. To achieve expansion of the isolated cholangiocytes, the cells
are embedded in Matrigel and treated with a combination of epidermal growth factor (EGF),
R-spondin-1 and DKK-1. We have previously demonstrated that the combination of EGF and 3D
culture can promote limited growth of partially mature, fetal cholangiocyte-like cell (CLC) organoids
derived from induced pluripotent stem (iPS) cells5,6. In addition, primary adult stem cell organoids
have been isolated from murine biliary tissue7. To support the long-term expansion of adult
cholangiocytes, we use R-spondin-1, a WNT agonist reported to stimulate organoid derivation from
multiple adult epithelia8–13. However, R-spondin promotes the propagation of adult stem cells rather
than mature epithelial populations by enhancing canonical Wnt signaling14. To avoid the amplifi-
cation of adult stem cells, we introduce DKK-115, a canonical WNT/β-catenin pathway antago-
nist16,17. When used in combination with R-spondin, DKK-1 inhibits canonical and enhances
non-canonical WNT signaling through the planar cell polarity pathway4, which has been reported to
play a role in cholangiocyte maturation18,19. The combination of EGF, R-spondin-1 and DKK-1
allows for long-term, large-scale expansion of functional, genetically stable, primary adult COs.
Our system was developed and optimized for the culture of CBD COs isolated from fresh excised
bile ducts. However, this isolation method requires a complex operation, thereby posing substantial
limitations related to access to biliary tissue. To overcome this issue, we subsequently validated the
capacity of our culture system for the derivation of COs from multiple sources, such as excised
gallbladders, endoscopic retrograde cholangiopancreatography (ERCP) brushings and liver biopsy
samples. With this platform, COs can be isolated and expanded using samples from any area of the
biliary tree and acquired by any of these isolation methods.
Choice of scaffolds
Our next goal was to identify appropriate scaffolds that could be combined with the cells to generate
tissue-like constructs. Important considerations for the choice of scaffolds were their potential to
support growth of the cells, their capacity to be integrated into the host tissue following transplan-
tation with minimal inflammatory response and the use of biodegradable materials allowing for tissue
remodeling, which is critical to neo-vascularization. Furthermore, to support future clinical trans-
lation, the materials used should be compatible with human transplantation.
Importantly, both synthetic and biological polymer scaffolds with these specifications are available.
As there are advantages and disadvantages associated with each approach, we decided to explore
both. Synthetic polymer scaffolds are widely used, as they can be easily processed using a wide range
of techniques and adapted for multiple tissue engineering applications20. They have tunable and
reproducible physicochemical properties, mechanical strength and degradation rates, making them
highly customizable as a scaffold material20,21. Biological polymer scaffolds are more challenging to
tailor to a particular application, owing to purity, immunogenicity, and scaffold homogeneity and
reproducibility issues22. However biological polymer scaffolds have superior bioactive properties (e.g.,
cell attachment, migration, cell scaffold remodeling) and thus better cell and tissue interactions22,23.
Generation of bioengineered tissue using synthetic scaffolds
First, we focused on synthetic scaffolds commercially available ‘off the shelf’ to optimize cell seeding,
attachment and culture of the resulting tissue. We decided to use a PGA matrix because of its
biodegradability, flexibility and lack of inflammatory response in vivo24. In addition, synthetic PGA
scaffolds can be easily processed into tailored architectures22,23. For these reasons, PGA is one of the
most commonly used synthetic polymers in tissue engineering21 and has been approved by the FDA
for use in human studies25.
We subsequently identified the optimal method for seeding COs on the scaffolds. Our results
demonstrated that the use of cell clumps concentrated in small volumes is the optimal seeding
method. Small volumes of cell suspension are absorbed by the scaffold, maximizing cell-to-scaffold
contact. An alternative method, the dissociation of organoids into single cells, requires aggressive
enzymatic digestion, which reduces cell viability and attachment because of the cleavage of multiple
cell-to-matrix adhesion molecules26. Seeding cell clumps resulted in the generation of confluent PGA
scaffolds seeded with COs, which were used to successfully repair biliary tree wall defects in
immunocompromised mice following transplantation.
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Generation of bioengineered tissue using biological scaffolds
We subsequently used the same seeding methodology to populate biological scaffolds. Here, we chose
densified collagen hydrogel because of its biocompatibility, low immunogenicity, ability to favor cell
attachment and growth, biodegradability and ability to be naturally remodeled by cells27. Importantly,
as compared with standard collagen gel, densified collagen gel demonstrates superior mechanical
properties for surgical applications27,28. Densification expels the majority of the water content of the
collagen gel, vastly reducing its volume, resulting in a polymer scaffold of higher concentration and
fibrillar alignment28. Through the use of appropriate molds, the densification process can be custo-
mized to generate constructs of more complex geometries, which can be successfully seeded with COs.
Generation of bioengineered mouse bile ducts
One of the most relevant clinical applications of bioengineered biliary tissue is the generation of
tubular constructs suitable for biliary reconstruction. However, bile duct transplantation can be
associated with a substantial inflammatory response, epithelial damage and the formation of ana-
stomotic strictures in humans29,30. Consequently, in vivo validation of the function, biocompatibility
and patency of bioengineered ducts following reconstruction is required. To achieve this goal, we
decided to generate bioengineered constructs populated with human COs, transplant them into
immunocompromised mice and characterize them.
The fabrication of tubular structures with dimensions comparable to those of the mouse CBD
(250-µm inner diameter and 30-µm wall thickness) was a key challenge. Indeed, commercially
available fibrous PGA scaffolds31 were incompatible with these requirements because their minimum
thickness (300 µm) is substantially larger than the required wall thickness. Appropriate-thickness
predensified collagen gel sheets could be fashioned into a tube using sutures; however, interruption of
the collagen fibrils along the seam led to partial collapse of the lumen under the weight of the wall. To
overcome these challenges, we developed a method in which collagen was cast around a central rod
and densified afterward, to yield a seamless tube with a thin and robust wall. Furthermore, a conical
funnel mold was used, which allowed a proportionately large volume of collagen to densify into a
short length of tube and enabled efficient water removal via multiple routes (through on-axis
absorption and radial evaporation). These techniques yielded bioengineered tubes with a patent
lumen and dimensions similar to those of the mouse CBD32.
We subsequently used the approach that we developed for seeding COs on flat collagen scaffolds
to seed the luminal surface of the construct with cells and generate mouse-sized bioengineered bile
ducts populated with human cells. Importantly, the potential of these constructs for biliary recon-
struction in vivo was illustrated through their successful transplantation into immunocompromised
mice4.
Applications and target audience
The propagation of COs and the generation of bioengineered biliary tissue are likely to be of interest
to a broad scientific audience, including clinician scientists focusing on translation of new therapies to
the clinic, bioengineers working on whole-organ reconstruction, groups focusing on biliary phy-
siology and disease and the pharmaceutical industry. Currently the only therapeutic option for biliary
disorders is liver transplantation. The generation of bioengineered biliary tissue could provide one of
the first alternative treatments and pioneer the use of regenerative medicine for cholangiopathies33,34.
Furthermore, a limitation of complex liver co-culture systems is the lack of a biliary system. The
capacity of COs to grow in a variety of matrices and scaffolds makes them an ideal addition to
complex tissue engineering applications that focus on recapitulating the microanatomy of the liver
and the development of artificial whole-organ systems35.
Cholangiocytes constitute a rare liver cell type, and access to primary tissue has limited large-scale
analyses in the past. COs closely resemble primary biliary epithelium in terms of transcriptional profile
and function4. Consequently, extrahepatic COs (ECOs) and intrahepatic COs (ICOs) could serve as
surrogates for primary cholangiocytes from any region of the biliary tree, enabling in-depth, large-scale
studies of biliary physiology and pathophysiology. Similarly, COs recapitulate the effects of com-
pounds such as verapamil and somatostatin, rendering them suitable for drug-screening applications.
Comparison to other methods
A unique feature of our culture system is that it enables the long-term culture of mature
cholangiocytes through inhibition of canonical WNT signaling by DKK-1, maintaining adult
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characteristics and functionality with no need for additional differentiation. Therefore, our system is
distinct from alternative primary organoid platforms based on canonical WNT signaling, which
propagate adult stem cells8,11,13,36 rather than bona fide biliary epithelium. Consequently, COs may be
better suited to studies on biliary physiology and disease requiring high-fidelity cholangiocytes,
whereas adult stem cells are optimal for studies on liver repair and regeneration.
Although methods for short-term culture of murine37 and human primary cholangiocytes have
been reported38,39, these systems are technically challenging and allow for only limited expansion,
restricting large-scale analyses, and the function of the resulting cells has not been extensively
characterized. COs combine high proliferative capacity, increased functionality and the potential for
large-scale expansion, which is critical to regenerative medicine or for high-throughput applications.
Importantly, cholangiocytes can be derived from iPS cells5,6,40,41. However, these cells have the
characteristics of fetal intrahepatic cholangiocytes, whereas our method can generate cells similar to
both intrahepatic and extrahepatic adult cholangiocytes. In addition, COs can be rapidly isolated and
expanded, unlike iPS cell systems, which require a lengthy differentiation process and cannot be
further propagated once terminally differentiated. Consequently, stem cell–derived cholangiocytes are
optimal for studies of intrahepatic bile duct development and its disorders, whereas COs are better
suited to studies of adult intra- and extrahepatic cholangiocyte physiology or regenerative medicine
applications requiring large numbers of highly functional cells in little time.
Our system provides multiple advantages for tissue engineering and regenerative medicine. The
generation of bioengineered tissue is versatile, allowing the use of synthetic (PGA) or biological
scaffolds (collagen). Furthermore, it is compatible with Good Manufacturing Practice (GMP)-com-
pliant materials, such as collagen, which has an excellent in vivo profile and is used extensively in
clinical applications24. The method by which the densified collagen tubes are formed allows their
generation at customizable length scales compatible with small animal studies. Furthermore, the
densification process does not impart substantial stress upon the cells, which can be mixed in the gel
if required. The resulting constructs can be maintained for >2 months in culture, enabling the
generation of large batches of bioengineered tissue with prolonged ‘shelf life’. Importantly, our
bioengineered biliary tissue provides the first proof of principle for organ reconstruction using
primary epithelial organoids, in which the resulting bioengineered construct was used to fully replace
the native organ4.
Limitations
A limitation of our system is that COs, as adult primary cholangiocytes, are not suitable for studying
biliary development, an application for which stem cell–derived systems are more appropriate. In
addition, as COs represent a pure epithelial population, this system does not currently allow for the
study of epithelial and mesenchymal interactions, although the potential exists within our system to
generate bioengineered tissue with additional cell types. A further, technical, limitation is that COs
currently rely on the use of Matrigel, a non-GMP-compliant extracellular matrix. However, multiple
chemically defined hydrogel matrices, which could replace Matrigel, are currently in development42.
For research groups without access to a hospital with hepatobiliary services, access to primary
tissue may present a challenge, as primary samples must be processed promptly following isolation.
We note that samples can be obtained in any hospital that offers a cholecystectomy, ERCP or liver
biopsy service, and that organoid derivation is still feasible after small delays associated with tissue
transfer over short distances. Nevertheless, to compensate for transport-associated delays when
multiple samples from distal centers are processed, a team of trained technicians working in parallel
may be required.
Finally, although mouse-sized (submillimeter) constructs serve as proof of principle for the gen-
eration of bioengineered ducts populated with human cells, their mechanical properties do not
translate to those of the human bile duct (7-mm diameter, 1-mm wall thickness). Therefore, opti-
mization of our technique for the generation of human-sized constructs with appropriate physical
attributes will be required before clinical translation.
Experimental design
Our method describes a system for isolating primary extrahepatic and intrahepatic cholangiocytes
from primary tissue, culturing these primary cholangiocytes in a 3D organoid system and generating
bioengineered biliary tissue using artificial scaffolds (Fig. 1). In this section, we describe infrastructure
and experimental setup considerations that one must take into account before using this protocol.
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Isolation of cholangiocytes from primary tissue
Our protocol requires the isolation of cholangiocytes from primary human tissue, either from living
patients or from deceased organ donors. As such, appropriate ethical approval from the relevant



















































Fig. 1 | Flowchart of key steps in the generation of bioengineered biliary tissue. a, Overview flowchart showing
the three major protocol steps: cell isolation, scaffold preparation and generation of bioengineered biliary tissue.
b, Flowchart summarizing the process of cell isolation from different biliary tissue samples with reference to the
relevant protocol sections. c, Flowchart illustrating the different types of biological or synthetic scaffolds used, with
reference to the relevant protocol sections. d, Flowchart summarizing the seeding of acellular scaffolds with CO cells,
with reference to the relevant protocol sections. BD, primary bile duct; GB, gallbladder.
PROTOCOL NATURE PROTOCOLS
1888 NATURE PROTOCOLS | VOL 14 | JUNE 2019 | 1884–1925 |www.nature.com/nprot
Obtaining fresh human tissue samples will require access to a hospital with one of the following
services: hepatology, advanced endoscopy, hepatobiliary surgery, transplant organ procurement or
liver transplantation. Importantly, donor tissue viability decreases in proportion to ex vivo storage
and bile exposure. Therefore, bile must be flushed from the tissue, which should then be stored
immediately in cold preservation solution (such as University of Wisconsin (UW) solution) or
supplemented William’s E+ medium at 4 °C until it can be processed43.
When multiple tissue samples are obtained simultaneously (such as from a deceased organ donor),
the tissue should be processed in order of sensitivity to cold storage (Supplementary Fig. 1). Liver
biopsies require immediate processing, whereas extrahepatic tissue can be stored at 4 °C for several
hours, provided that it is appropriately flushed of bile. Furthermore, all tissue handling should be
performed under aseptic conditions to avoid contamination. Consequently, good communication
with the clinicians obtaining the sample is critical. Long-distance transport of samples is likely to
impact the viability of explanted tissue, so samples must ideally be processed in a facility close to the
site of collection. Tissue must be processed in a class II biological safety cabinet under aseptic
conditions, and sterile surgical equipment must be used.
CO lines can be generated using multiple approaches, depending on the source of available tissue
and the method of sample collection (Fig. 1). Surgically excised tissue samples, such as gallbladders
and bile ducts, can be used for the generation of COs following isolation of the luminal layer of
cholangiocytes through mechanical scraping (Fig. 2). ERCP brushings provide an alternative source
of tissue for patients having endoscopy (Fig. 3). One can isolate COs from liver biopsy tissue by
dividing a liver biopsy core into small pieces (~1 mm3) and plating them directly in CO organoid
culture conditions (Fig. 4). Alternatively, CO lines can be derived from a population of EpCAM+
sorted single cells (Supplementary Fig. 2). Tissue can be enzymatically digested to a single-cell
suspension and then EpCAM-sorted through either FACS or magnetic-activated cell sorting (MACS).
Provided the tissue has been appropriately and promptly processed, the methods described should
produce CO lines with almost 100% efficiency, apart from EpCAM sorting, which yields viable lines
with an efficacy of 66% (Supplementary Table 1) owing to the impact of single-cell dissociation on
cell viability. This method of derivation will produce a highly purified CO population, in contrast to
derivation from whole-liver tissue, which can take up to three passages to establish a pure CO
population. Flushing the tissue of bile is critical to achieving these results. Indeed, derivation effi-
ciency is reduced from 95% to 40% if flushing is not performed (Supplementary Table 1). The optimal
technique for CO line derivation should be decided on the basis of sample availability and access
to tissue.
Establishment and maintenance of COs
Once plated, primary cholangiocytes should form organoids in 3–10 d. Clump size and seeding
density can affect the speed and efficiency of derivation. Single cells tend to require longer culture and
yield lower numbers of organoids from the same number of starting cells. Large clumps of >50–100
cells and high seeding density may result in cell attachment and limit organoid growth.
CO lines should be passaged approximately every 5 d (Fig. 5), although the cells should be
monitored daily to check whether confluency has been reached (Fig. 5b, Supplementary Fig. 3).
Delays in passaging of confluent wells can result in organoid collapse and affect the long-term health
of the organoid line (Supplementary Fig. 4b). The same considerations as for organoid derivation
apply with regard to clump size and seeding density during passaging (Supplementary Fig. 4b).
Importantly, our protocol relies on Matrigel as an extracellular matrix, which has a profound impact
on the quality of the resulting organoid lines. Therefore, Matrigel must be batch-tested before use. It
is also important to ensure that no reagent or medium used in the maintenance of CO lines is used
for longer than 3 months, as this can impact organoid quality.
Organoids can be analyzed through a variety of methods, such as qPCR, immunofluorescence (IF)
and flow cytometry, as we have previously described5,6. COs should show robust expression of key
biliary markers such as cytokeratin 19, cytokeratin 7, Sox9 and gamma-glutamyl transferase (GGT),
as well as key cholangiocyte functions such as alkaline phosphatase (ALP) and GGT activity (Fig. 6),
which can be used to assess the quality of CO derivation and culture.
Scaffold preparation
Bioengineered tissue can be generated using both synthetic (PGA) and biological (densified collagen
gel) polymeric scaffolds, each of which may be suited to different applications. PGA scaffolds
can be commercially sourced, are cheap and require minimal processing to yield positive results.
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The mechanical properties of the scaffold (e.g., Young’s modulus, strength) are tunable and can be
customized through adjustment of the density and pore size. Furthermore, PGA constructs can be
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Fig. 2 | Derivation of ECOs from extrahepatic biliary tissue. a, Schematic representation of key stages of the
derivation of ECOs from primary bile duct (BD) and gallbladder (GB) tissue (Step 2A). b,c, Representative images of
key stages of the derivation of cholangiocytes from primary BD (b) and GB (c) tissue. Numbers in b and c correspond
to the schematic stages illustrated in a. 1A(i), 1B(i): resected biliary tissue before dissection. 1A(ii), 1B(ii): tissue
dissection. 1A(iii), 1B(iii): exposed luminal surface following dissection. 2: PBS wash. 3: Mechanical dissociation of the
biliary epithelium. 9: Primary cholangiocytes in suspension following dissociation. Scale bars: b, images 1A(i)–3, 1 cm;
c, images 1B(i)–3, 2 cm; b, image 9 and c, image 9, 100 μm. d, Representative bright-field images demonstrating key
time points of ECO derivation. Scale bars, 200 μm. (Top) Primary cholangiocytes 24 h after plating, demonstrating the
formation of early organoid structures. (Bottom) ECOs following long-term culture (passage 20). e, Flow cytometry
analysis of the primary cell suspension, demonstrating >90% cholangiocyte isolation efficiency (Step 2A(i–viii); gating
strategy demonstrated in Supplementary Fig. 6). APC, allophycocyanin; FITC, fluorescein isothiocyanate.
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Collagen constitutes a physiological component of the extracellular matrix44 with high bioactiv-
ity45, which can interact with cells and present multiple cues that enhance attachment, survival,
proliferation and tissue remodeling44,46. Furthermore, unlike PGA, cells can be mixed directly into
the collagen gel precursor solution before gelation and densification, generating a uniform network of
cells throughout the scaffold, which is useful for applications such as complex co-culture systems.
However, it is more expensive than synthetic alternatives, and scaffolds with adequate mechanical
strength for surgical manipulation47,48 are not commercially available and need to be custom-made.
Indeed, densified collagen sheets must be fabricated from collagen gels through water absorption
(Fig. 7), whereas densified collagen tubes must be formed through molding of collagen gel around a


































Fig. 3 | Derivation of ECOs through ERCP brushings. a, Schematic representation of stages of ECO derivation from
ERCP brushings (Step 2B). b, Representative images of key stages of the derivation procedure. Numbers correspond
to schematic stages in a. 1: ERCP brush. 2: Medium wash to dislodge the collected cholangiocytes from the brush. 3:
Representative cell pellet after isolation. 5: Bright-field image of ERCP isolated cholangiocytes following plating. Scale
bars, 1 cm (1–3) or 200 μm (5). c, Bright-field images demonstrating representative time points in the derivation of
organoids from cholangiocytes obtained through ERCP brushings. (Top) Primary cholangiocytes 24 h after plating,
demonstrating the formation of early organoid structures. (Bottom) COs 1 week after plating. Scale bars, 200 μm.
d, Flow cytometry analysis of the cell suspension obtained through ERCP, demonstrating >90% cholangiocyte
isolation efficiency (Step 2B(i–v); gating strategy demonstrated in Supplementary Fig. 6). APC, allophycocyanin;
FITC, fluorescein isothiocyanate.
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densified collagen scaffolds are more physiological but require a higher level of expertise and pose a
greater number of potential pitfalls, whereas PGA scaffolds may be appropriate for settings in which
the expertise and equipment for the generation of custom-made scaffolds are not available.
Scaffold seeding
PGA and densified collagen scaffolds (both flat and tubular) can be seeded with COs to generate
bioengineered biliary tissue within 2–4 weeks. The cells are seeded as clumps in small volumes to
maximize their contact with the scaffold and are incubated for 1 h to allow attachment before the
addition of medium. For tubular scaffolds, cannulation with a small-gauge (<30-gauge) needle is
necessary for seeding. This procedure is technically challenging and may require the assistance of a
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Fig. 4 | Derivation of intrahepatic organoids. a, Schematic representation of stages of ICO derivation (Step 2C). b,c, Representative images of key
stages of ICO derivation for liver biopsies (b) and surgically resected liver tissue (c). Numbers correspond to schematic stages in a. 1: Dissection of
liver tissue. 2: Manual dissociation and collection of dissected tissue. 3 and 4: Dissected tissue before (3) and after (4) centrifugation. 6: Plating. 6(i):
Representative images of liver tissue after embedding in Matrigel, before medium addition. Scale bars, 1 cm (1–6(i)). 6(ii): Representative bright-field
images of liver tissue after plating. Scale bars, 200 μm. d, Representative bright-field images demonstrating key time points of ICO derivation. (Left)
ICO culture 5 d after plating, demonstrating the emergence of an organoid from a segment of liver tissue. (Right) Established ICO line (passage 20).
Scale bars, 200 μm. e, Flow cytometry analysis of ICO cells, demonstrating >95% cholangiocyte isolation efficiency (gating strategy in Supplementary
Fig. 6). APC, allophycocyanin; FITC, fluorescein isothiocyanate.
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The efficiency and quality of cell attachment following seeding (Figs. 9 and 10) depend on clump
size, cell number, seeding cell suspension volume and drying time for the scaffold. Single cells and low
cell numbers are associated with reduced seeding efficiency, whereas large clumps may attach only
partially. Importantly, parts of a clump that have not attached may remodel to form organoid-like
structures connected to the scaffold or overlap with neighboring clumps that have attached,
generating a pseudostratified epithelium. Consequently, the use of 30–50 cell clumps is critical to
achieving optimal seeding results.
Low cell-suspension volumes result in poor scaffold coverage and therefore suboptimal seeding,
whereas cell viability may be reduced because of medium evaporation during the incubation period.
High volumes may lead to overflow and ‘spillage’ of the cell suspension from the scaffold to the plate,
resulting in a reduced cell-to-surface ratio and poor seeding efficiency. Consequently, the seeding volume
must be optimized on the basis of the scaffold surface, as described in the Procedure. This is particularly
important when seeding on the luminal surface of a tubular scaffold, where the cell suspension must be
optimized for minimal volume and maximal density, to be contained within the tube lumen.
Reduced incubation time does not allow an adequate period for the cells to attach. Consequently,
the addition of medium at the end of the incubation phase results in washing of poorly attached cells
off the scaffold. Prolonged incubation can result in scaffold drying and reduced cell viability.
Importantly, the scaffold is rarely confluent following seeding. Indeed, in most cases only a
proportion of the scaffold is covered with cells. However, these expand to generate a confluent layer
within weeks. The time to confluency can be reduced by seeding of higher numbers of cells or by
repeated rounds of seeding. Importantly, if an additional round of seeding is performed, the scaffold
should not be allowed to dry before the new cells are added, in order to preserve the viability of the
cells already attached.
Bioengineered biliary tissue can be analyzed through IF or functional assays as previously
described4 and should show robust expression of key biliary markers such as cytokeratin 19 and
cytokeratin 7 (Fig. 11a,c,e), as well as key cholangiocyte functions such as GGT activity (Fig. 11b,d,f).
Once confluent, the scaffolds can be transplanted in vivo or maintained in culture for several months.
Scaffold-specific considerations
Pore size is an important consideration for PGA scaffolds. The scaffold pore size will determine the
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Fig. 5 | Passaging of COs. a, Schematic representation of the stages of the CO passaging procedure (Steps 15–30). b, Representative images of key
stages of the CO passaging procedure. Numbers correspond to schematic stages in a. 1: Confluent COs before passaging. 4: Representative organoid
pellet yielding nine organoid wells following plating (~4.0 × 105 cells). 5: Suspension of COs after manual dissociation, demonstrating representative
clump size for passaging (~30–100 cells per clump) (Step 28). 7(i): COs immediately after plating (Steps 9–13), demonstrating that the majority of
cells remain in small clumps and have not yet formed organoids at this stage. 7(ii): COs 24 h after passaging, demonstrating that the majority of CO
clumps have remodeled into organoids at this point. Scale bars, 100 μm (1, 5, 7(i) and 7(ii)); 5 mm (4).
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Fig. 6 | Characterization of COs. a, Immunofluorescence images demonstrating expression of key biliary markers in
COs (10 passages). Scale bars, 50 μm. (See Supplementary Table 2 for a detailed list of antibodies and
concentrations used). b, qRT–PCR confirming the expression of key biliary markers in ECOs (20 passages) compared
to freshly isolated primary cholangiocytes (PCs); n = 4 biological replicates. Center line, median; box, interquartile
range (IQR); whiskers, range (minimum to maximum). Values relative to those of the housekeeping gene HMBS
(for hydroxymethylbilane synthase). #P > 0.05 (two-tailed Student’s t-test). qRT–PCR analyses were conducted as
previously described49. c, COs (10 passages) demonstrate ALP activity. Scale bars, 100 μm. ALP assays were
conducted as previously described5. d, GGT activity of COs (20 passages) measured in absorbance units (a.u.);
n = 3; MEFs (mouse embryonic feeders) were used as a negative control. Error bars, s.d.; individual data points are
demonstrated; **P < 0.0001, two-tailed Student’s t-test. GGT activity was assessed using a commercially available kit
(MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit) according to the manufacturer’s
instructions and as previously described5. e, Flow cytometric analyses performed on COs after long-term culture (20
passages), demonstrating >99% CK7+/CK19+ expression (gating strategy demonstrated in Supplementary Fig. 6).
APC, allophycocyanin; FITC, fluorescein isothiocyanate.
PROTOCOL NATURE PROTOCOLS
1894 NATURE PROTOCOLS | VOL 14 | JUNE 2019 | 1884–1925 |www.nature.com/nprot
penetration, provided there is good interconnectivity between pores. However, constructs with larger
pores are weaker, and seeding with large clumps is required to ensure that the cells do not ‘fall
through’ the spaces between fibers. Furthermore, preparation of the scaffolds for seeding includes
treatment with ethanol (EtOH) and concentrated sodium hydroxide (NaOH). It is critical that, at the
point of seeding, the scaffold be completely free of EtOH or NaOH remnants, which could result in
cell death and poor attachment.
For collagen scaffolds, the quality of collagen plays a key role in the attachment and growth of
cells. As collagen solutions are not 100% pure, we recommend testing of each new collagen batch for
cell attachment, proliferation, expression of biliary markers and function.
For the generation of tubular densified collagen scaffolds, assistance of an experienced engineer
and access to engineering facilities, including a 3D printer, are essential. Furthermore, transplantation
of bioengineered ducts into small animal models requires substantial skill because of the construct
size, and the procedure must be performed by an experienced surgeon.
Appropriate controls
Freshly isolated primary biliary tissue should be used as a positive control for the expression of biliary
markers. For histology or IF analyses, whole tissue can be frozen in optimal cutting temperature
compound (OCT) or fixed in 10% (vol/vol) formalin and embedded in paraffin for sectioning. Cells
can be isolated as described in Steps 2A and 2D and dissociated to a single-cell suspension for flow
cytometry or resuspended in RNA lysis buffer for RNA extraction and qPCR, as described in
Step 41C. Alternatively, RNA can be extracted from snap-frozen tissue. Although primary tissue
represents the ideal control for CO function and marker expression, it is also possible to compare
COs with established cholangiocyte cell lines if access to primary tissue is not possible.
Starting population considerations
We have demonstrated that our protocol for CO derivation is reproducible with >70 CO lines
(Supplementary Table 1). In addition, CO lines can be generated from very low numbers (<20,000) of
viable primary cells (Supplementary Fig. 5). CO lines can be maintained in culture for >20 passages
or 6 months. COs represent primary cells rather than immortalized cell lines; therefore it is possible
that a reduction in the growth potential or function of the line will be observed after this time.
























Fig. 7 | Generation of densified collagen sheets. a, Schematic representation of key stages of the procedure for generating densified collagen sheets
(Step 39A). b, Representative images of key stages of the collagen densification process. Numbers correspond to schematic stages in a. 1: Specimen
tube containing 5% collagen gel before densification (25-mm height). 2 and 3(i): Representative gel height following water absorption for 0 (2(i)),
30 (2(ii)) and 60 (3(i)) min. 3(ii): Specimen tube containing fully densified collagen scaffold (indicated by the black arrow). 4: Removal of nylon mesh.
5: Representative image of the resulting densified collagen sheet. Scale bars, 1 cm (1–4) or 5 mm (5).
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biliary markers and function should be regularly tested after passage 20 to periodically validate the
quality of the line.
For the generation of bioengineered tissue, some variability in cell attachment and expansion
potential following seeding and after transplantation is expected. Therefore, minor optimization may
be required for certain CO lines, as described in the following sections.
Materials
Biological materials
● Human bile duct (minimum 1-cm length), gall bladder (minimum 1-cm2 area) or liver tissue samples
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Fig. 8 | Generation of densified collagen tubes. a, Representative images of densification chamber assembly (Equipment setup). 1: Densification
chamber components: (i) funnel, (ii) base, (iii) wire, (iv) 23-gauge needle, (v) paper towels, (vi) M4 screws and (vii) nuts. 2: Mounting of the rigid
metal wire on the chamber base. 3: Addition of paper towels. 4: Addition of funnel. 5: Chamber assembly. Scale bars: 20 mm. b, Schematic
representation of stages of collagen tube densification (Step 39B(i–ix)). c, Representative images of stages of tube densification. Numbers correspond
to schematic stages in b. 1: Addition of collagen precursor solution. 2: Peeling of collagen from funnel walls. 3: Gel optimally positioned for evaporation.
4: Completion of densification. 5: Removal of densified tube from wire. Scale bars, 15 mm. d, Tube trimming following densification (Step 39B(x–xv)).
1: Collagen tubes immediately after densification. 2: Washed tube. 3, 4: Tube trimming. 5: Trimmed tube with patent lumen (white dashed lines).
Scale bars: 2 cm (1–3), 2 mm (4) or 1 mm (5).
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2 × 1-cm2 whole-liver pieces, if following Step 2D) or cholangiocytes from ERCP brushings.
! CAUTION All human tissue samples must be collected with the appropriate ethical approval in place
and with full informed consent. Donors should be tested to exclude use of HIV-, hepatitis B– or
hepatitis C–infected material. Informed consent was obtained for the use of all human tissues used in
our experiments. Approval for our experiments was obtained from the NRES Committee East of
England, Cambridge South (REC reference 15/EE/0152).
Reagents
● William’s E basal medium, no phenol red (Invitrogen, cat. no. A12176-01)
● Nicotinamide (Sigma Life Science, cat. no. N0636-100G)
● Sodium bicarbonate (Sigma Life Science, cat. no. S6014-500G)
● Sodium pyruvate (Invitrogen, cat. no. 11360-070)
● D-Glucose (Gibco, cat. no. 15023-021)
● HEPES (Sigma, cat. no. H0887-20ml)
● ITS+ Universal Cell Culture Premix (20 ml; SLS, cat. no. 354352)
● Dexamethasone (R&D Systems, cat. no. 1126/100)
● L-Glutamine (Life Technologies, cat. no. 25030)
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Fig. 9 | Seeding of flat densified collagen or PGA scaffolds. a, Schematic representation of the stages of the procedure for seeding densified collagen
sheets and PGA scaffolds (Steps 40A and 40C, respectively). b,c, Representative images of key stages of the seeding procedure for densified collagen
(b) and flat PGA (c) scaffolds. Numbers correspond to schematic stages in a. 1: Dried scaffold before seeding. 3(i): Addition of cell suspension on the
scaffold at the start of seeding process. William’s E+ medium with phenol red used for illustrative purposes. The use of phenol red in the medium
is optional. 3(ii): Scaffold after completion of seeding and before incubation. 5: Seeded scaffold following medium addition. Scale bars, 1 cm.
d, Representative fluorescent image of a flat densified collagen scaffold confluently seeded with RFP+ COs (4 weeks after seeding). Scale bar, 100 µm.
e, Representative fluorescent image of a PGA scaffold confluently seeded with GFP+ COs (4 weeks after seeding). Scale bar, 50 µm.
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● L-Phospho-ascorbic acid (Sigma Life Sciences, cat. no. 49752-10G)
● Matrigel (BD Biosciences, cat. no. 356237)
● Cell recovery solution (SLS, cat. no. 354253)
● CellBanker 2 (Amsbio, cat. no. 11891)
● Recombinant human epidermal growth factor (EGF; R&D Systems, cat. no. 236-EG)
● Recombinant human DKK-1 protein (R&D Systems, cat. no. 5439-DK-01M/CF)
● Recombinant Human R-spondin-1 (R&D Systems, cat. no. 4645-RS)
● Recombinant Human HGF (PeproTech, cat. no. 100-39)
● Recombinant human forskolin (FSK; Sigma-Aldrich, cat. no. F6886-10MG)
● Y27632 (Stratech Scientific, cat. no. S1049-SEL)
● Liberase DL, research grade (Sigma-Aldrich, cat. no. 5466202001)
● Deoxyribonuclease I (DNase I) from bovine pancreas (Sigma-Aldrich, cat. no. D5025-150KU)
● University of Wisconsin (UW) cold storage solution (Bridge to Life (Europe) Ltd., cat. no. BTLBUW-1000)
● Dulbecco’s PBS (PBS; Life Technologies, cat. no. 14190)
● Red blood cell lysis solution (10×; MACS Miltenyi Biotech, cat. no. 130-094-183)
● BSA (Sigma Life Sciences, cat. no. A3059)
● Polyglycolic acid BIOFELT scaffold (1-mm thickness, 50-mg/cm3 PGA density; Biomedical Structures,
custom order)
● CD326 (EpCAM) MicroBeads (human; MACS Miltenyi Biotech, cat. no. 130-061-101)
● FcR blocking reagent (MACS Miltenyi Biotech, cat. no. 130-059-90)
● MACS BSA stock solution (MACS Miltenyi Biotech, cat. no. 130-091-376)
● AutoMACS rinsing solution (MACS Miltenyi Biotech, cat. no. 130-091-222)
● AutoMACS running buffer (MACS Miltenyi Biotech, cat. no. 130-091-221)
● AutoMACS pro washing solution (MACS Miltenyi Biotech, cat. no. 130-092-987)
● Collagen I, high-concentration rat-tail collagen solution (100 mg; Scientific Laboratory Supplies,
cat. no. 354249)
● Medium 199 (10×; Sigma-Aldrich, cat. no. M0650)
● Sodium hydroxide (NaOH, 1 M; Sigma-Aldrich, cat. no. 2770) ! CAUTION NaOH can cause
inflammation, irritation or corrosion upon contact with skin or eyes, or when ingested or inhaled.
















Fig. 10 | Seeding of densified collagen tubular scaffolds. a, Schematic representation of stages of densified collagen
tube seeding (Step 40B). b, Representative images of the seeding process. Image numbers refer to the
corresponding stages illustrated in the schematic in a. 2: Cannulation of tube lumen with 34-gauge needle. 3: Seeding
of tube lumen with COs. Note the change in the tube color as the lumen fills with phenol red–containing medium.
Scale bars: 1 mm (2) or 5 mm (3). c, Representative bright-field image of a CO-seeded densified collagen tube
(4 weeks after seeding). Scale bar, 200 µm. d, Representative fluorescent image of a densified collagen tube
(4 weeks after seeding) seeded with RFP+ COs. Scale bar, 200 µm.
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● Deionized (DI) water (Evoqua Water Technologies, cat. no. 2111-TR)
● Water for embryo transfer (Sigma, cat. no. W1503)
● Trigene (Distel disinfectant concentrate; Starlab, cat. no. TM309-C)
● Absolute ethanol (EtOH; Fisher Scientific, cat. no. 10041814)
● Trypan blue solution (Thermo Fisher Scientific, cat. no. 15250061) ! CAUTION Trypan blue is a
potential carcinogen and can potentially cause damage to fertility.
● Donkey serum (AbD Serotec, cat. no. c06sb)
● Triton X-100 solution (Sigma, cat. no. X100-500ML)
● Paraformaldehyde (16% (wt/vol) PFA; Alfa Aesar, cat. no. 30525-89-4) ! CAUTION PFA contains
formaldehyde, which is carcinogenic. Paraformaldehyde can cause tissue damage upon inhalation,
ingestion, or contact with the skin; it should be handled using appropriate safety measures.
● Cytokeratin 7 antibody (Abcam, cat. no. ab68459; Supplementary Table 1)
● Cytokeratin 19 antibody (Abcam, cat. no. ab7754; Supplementary Table 1)
● Goat anti-human Sox9 (R&D Systems, cat. no. AF3075; Supplementary Table 1)
● Rabbit anti-human albumin (Abcam, cat. no. ab137885; Supplementary Table 1)
● Mouse anti-human GGT-1 (Abcam, cat. no. ab55138; Supplementary Table 1)
● Donkey anti-mouse Alexa Fluor 488 (Life Technologies, cat. no. A2102; Supplementary Table 1)
● Donkey anti-rabbit Alexa Fluor 568 (Life Technologies, cat. no. A10042; Supplementary Table 1)
● Donkey anti-goat Alexa Fluor 488 (Life Technologies, cat. no. A21447; Supplementary Table 1)
● GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, cat. no. RTN70-1KT)
● MaxDiscovery gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit (Newmarket Scientific,
cat. no. 5601-01)


























































Fig. 11 | Characterization of bioengineered biliary tissue. a, Immunofluorescence images demonstrating expression
of key biliary markers in CO-seeded PGA scaffolds (6 weeks after seeding). Scale bar, 100 μm. b, CO-seeded
PGA scaffolds demonstrate GGT activity (4 weeks after seeding). n = 3; MEFs used as a negative control. Error bars,
s.d.; individual data points are shown; ****P < 0.0001, two-tailed Student’s t-test. c, Immunofluorescence images
showing expression of key biliary markers in CO-seeded densified collagen sheets (4 weeks after seeding). Scale bar,
100 μm. d, CO-seeded collagen scaffolds demonstrate GGT activity (4 weeks after seeding). n = 3; MEFs used as
a negative control. Error bars, s.d.; individual data points are shown; **P = 0.0055, two-tailed Student’s t-test.
e, Immunofluorescence images showing expression of key biliary markers in CO-seeded densified collagen tubes
(6 weeks after seeding). Scale bar, 100 μm. f, CO-seeded collagen tubes demonstrate GGT activity (4 weeks after
seeding). n = 3; MEFs used as a negative control. Error bars, s.d.; individual data points are shown; ****P = 0.0001,
two-tailed Student’s t-test. GGT activity was assessed using a commercially available kit (MaxDiscovery gamma-
Glutamyl Transferase (GGT) Enzymatic Assay Kit) according to the manufacturer’s instructions. a.u., absorbance
units; MEFs, mouse embryonic feeders.
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● Hoechst 33258 (Sigma-Aldrich, cat. no. B2883)
● Dimethyl sulfoxide (DMSO; Sigma-Aldrich, cat. no. D8418)
● Superglue (Everbuild, cat. no. 78871)
● Red cell lysis buffer (Sigma-Aldrich, cat. no. 11814389001)
● RNA lysis buffer (Sigma-Aldrich, cat. no. L8285)
● Accutase (Thermo Fisher Scientific, cat. no. A1110501)
Equipment
● Plate heater (TAP Biosystems, cat. no. 016-0R10)
● Inverted microscope (Olympus, cat. no. CKX41)
● Tissue culture (TC)-treated culture dish (100 mm; Corning, cat. no. 430167)
● Costar 24-well, clear, TC-treated multiple-well plates (Corning, cat. no. 3526)
● Surgical scalpel blade (no. 22, sterile; Swann Morton, cat. no. 0508)
● Dumont no. 5 fine forceps (FST, cat. no. 11254-20)
● Centrifuge tubes (15 and 50 ml; Corning, cat. nos. 430791 and 430291)
● Vacuum filter/storage bottle system (500 ml; 0.22-μm pore; Corning, cat. no. 431097)
● CO2 incubator (37 °C, 5% CO2; Sanyo, cat. no. MCO-18AC)
● Centrifuge (Eppendorf, cat. no. 5804)
● Orbital shaking incubator (New Brunswick Scientific, cat. no. M1299-0082)
● Disposable serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489)
● Graduated filter tips (1,000, 200, 20 and 10 μl; Starlab, cat. nos. S1122-1830, S1120-8810, S1120-1810
and S1120-3810)
● Cryotube vials (2 ml; Thermo Scientific, cat. no. 368632)
● AutoMACS Pro Separator (MACS Miltenyi Biotech, cat. no. 130-092-545)
● Cell strainers (40 μm; Corning, cat. no. 352340)
● Countess II automated cell counter (Thermo Fisher Scientific, cat. no. AMQAX1000)
● Countess cell counting chamber slides (Thermo Fisher Scientific, cat. no. C10283)
● Insulin syringes (1 ml; VWR, cat. no. 613-4892)
● Syringes (20 ml; Fisher Scientific, cat. no. 15829152)
● Needles (18 and 23 gauge; Camlab, cat. nos. 305180 and 300700)
● Stainless steel fine tweezers (Onecall, cat. no. 1779183)
● Dissecting scissors (straight; Fisher Scientific, cat. no. 15207266)
● Precision wipes (Kimtech; Fisher Scientific, cat. no. 12660543)
● Self-seal sterilization pouches (Fisher Scientific, cat. no. 15428782)
● Syringe filters (0.2 µm; Fisher Scientific, cat. no. 10268401)
● Six-well plates (Fisher Scientific, cat. no. 10396482)
● Autoclave tape (Greiner Bio-One, cat. no. TAP02)
● Micro-spatula (21-mm length; VWR, cat. no. 231-0446)
● Specimen tubes (flat bottom, 10 mm; Samco, cat. no. G05017)
● Nylon membrane (10-μm pore size, hydrophilic; Millipore, cat. no. NY1002500)
● Syringe (25 μl; model no. 1702; Hamilton, cat. no. 80265)
● Small-hub removable needle (34-gauge; Hamilton, cat. no. 207434) c CRITICAL Although the exact
make and model of syringe and removable needle can vary according to the researcher’s preference, it
is essential that small-volume syringes and removable needles with no dead space be used for seeding
the tubular scaffolds (Step 40B), because of the very small (25-μl) volumes needed for seeding.
● Funnel (3D-printed in-house)
● Metallic wire (Alfa Aesar, cat. no. 010408.G6)
● Base (3D-printed in-house)
● M4 screws and nuts (4×; RS Components, cat. no. 8199004)
● Screwdriver (RS Components, cat. no. 459-3972)
● Class II biological safety cabinet (Esco Airstream Class II, model no. AC2-6S1)
● Falcon tube (15 ml; Appleton Woods, cat. no. BF031)
● Cryovial (Elkay Laboratory Products, cat. no. 127-T311-200)
● Parafilm (Fisher Scientific, cat. no. 11762644)
● Confocal microscope (Zeiss, model no. LSM 700)
● 3D printer (RS PRO IdeaWerk Pro; RS Components, cat. no. 8625705)
● Hemocytometer or an automated cell counter (Fisher Scientific, cat. no. 13444890)
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Software
● FlowJo v.10.4.2 (https://www.flowjo.com/)
● Computer-aided design (CAD) package (Autodesk Inventor; https://www.autodesk.com/products/
inventor/overview)
● 3D printer software (Doraware; https://www.dysoncentre.eng.cam.ac.uk/DoraWare)
● ImageJ v1.51h software (Wayne Rasband, NIHR; http://Imagej.nih.gov/ij)
Reagent setup
Human biliary and liver tissue
Primary tissue can be obtained from surgically excised gallbladder or bile duct tissue, ERCP brushings
or liver biopsies. Once collected, tissue should be stored immediately at 4 °C in William’s E+medium
with 50 ng/ml of EGF and 10 μM Y27632 or in UW cold storage solution. ! CAUTION Leaving
primary tissue in cold storage in either William’s E+ or UW for longer than 8 h before processing will
negatively affect the viability of the isolated cells.
Nicotinamide 0.4 M stock solution
Dissolve 24.4 g of nicotinamide powder in 500 ml of embryo transfer water. c CRITICAL Sterilize the
nicotinamide stock solution using a vacuum filter/storage bottle system. Mix it well before filtration.
Store the solution at 4 °C for up to 3 months.
Sodium bicarbonate 1 M stock solution
Dissolve 42 g of sodium bicarbonate powder in 500 ml of embryo transfer water. c CRITICAL Sterilize
the sodium bicarbonate stock solution using a vacuum filter/storage bottle system. Mix it well before
filtration. Store the solution at 4 °C for up to 3 months.
Ascorbic acid trisodium salt 100 mM stock solution
Dissolve 16.1 g of ascorbic acid trisodium salt powder in 500 ml of embryo transfer water.
c CRITICAL Sterilize the ascorbic acid trisodium salt stock solution using a vacuum filter/storage
bottle system. Mix the solution well before filtration. Store it at 4 °C for up to 3 months. Protect it
from light.
D-Glucose 1 M stock solution
Dissolve 90.1 g of D-glucose powder in 500 ml of embryo transfer water. Warm the mixture
to 50 °C to facilitate dissolution. c CRITICAL Sterilize the D-glucose stock solution using a
vacuum filter/storage bottle system. Mix the solution well before filtration. Store it at 4 °C for up to
3 months.
Dexamethasone 10 mM stock solution
Dissolve 100 mg of dexamethasone in 25.4797 ml of DMSO. Prepare 50- to 100-μl aliquots. Store
them at −80 °C for up to 12 months.
Supplemented William’s E medium (William’s E+ medium)
Mix 443 ml of William’s E medium with 12.5 ml of nicotinamide stock solution, 8.5 ml of sodium
bicarbonate stock solution, 1 ml of ascorbic acid trisodium salt stock solution, 7 ml of glucose stock
solution, 3.15 ml of sodium pyruvate, 10 ml of HEPES solution, 5 ml of ITS+ premix, 5 μl of
dexamethasone, 5.3 ml of glutamine and 5 ml of pen–strep. c CRITICAL Sterilize William’s E+
medium using a vacuum filter/storage bottle system. Mix the medium well before filtration. Store it at
4 °C for up to 1 month. Warm it to 37 °C before use.
Sodium bicarbonate 7.5% (wt/vol) stock solution
Dissolve 3.75 g of sodium bicarbonate powder in 46.25 ml of DI water. c CRITICAL Sterilize the
sodium bicarbonate stock solution using a 50-ml syringe and a 0.2-μm syringe filter. Mix it well before
filtration. Store the solution at 4 °C for up to 3 months.
70% (vol/vol) EtOH
Mix 700 ml of absolute EtOH and 300 ml of DI water. This solution can be stored indefinitely.
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Matrigel
10-ml Matrigel vials should be thawed slowly in a refrigerator at 4 °C overnight. Thawed Matrigel
should be mixed well and then divided into 1-ml aliquots. Aliquots of Matrigel should always be
made in a class II biological safety cabinet to avoid bacterial contamination. Matrigel should be kept
constantly on ice to avoid solidification. All equipment coming into contact with Matrigel should be
precooled to 4 °C. This includes pipette tips and media for diluting Matrigel. Tubes used for making
aliquots should be kept on ice. Store Matrigel aliquots at −20 °C or −80 °C for up to 3 months.
c CRITICAL Each aliquot should undergo a maximum of two freeze–thaw cycles. This can be achieved
by adjusting aliquot volumes accordingly.
3× supplemented William’s E+ solution
Supplement William’s E+medium with 1.5 μg/ml R-spondin-1, 300 ng/ml DKK, 150 ng/ml EGF and
3 μM Y27632 (3× is the typical concentration for all supplementary cytokines). The supplemented
medium should be prepared immediately before use and should not be stored.
Matrigel–supplemented William’s E+ solution droplets
COs are cultured in 3D conditions, suspended in 50-μl droplets composed of a 66.7% (vol/vol)
Matrigel and 33.3% (vol/vol) 3× supplemented William’s E+ solution, which form a dome after
plating (Fig. 4b, image 6(i)). Before plating, prepare a master mix with a volume corresponding to the
number of droplets that will be plated (as described in Steps 3–10). Importantly, for generating this
master mix, COs or primary cholangiocytes are first resuspended in the 3× supplemented William’s
E+ solution (Step 3) and Matrigel is subsequently added (Step 5). To calculate the volume of
supplemented William’s E+ solution needed for resuspension of the CO pellet, the following formula
can be used:
Volume of supplementedWilliam’s Eþmedium¼ Number of COwellsð Þ ´ 50 μl½ =3
The master mix must be kept at 4 °C and used immediately after preparation. c CRITICAL As the
volume of medium needed to resuspend the CO pellet will typically be very small, it is advisable to
instead prepare a larger volume of 3× concentrated William’s E+ solution. This can then be diluted to
1× and added to the wells after plating as their plating medium. This volume corresponds to 1/3 of the
total number of wells to be plated (e.g., if plating 12 wells, prepare 4 ml of 3× William’s E+ solution),
assuming 1 ml of medium/well is used. A small aliquot of the resulting 3× solution can then be used to
resuspend the pellet, and the remaining solution can be diluted to 1× with William’s E+ medium devoid
of additional cytokines and used as plating medium. For example, if plating 12 wells, resuspend the
pellet in 200 μl of 3× supplemented William’s E+ solution, taken from the initial 4 ml of 3× supple-
mented William’s E+ solution. After CO plating (Steps 3–10), add 8 ml of non-supplemented William’s
E+ medium to the 4 ml of supplemented William’s E+ solution to make a 1× supplemented William’s
E+ solution. c CRITICAL This solution should be kept on ice for the duration of the Procedure to avoid
Matrigel solidification.
Matrigel (66.7% (vol/vol)) solution
To obtain the volume of Matrigel needed when plating, multiply the volume of 3× supplemented
William’s E+ solution by 2. For example, if plating 12 wells, 200 μl of supplemented William’s E+
solution should be added to the pellet, followed by 400 μl of Matrigel. c CRITICAL The 3× supple-
mented William’s E+ solution should be precooled to 4 °C. c CRITICAL This solution should be kept
on ice for the duration of the Procedure to avoid Matrigel solidification.
Liberase
Reconstitute the lyophilized Liberase enzyme with 10 ml of sterile embryo transfer water, per the
manufacturer’s instructions, to obtain a stock solution. c CRITICAL Divide the reconstituted Liberase
stock solution into 1-ml aliquots to avoid repeated freeze–thaw cycles and store at −15 °C to −25 °C for
up to 6 months. Reconstitution and aliquot preparation should take place in a class II biological safety
cabinet to avoid contamination.
DNase I
Reconstitute the lyophilized DNase I to a 4 mg/ml stock solution using sterile PBS. c CRITICAL Divide
the reconstituted DNase I stock solution into 100-μl aliquots to avoid repeated freeze–thaw cycles and
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store at −80 °C for up to 6 months. Reconstitution and aliquot preparation should take place in a
class II biological safety cabinet to avoid contamination.
1% (wt/vol) BSA in PBS
Weigh out 5 g of BSA powder and dissolve in 500 ml of PBS to obtain a 1% solution. c CRITICAL Sterilize
1% (wt/vol) BSA in PBS solution using a vacuum filter/storage bottle system. Mix the solution
well before filtration. Prepare aliquots in 50-ml centrifuge tubes and store at −20 °C to avoid
contamination.
MACS buffer
Prepare a 1-in-20 dilution of MACS BSA stock solution in AutoMACS rinsing solution.
c CRITICAL MACS buffer should be freshly prepared at the point of use and should be kept at
4 °C. Buffer preparation should take place in a class II biological safety cabinet to avoid
contamination.
0.1% (vol/vol) Triton X-100 solution
Add 50 μl of Triton X-100 to 50 ml of PBS in a 50-ml centrifuge tube. Gently shake the tube by
inversion until the Triton X-100 is fully dissolved. This solution can be stored at room temperature
(23 °C) for up to 3 months or at 4 °C for up to a year.
Equipment setup
Plate heater setup
Clean the plate heater with Trigene and 70% (vol/vol) EtOH and place it in a class II biological
safety cabinet. Set the temperature to 37 °C and place a 24-well plate on the heating surface.
c CRITICAL Allow a minimum of 30 min for the plate to warm up before plating Matrigel with cells. If
you are using multiple plates, these can be prewarmed in an incubator for a minimum of 30 min, with
each plate placed on the plate heater immediately before plating.
AutoMACS Pro Separator setup
Run column exchange before use. Check that the columns are secured and that there are no
leaks anywhere in the system. Check that there is sufficient running buffer, washing solution and
70% (vol/vol) EtOH and that the waste bottle is not too full. Run an additional ‘Qrinse’ before starting
cell sorting. To save time, this can be done while the cells are incubating with the MACS beads. To
shut down the machine after EpCAM sorting, select the ‘Sleep’ program. Turn off the machine once
the ‘Sleep’ program has finished.
Fabrication and assembly of densification chamber for densified collagen tubes
The densification chamber, used to form the densified collagen tubes, requires fabrication and
assembly ahead of the collagen gel preparation. This involves 3D printing of the base and funnel
pieces, mounting a rigid metal wire in the base and fixing paper towels between the base and funnel
as follows.
1 Design the chamber geometry using a CAD package (e.g., Autodesk Inventor). See Supplementary
Software 1 and 2 for examples of designs we have used successfully.
2 Export the design as a .stl file and prepare the file for 3D printing using 3D printer software
(e.g., Doraware).
3 3D-print the chamber model using polylactic acid filament and assemble the components shown in
Fig. 8a, image 1.
4 Mount a straight rigid wire in the hole in the base piece of the chamber by gluing it into place with
superglue (Fig. 8a, image 2). c CRITICAL STEP Let the superglue cure before continuing (1 h).
5 Fold two sheets of absorbent precision wipes four times and, using scissors, cut to the size of the
base plate. Autoclave these paper towels in an autoclave pouch. c CRITICAL STEP Let the towels
dry fully before continuing.
6 Sterilize the base plate and funnel piece by immersion in 70% (vol/vol) EtOH.
7 Place the 3D-printed components under a sterile class II biological safety cabinet until dry.
8 Autoclave 4× M4 screws and nuts.
9 Using a sterile 23-gauge needle, punch a hole through the center of the sheets and feed the mounted
metallic wire through the needle (Fig. 8a, image 3).
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10 Remove the 23-gauge needle and push the paper towels down.
11 Feed the metallic wire through the funnel piece (Fig. 8a, image 4) and fix the funnel piece to the
base piece, using 4× M4 screws and nuts (Fig. 8a, image 5).
12 Tighten the screws, using a screwdriver. The chamber is now ready for the densification process.
c CRITICAL STEP The screws must be tight in order to prevent leakage of water into the towels
before a collagen gel forms. c CRITICAL STEP The top of the metallic wire must not extrude above
the top of the funnel. This is a necessary condition for successful collagen densification for tube
formation.
Procedure
Derivation of COs from primary human tissue ● Timing 1.5–10 h
1 Obtain primary tissue from surgically excised gallbladder or bile duct tissue, ERCP brushings or
liver biopsies (Fig. 1b). Once collected, tissue should be stored immediately as described in the
‘Reagent setup’ section.
! CAUTION Dissection of tissue should take place in a class II biological safety cabinet under aseptic
conditions.
j PAUSE POINT Tissue can be kept in medium/cold storage solution for up to 8 h, although for
optimal viability, tissue should be processed as soon as possible after collection. Guidance on the
maximum length of storage before processing for each tissue type is shown in Supplementary Fig. 1.
2 For derivation of COs from excised bile ducts or gall bladders, see option A. For derivation of COs
from ERCP brushings, see option B. For derivation of COs from liver tissue, see option C, and for
derivation of COs from an EpCAM+ single-cell suspension, see option D.
c CRITICAL STEP Following of Step 2D is recommended if a highly purified CO population is
required in early passages, whereas following of Step 2C is advised in instances in which limited
primary tissue is available (e.g., liver biopsies from live donors).
(A) Derivation of ECOs from deceased organ donors ● Timing 1 h 20 min–1 h 50 min,
including plating
c CRITICAL All equipment used should be sterile and all work must be done under aseptic
conditions in a class II biological safety cabinet.
(i) Transfer the tissue from the storage container to an empty 10-cm plate.
(ii) Using a scalpel and forceps, make a longitudinal incision along the length of the excised
bile duct or from the fundus to the neck of the excised gallbladder (Fig. 2b, images 1A(ii)
and 2) to expose the lumen. This step should result in a flat sheet of biliary tissue
with the biliary epithelium on the luminal surface, usually pigmented yellow by
bile, and an ‘exterior’ surface corresponding to the outer wall of the bile duct or
gallbladder.
! CAUTION Ensure the luminal surface is facing upward to avoid the loss of cholangiocytes.
(iii) Wash the tissue by transferring it to a 50-ml centrifuge tube containing PBS to remove
excess bile (Fig. 2b,c, image 2). Repeat twice, using a fresh tube each time.
c CRITICAL STEP PBS washes must be performed cautiously to prevent detachment of the
biliary epithelial layer. This is particularly important if the bile duct or gallbladder tissue
has been kept on ice for <2–4 h after surgical excision.
? TROUBLESHOOTING
(iv) Transfer the tissue to an empty plate.
(v) Add William’s E+ medium to the plate until the tissue is fully submerged in the medium.
It is not necessary to supplement the medium with additional cytokines.
! CAUTION The tissue must be submerged in the medium quickly to prevent it from
drying.
(vi) Gently scrape the luminal surface of the tissue with a scalpel to release the cholangiocytes
into the medium (Fig. 2b,c, image 3).
c CRITICAL STEP Examine the cell suspension under a microscope after scraping the
tissue and before collecting the cells into a centrifuge tube to ensure the mechanical
dissociation has been successful. The epithelial cells should be released from the tissue as
small clumps and should display columnar morphology (Fig. 2b,c, image 9).
(vii) Collect the medium and cells into a 50-ml centrifuge tube using a 10-ml pipette.
(viii) Wash the tissue again by adding ~10 ml of fresh medium directly to the luminal surface of
the tissue in the plate with a 10-ml pipette.
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(ix) Repeat the process of scraping and washing until the entire epithelial layer is collected. By
the end of this stage, the luminal side of the biliary tissue will appear smooth, losing
the characteristic velvet-like appearance of the biliary epithelium (Fig. 2b,c, images 1A(iii)
and 1B(iii)).
c CRITICAL STEP Scrape cautiously to avoid releasing fibrous tissue and debris into the
cell suspension.
? TROUBLESHOOTING
(x) Centrifuge the cells at 444g for 4 min at room temperature.
? TROUBLESHOOTING
(xi) Aspirate the supernatant.
(xii) Resuspend the pellet in 10 ml of William’s E+ medium (regardless of pellet size) to
wash the cells. If there is bile or debris remaining in the suspension, repeat this
wash step.
c CRITICAL STEP Remove large pieces of debris and fibrous tissue using a p1000 pipette,
as these may not be easily removed by washing.
? TROUBLESHOOTING
(xiii) Centrifuge the cells at 444g for 4 min at room temperature.
(xiv) If you wish to lyse red cells to avoid erythrocyte contamination, resuspend the cells in 10
ml of ice-cold red cell lysis buffer and incubate the cell suspension on ice for up to 10 min.
c CRITICAL STEP If red blood cells can be seen in the pellet after washing, red cell lysis is
recommended in order to obtain as pure a population of cholangiocytes as possible upon
initial plating, to encourage rapid formation and proliferation of COs. However, this step
can be omitted, if the yield of primary cholangiocytes is very low, to avoid cell loss during
the incubation and washing steps.
(xv) If you have lysed red cells, wash twice in William’s E+medium as described in Step 2A(xii)
before continuing with Step 2A(xvi).
(xvi) Aspirate the supernatant.
(xvii) Wash the pellet in William’s E+ medium.
(xviii) Plate the cells as described in Steps 3–10.
c CRITICAL STEP Typical morphology for COs plated from gallbladder or bile duct tissue
after 1 week and >20 weeks after plating is displayed in Fig. 2d, top and bottom,
respectively. COs should begin to form ~3 d after plating, and debris should disappear
from the CO culture after the first two passages.
? TROUBLESHOOTING
(B) Derivation of ECOs from ERCP brushings ● Timing 30 min
(i) Prepare a 50-ml centrifuge tube of William’s E+medium with 50 ng/ml of EGF and 10 μM
Y27632. Provide this tube to the clinicians before the start of the ERCP procedure.
(ii) Following brushing, wash the ERCP brush in the tube of medium to dislodge the collected
cells (Fig. 3a, image 2).
(iii) Transport the centrifuge tube at 4 °C to a class II biological safety cabinet under aseptic
conditions.
(iv) Centrifuge the 50-ml tube at 444g for 4 min at room temperature.
(v) Plate the resulting pellet of cells as described in the ‘Plating of primary cholangiocytes in
organoid format’ section below (Steps 3–10).
c CRITICAL STEP Typical morphology of COs derived from ERCP brushings immediately
after plating, 24 h after plating and 1 week after plating are displayed in Fig. 3b (image 5)
and 3c (top and bottom), respectively. Organoids should begin to form within 24 h of
plating, and debris should disappear from the organoid culture after the first two passages.
? TROUBLESHOOTING
(C) Derivation of ICOs from liver tissue ● Timing 30–45 min, including plating
(i) Place a liver biopsy core into a well of a six-well tissue culture plate. Alternatively, place a
small piece of liver tissue (~1 cm3) on a sterile 10-cm tissue culture dish and cut into small
pieces (~3–4 mm3) before transferring to a well of a six-well plate for further dissection.
(ii) Using a scalpel, carefully dissect the tissue into pieces as small as possible, approximately
<1 mm3 (Fig. 4b, image 1A, and Fig. 4c, image 1B).
c CRITICAL STEP Care should be taken to ensure that the tissue is cut as small as possible
so it can fit into a p1000 pipette tip (Fig. 4b,c, image 2). Tissue dissection should be done as
quickly as possible to prevent the tissue from drying out.
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(iii) Add 1 ml of William’s E+ medium with 50 ng/ml EGF and 10 μM (1 μl/ml) Y27632 to the
dissected liver tissue.
(iv) Transfer the dissected tissue and media to a 15-ml centrifuge tube, using a p1000 pipette
(Fig. 4b,c, image 3), and centrifuge at 300g for 2 min at room temperature (Fig. 4b,c,
image 4).
(v) Carefully aspirate the supernatant.
(vi) Wash the pellet in William’s E+ medium.
(vii) Centrifuge at 300g for 2 min at room temperature.
(viii) Plate the dissected tissue pieces, following the instructions in the ‘Plating of primary
cholangiocytes in organoid format’ section below (Steps 3–10) (Fig. 4b,c, image 6(i)).
c CRITICAL STEP Typical morphology for COs plated from diced liver tissue <1 week
after plating and >20 weeks after plating is displayed in Fig. 4d, left and right,
respectively.
? TROUBLESHOOTING
(D) Derivation of ICOs through EpCAM MACS sorting ● Timing 2–3 h
c CRITICAL The Liberase and DNase I solutions should be prewarmed to 37 °C before
starting the isolation process.
(i) Place a liver biopsy core into a well of a six-well tissue culture plate. Alternatively, place a
small piece of liver tissue (~1 cm3) on a sterile 10-cm tissue culture dish and cut it into
small pieces (~3–4 mm3) before transferring them to a well of a six-well plate for further
dissection.
(ii) Using a sterile scalpel, dissect the tissue into very small pieces (<1 mm3; Fig. 4b,c, image 2).
(iii) Add 1.5 ml of prewarmed Liberase digestion solution (0.5 U) with 4 mg/ml DNase I
(Supplementary Fig. 2b, image 3).
c CRITICAL STEP DNase I must be added during the dissociation to prevent the cells from
forming clumps.
(iv) Place the plate on a heated orbital shaker at 170 r.p.m. and 37 °C for 30 min. Ensure that
the plate is secured to the orbital shaker.
(v) Every 10 min, remove the tube from the rocker and gently pipette up and down with a
p1000 pipette.
c CRITICAL STEP Examine the cells under a microscope at these 10-min intervals to check
the progress of the dissociation. The dissociation will be finished once all the tissue has
been dissociated to a single-cell suspension, with only the collagen scaffold of the tissue
remaining (Supplementary Fig. 2b, image 4).
? TROUBLESHOOTING
(vi) After 30 min, or when a single-cell suspension has been obtained, stop the reaction by
adding an equivalent volume of cold 1% (wt/vol) BSA in PBS.
(vii) Filter the mixture through a 40-μm filter into a 15-ml centrifuge tube.
c CRITICAL STEP Filter gently and do not force any material through the filter, as this will
reduce viability and result in fibrous material in the final cell suspension.
? TROUBLESHOOTING
(viii) Centrifuge at 444g for 4 min at room temperature.
(ix) Aspirate the supernatant, using a p1000 pipette.
(x) Resuspend the pellet in 10 ml of red cell lysis buffer with 4 mg/ml DNase I and 10 μM
Y27632.
c CRITICAL STEP From this stage onward, aspiration of the supernatant should not be
done using a vacuum pump aspirator, as this presents a risk of losing the pellet.
(xi) Incubate the cells on ice in red cell lysis buffer for up to 10 min.
(xii) Add an equivalent volume of 1% (wt/vol) BSA in PBS to the red cell lysis buffer and
centrifuge at 444g for 4 min at room temperature.
(xiii) Aspirate the supernatant, using a p1000 pipette, and resuspend in 1 ml of cold 1% (wt/vol)
BSA in PBS with 4 mg/ml DNase I and 10 μM Y27632.
(xiv) Repeat this wash step one more time to ensure the complete removal of the red cell lysis
buffer, and resuspend the pellet once more in 1 ml of cold 1% (wt/vol) BSA in PBS with
4 mg/ml DNase I and 10 μM Y27632.
(xv) Take a 10-μl aliquot of the cell suspension and mix it with an equivalent volume of trypan
blue. Count the cells using a hemocytometer or an automated cell counter.
? TROUBLESHOOTING
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(xvi) Centrifuge the pellet at 444g for 4 min at room temperature.
(xvii) Resuspend the pellet in the appropriate volume of MACS buffer, FcR blocking reagent and
CD326 (EpCAM) MicroBeads according to the manufacturer’s instructions.
c CRITICAL STEP Use the cell count obtained in Step 2D(xv) to determine the appropriate
volume of each reagent to add for the number of cells according to the manufacturer’s
instructions (300 μl MACS buffer, 100 μl FcR blocking reagent and 100 μl CD326
(EpCAM) MicroBeads for every 5 × 107 total cells).
(xviii) Incubate the cells for 30 min at 4 °C.
(xix) While the cells are incubating, prepare the AutoMACS Pro Separator for cell sorting. See
‘AutoMACS Pro Separator setup’ in the ‘Equipment setup’ section for instructions.
(xx) Wash the cells with 5 ml of 1% (wt/vol) BSA in PBS.
(xxi) Centrifuge at 300g for 10 min at room temperature.
(xxii) Aspirate the supernatant and resuspend in 5 ml of 1% (wt/vol) BSA in PBS with 4 mg/ml
DNase I and 10 μM Y27632.
(xxiii) Filter the sample through a 40-μm filter immediately before sorting (Supplementary
Fig. 2b, image 6)
(xxiv) Run the sample through the AutoMACS Pro Separator on a ‘POSSELD’ program. This will
select for the EpCAM+ fraction. Collect the EpCAM+ fraction in a 15-ml centrifuge tube.
c CRITICAL STEP Ensure this takes place under aseptic conditions; the AutoMACS Pro
Separator should be in a class II biological safety cabinet, and all buffers and running
solutions should be kept sterile.
c CRITICAL STEP The MACS centrifuge tube rack should be precooled in the refrigerator
for at least an hour before use.
? TROUBLESHOOTING
(xxv) Top up the 15-ml centrifuge tube with 1% (wt/vol) BSA in PBS.
(xxvi) Centrifuge at 444g for 4 min at room temperature.
(xxvii) Plate the cell suspension, following the instructions in the ‘Plating of primary
cholangiocytes in organoid format’ section (Steps 3–10) below.
c CRITICAL STEP Typical morphology for COs plated from EpCAM+ liver tissue <1 week
after plating is displayed in Supplementary Fig. 2c. Organoids will grow from single cells
over the course of 5–15 d after plating. After the first passage, EpCAM+ organoids will
display typical CO morphology, as demonstrated in Supplementary Fig. 4a, image 5.
? TROUBLESHOOTING
Plating of primary cholangiocytes in organoid format ● Timing 10–40 min
c CRITICAL Preheat an adequate number of 24-well tissue culture plates at 37 °C for at least 1 h before
use (preheating overnight is preferable).
c CRITICAL Thaw Matrigel on ice for 2 h to overnight before starting the isolation procedure. Matrigel
will solidify at room temperature and so should always be kept on ice when in use. It is important to
work quickly to prevent the Matrigel solidifying during the plating procedure.
c CRITICAL COs should be plated in 3DMatrigel domes composed of a 2:1 ratio (33.3% to 66.7% (vol/vol)
solution) of Matrigel and William’s E+ medium. The CO pellet must first be resuspended in 3×
supplemented William’s E+ solution before the separate addition of Matrigel. See ‘3× supplemented
William’s E+ solution’ in the ‘Reagent setup’ section for instructions on how to calculate the volumes of
3× William’s E+ and Matrigel required to prepare this solution.
3 Resuspend the CO pellet in a volume of the 3× supplemented William’s E+ solution appropriate
for the number of wells being plated. For example, if plating nine wells, resuspend in 150 μl of
William’s E+ medium with 1.5 µg/ml R-spondin, 150 ng/ml EGF, 30 μM (3 μl/ml) Y27632 and
300 ng/ml DKK-1.
c CRITICAL STEP Y27632 should always be freshly added at this stage and kept in the culture
medium for 48 h to ensure maximal survival of the cholangiocyte cells.
4 Mix the Matrigel stock thoroughly with a p1000 pipette.
c CRITICAL STEP Matrigel should be kept on ice throughout the entire procedure and must be
mixed with care to avoid bubbles.
5 Add Matrigel to the cell suspension in a 2:1 ratio (66.7% (vol/vol)) and mix well. See ‘Matrigel
(66.7% (vol/vol)) solution’ in the ‘Reagent setup’ section for instructions on how to calculate the
amount of Matrigel required.
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6 Use a p1000 pipette to plate the organoids in 50-µl Matrigel–medium domes, each in a well of a
24-well plate. To plate the dome, hold the tip of the p1000 pipette very close to the surface of the
well, in the center, and slowly start pipetting. Move the pipette upward as the droplet forms.
c CRITICAL STEP Do not go down to the second stop of the pipette, as this will form bubbles in the
Matrigel dome.
c CRITICAL STEP Mix thoroughly before plating each dome.
? TROUBLESHOOTING
7 Allow the Matrigel to solidify for 1–2 min in the plate heater. Gently tilt the plate to test that the
Matrigel has solidified.
8 Invert the plate and keep it in the 37 °C incubator for 30 min. This step should be omitted when
plating dissected liver tissue (Step 2C) or EpCAM+ single cells (Step 2D).
c CRITICAL STEP Without the plate inversion step, cell clumps are likely to migrate to the
bottom of the well and attach to the plate. If this happens, the cells will not be able to form
organoids.
? TROUBLESHOOTING
9 Make up the 3× William’s E+ medium solution to a final concentration of 500 ng/ml R-spondin,
50 ng/ml EGF, 10 μM (1 μl/ml) Y27632 and 100 ng/ml DKK-1 (±50 ng/ml HGF) by following the
formula below:
Final volume of medium ¼Initial volume of mediumprepared in Step 5
þ Initial volume of mediumprepared in Step 5 ´ 2½ 
For example, if 1 ml of medium was initially prepared with 1.5 μg/ml R-spondin, 150 ng/ml
EGF, 30 μM (3 μl/ml) Y27632 and 300 ng/ml DKK-1 (±50 ng/ml HGF and 6 μM FSK), add a
further 2 ml of William’s E+medium without cytokines, for a total of 3 ml of medium with 500 ng/
ml R-spondin, 50 ng/ml EGF, 10 μM (1 μl/ml) Y27632 and 100 ng/ml DKK-1 (±50 ng/ml HGF and
2 μM FSK).
10 Add 1 ml of this supplemented medium per organoid well, using a 5- or 10-ml pipette. Place the cell
cultures in the cell culture incubator.
c CRITICAL STEP Add the medium slowly to the side of each well to avoid disrupting the
Matrigel domes.
c CRITICAL STEP When plating from primary cells, organoids from the CBD and gallbladder
should begin to form within 2 d of plating and should be ready for the first passage within 5–7 d of
initial plating (Fig. 2d, bottom, and Fig. 3c, bottom). Organoids from liver biopsies or excised liver
tissue should take ~5–10 d to develop (Fig. 4d, right) and should be passaged when the plate is
approaching 80% confluency.
c CRITICAL STEP CO lines should always express the biliary markers CK19, CK7, Sox9 and GGT
(Fig. 6a,b) and display ALP and GGT activity (Fig. 6c,d, respectively). Established CO lines should
be composed of a <99% pure population of CK19+/CK7+ cells (Fig. 6e). After approximately
passage 2, CO lines derived from different tissues of origin or through different derivation methods
will appear morphologically identical (Supplementary Fig. 4a).
? TROUBLESHOOTING
Cell culture: changing medium for maintenance of CO lines ● Timing Variable, depending
on cell line; hands-on time is 20 min every 48 h
c CRITICAL Once primary cholangiocytes have been isolated and plated as described above, culture
conditions for all CO lines are the same, and the following procedural steps for CO maintenance
(Steps 15–30) apply equally to all CO lines, regardless of tissue of origin or derivation method. Equally,
the characterization data shown in Fig. 6 are representative of CO lines derived from all tissue types
or derivation methods.
c CRITICAL Change the medium approximately every 48 h.
11 Prepare 1 ml of William’s E+ medium per well, supplemented with 500 ng/ml R-spondin, 50 ng/ml
EGF and 100 ng/ml DKK-1, for each well of a 24-well plate. In addition, 50 ng/ml HGF and 2 μM
FSK can be added optionally for slow-growing lines requiring >5–7 d between passages.
? TROUBLESHOOTING
12 Carefully aspirate the old medium from the well.
c CRITICAL STEP Tilt the plate when aspirating and aspirate from the edge of the well to avoid
disrupting the Matrigel dome.
PROTOCOL NATURE PROTOCOLS
1908 NATURE PROTOCOLS | VOL 14 | JUNE 2019 | 1884–1925 |www.nature.com/nprot
13 Add the new medium to all the wells, using a 5- or 10-ml pipette.
14 Continue to culture cells.
c CRITICAL STEP When adding medium, tilt the plate and hold the pipette against the side of the
well to avoid disrupting the Matrigel dome. Add the medium slowly.
Passaging of CO lines for maintenance ● Timing 95 min
15 CO lines should be passaged approximately once every 5 d. However, the optimal time for
passaging should be decided on basis of the confluency of the organoids; therefore, the cells should
be examined daily (Fig. 5b, image 1).
c CRITICAL STEP Allowing the wells to become too confluent may lead to the collapse of organoids
and subsequent cell death (Supplementary Fig. 4b, image 2).
16 Remove the medium and add 500 μl of cell recovery solution to each well. The pipette should be
aimed at the center of the Matrigel dome and the cell recovery solution should be ejected forcefully
to disrupt the surface of the dome.
17 Mechanically dissociate the remaining Matrigel dome by scraping with a p1000 pipette (Fig. 5a,
image 1).
c CRITICAL STEP Ensure that the whole surface of the well has been scraped to remove as many
cells as possible.
18 Transfer the cells from each well to a 15-ml centrifuge tube.
19 Wash each well with 500 μl of cell recovery solution. (Optional) The same 500 μl can be carried
across to each of the wells at this step to minimize the volume of cell recovery solution required for
the washes.
20 Incubate the cells on ice at 4 °C for 30 min to fully dissolve the Matrigel.
21 Centrifuge at 444g for 4 min at room temperature.
? TROUBLESHOOTING
22 Aspirate the supernatant.
23 If appropriate, use this wash step to split the cell pellet into multiple fractions.
c CRITICAL STEP We recommend splitting the pellet appropriately to allow the generation of a
single plate of organoids from a single pellet fraction. This is important in order to avoid prolonged
use of the Matrigel master mix in the following steps. This can lead to Matrigel solidification and
gravitation of larger cell clumps to the bottom of the mix, compromising uniform distribution of
cells and seeding density.
c CRITICAL STEP CO pellets can typically be split at a ratio between 1:4 and 1:6, depending on the
number of wells in the initial plate and their confluency (Fig. 5a). For reference, Fig. 5b, image 4
depicts a representative pellet for plating nine CO wells (~4.0 ×105 cells), obtained after a 1:4 split.
24 Resuspend in William’s E+ medium, mixing well and using the following formula to calculate the
minimum volume of medium required:
Volume of medium to add mlð Þ¼ Number of pellets to bemade after splitting
For example, for a 1:4 split, resuspend in 4 ml of medium.
25 Divide the cell suspension among multiple 15-ml centrifuge tubes, adding 1 ml per tube (e.g., for a
1:4 split, share the 4-ml volume equally among four 15-ml centrifuge tubes).
26 Centrifuge at 444g for 4 min at room temperature.
27 (Optional) Cryopreserve CO pellets at this point, if necessary, by resuspending each in 1 ml of
CellBanker 2, transferring to a 2-ml cryovial and freezing immediately at −80 °C.
c CRITICAL STEP For long-term cryopreservation, COs should be stored in a liquid nitrogen
cryobank.
c CRITICAL STEP Cryovials should be transferred immediately to dry ice after removal from liquid
nitrogen storage, to prevent uncontrolled thawing. CO cryovials should be thawed in a 37 °C water
bath, and the cells should be transferred immediately to prewarmed William’s E+ medium
supplemented with 10 µM Y27632 and centrifuged at 444g for 4 min at room temperature. Thawed
cells can then be plated as described in Steps 3–10.
j PAUSE POINT Cryopreserved COs can be stored for short-term storage (<6 weeks) at −80 °C,
but long-term storage at this temperature will affect the viability and overall health of the line. COs
can be stored in a liquid nitrogen cryobank for an extended duration (>10 years), provided the
temperature is not permitted to rise above −130 °C.
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28 Resuspend the pellet in a volume of 3× supplemented William’s E+ medium (supplemented with
1.5 μg/ml R-spondin, 150 ng/ml EGF, 30 μM (3 μl/ml) Y27632 and 300 ng/ml DKK-1) as described
in Step 5. See the ‘3× supplemented William’s E+ solution’ in the ‘Reagent setup’ section for
instructions on how to prepare this solution and how to determine the appropriate volume to add.
c CRITICAL STEP The number of plated wells of COs depends on the size of the resulting cell
pellet. For example, a pellet of ~4.0 × 105 cells (Fig. 5b, image 4) should be plated in nine wells.
29 Use a p200 pipette to mechanically dissociate the pellet to break up the organoids. This should
typically be done ~30–50 times, although the exact number will vary according to the starting size
of the organoids.
c CRITICAL STEP Organoids must be dissociated into small clumps of ~10–20 cells to allow cysts
to reform after splitting (Fig. 5b, image 5). Mechanical dissociation should be done slowly to avoid
damaging the cells.
c CRITICAL STEP Organoid breaking must be carried out with a p200 pipette, even if the volume of
3× William’s E+ medium required exceeds 200 μl. In that case, add the initial 200 μl and break the
organoids as described in this step before adding the remaining volume of the medium.
? TROUBLESHOOTING
30 Plate the organoids onto a preheated 24-well tissue culture plate as described in Steps 3–10.
c CRITICAL STEP Organoids should reform from small clumps into organoids 24–48 h after
plating (Fig. 5b, image 7(ii); enlarged image in Supplementary Fig. 2, image 2). Organoids should
proliferate rapidly and should reach ~80% confluence 5 d after plating.
? TROUBLESHOOTING
Preparation of 5 mg/ml collagen gel before generation of densified collagen scaffolds
● Timing 10 min
c CRITICAL Densified collagen scaffolds can be prepared to yield a sheet or tubular form. The sheet
form produces a structure that has a well-defined thickness and density, and yields highly reproducible
scaffolds, owing to the controlled nature of the process, whereas the collagen tube method is more
technically challenging.
c CRITICAL To produce a collagen gel, first mix a collagen gel precursor solution. This neutralizes the
pH of the stock collagen solution and raises the ionic content, which induces the collagen fibrils to form
a gel. Here, we produce two collagen sheets by preparing 2.5 ml of collagen precursor solution, which is
prepared to a final collagen concentration of 5 mg/ml. 1 ml of this volume is sufficient to produce a
collagen scaffold of a reproducible thickness (~750 μm), using the recommended specimen tubes. The
quantities in parentheses represent the volumes required for a final volume of 2.5 ml, which is enough
for two collagen sheets.
c CRITICAL All equipment and reagents must be sterilized before use, and the following steps must take
place in a class II biological safety cabinet under aseptic conditions.
31 Transfer 10× Medium 199 at a 10% (vol/vol) final volume to a sterile 50-ml tube (0.25 ml).
32 Calculate the volume of stock collagen solution required to yield a final collagen concentration of
5 mg/ml (1.25 ml). This is calculated by the following formula:
Volume stock collagen mlð Þ ¼ 5 mg=mlð Þ
Stock collagen concentration mg=mlð Þ
´Precursor solution final volume mlð Þ
33 Add sterile 1 M NaOH solution to the precursor solution at 2.5% (vol/vol) the volume of stock
collagen solution to be added (31 μl).
34 Add sterile 7.5% (wt/vol) sodium bicarbonate solution to the precursor solution at 3% (vol/vol) the
final volume (75 μl).
c CRITICAL STEP This volume makes up a constituent volume of the collagen gel precursor
solution and so must be accurate, or the concentration of collagen after gelation will vary.
35 Using a 1-ml syringe, transfer stock collagen solution, at the precalculated volume, to the precursor
solution (1.25 ml).
c CRITICAL STEP The stock collagen solution will be viscous because of its high concentration; use
a syringe rather than a pipette to transfer the collagen accurately.
? TROUBLESHOOTING
36 Shake the collagen precursor solution vigorously until it develops a uniform color.
? TROUBLESHOOTING
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37 Calculate the remaining volume of cell medium to be added to the precursor solution to reach the
required final volume (0.894 ml) and transfer it to the Falcon tube containing the precursor
solution.
38 Centrifuge the collagen precursor solution at 200g for 1 min at 4 °C to remove air bubbles and then
return the liquid to the bottom of the Falcon tube.
Generation of densified collagen scaffolds
39 Generate collagen scaffolds either as flat sheets (option A) or as tubes (Fig. 1c; option B). If using
commercially produced PGA scaffolds, proceed to the next step.
(A) Fabrication of densified collagen sheets ● Timing 1–2 h
c CRITICAL Larger-sized densified collagen sheets are possible with larger (flat-bottom)
containers (e.g., a 24-well plate). To produce collagen sheets of the same thickness, the collagen
precursor solution should be poured into the container such that the height of the solution
is 25 mm.
(i) Using a 1-ml syringe and 18-gauge needle, transfer the 5 mg/ml collagen precursor solution to
a specimen tube until the height of the solution is 25 mm (Fig. 7b, image 1). Repeat as
necessary.
c CRITICAL STEP Avoid inserting air bubbles into the mixture. Add collagen solution slowly.
(ii) Gel the collagen solution by placing the specimen tube in a 37 °C incubator for 30 min.
c CRITICAL STEP To maintain sterility, transfer the specimen tube within an upside down
15-ml Falcon tube.
? TROUBLESHOOTING
(iii) Tightly roll three sheets of absorbent paper towels into a cylinder roughly 5 mm in diameter
and secure it with autoclave tape.
(iv) Using scissors, cut the paper cylinder to 25 mm in length. Flatten the end by pushing the
cylinder against a sterile surface (i.e., a 10-cm plate). Autoclave both the paper cylinder and a
nylon membrane.
c CRITICAL STEP The paper cylinder must have a flat edge in order to contact suitably and
thus dry the collagen gel evenly.
(v) Using scissors, cut a piece of nylon membrane into a round piece of a slightly smaller diameter
than that of the specimen tube.
(vi) Return the specimen tube to the class II biological safety cabinet. Carefully place the nylon
membrane on top of the gel and then place the paper towel wadding into the specimen tube,
on top of the membrane (Fig. 7b, image 2(i)).
(vii) Apply very light finger pressure to the top of the wadding so as to make good contact with the
gel and then leave the gel to densify for ~1 h (Fig. 7b, images 1–3(i)).
? TROUBLESHOOTING
(viii) Monitor the densification process every 5–10 min to ensure that the wadding is in contact with
the gel, and occasionally apply light pressure to keep the wadding in place.
c CRITICAL STEP Applying too much pressure will rip the top surface of the gel.
? TROUBLESHOOTING
(ix) The densification is terminated when the paper towel has almost reached the bottom of the
specimen tube and no water can be further removed (Fig. 7b, image 3(ii)). Once this has
occurred, remove the paper wadding; the collagen gel and nylon membrane should be adhered
to the wadding.
? TROUBLESHOOTING
(x) Using tweezers, carefully grip the edge of the collagen sheet and peel it away from the paper
wadding.
(xi) The nylon membrane is likely to remain attached to the collagen sheet. By gripping the nylon
sheet with tweezers, peel this away from the collagen sheet (Fig. 7b, image 4).
c CRITICAL STEP Avoid ripping the collagen sheet by gently peeling it away from the nylon
membrane.
? TROUBLESHOOTING
(xii) Wash the scaffold in William’s E+ medium in a six-well plate to remove the pink coloration.
(xiii) For storage, place the densified collagen sheet in fresh William’s E+ medium or PBS in a
six-well plate or another appropriate container (Fig. 7b, image 5). Seal the plate with Parafilm
and store it at 4 °C. Otherwise, proceed to the next step.
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j PAUSE POINT The densified collagen sheet can be stored at 4 °C for up to 3 months before
seeding.
(xiv) Warm the collagen sheet to 37 °C before cell seeding, by placing it in an incubator. Cells can be
seeded onto the surface of the collagen sheet at this point and cultured for several months as
described in the subsequent steps.
(B) Fabrication of densified collagen tubes ● Timing ~5–26 h
(i) Using a 1-ml pipette, transfer the precursor solution to the densification chamber until the
chamber is full (~1.5 ml; Fig. 8c, image 1).
c CRITICAL STEP Avoid inserting air bubbles into the mixture. Add collagen solution slowly.
(ii) Gel the collagen solution by placing the densification chamber in a 37 °C incubator for
30–60 min.
? TROUBLESHOOTING
(iii) To form a collagen tube, it is necessary to dislodge the collagen gel from the top of the funnel
to encourage the gel surface to drop. To do this, use a sterile pair of tweezers under a sterile
class II biological safety cabinet to gently peel the collagen gel away from the walls of the
chamber (Fig. 8c, image 2).
(iv) Loosen the screws attaching the base to the funnel.
(v) Return the densification chamber to the incubator. Monitor the chamber regularly for 30 min
until the level of the collagen gel drops to the top of the metallic wire (Fig. 8c, image 3).
c CRITICAL STEP The top end of the metallic wire, embedded in the collagen, will prevent the
gel surface from dropping further. Water will continue to be removed through evaporation
around the sides of the funnel to yield a tubular structure.
c CRITICAL STEP There should be a visible gap between the collagen gel and the edges of the
funnel.
? TROUBLESHOOTING
(vi) Monitor the densification chamber in the incubator for a further 4–24 h to allow for
evaporation of the water phase of the gel (Fig. 8b, panel 4).
c CRITICAL STEP It is important to monitor the collagen gel and prevent the tube from over-
drying, on the basis of the humidity conditions of the incubator.
(vii) Continue the process until the vast majority of water has evaporated. The collagen scaffold
should consist of a dense and thin cylindrical component around a wire core, with a larger
region near the top of the funnel (Fig. 8c, image 4).
? TROUBLESHOOTING
(viii) Transfer 4 ml of William’s E+ medium to a six-well plate. Use a sterile pair of tweezers to grip
the top of the collagen tube and slowly pull it upward over the end of the metallic wire (Fig. 8c,
image 5).
c CRITICAL STEP Be careful not to damage the collagen tube with the tweezers or the end of
the metallic wire.
? TROUBLESHOOTING
(ix) Place the collagen tube in a six-well plate containing William’s E+ medium for storage. The
pink coloration will disappear from the collagen tube over several hours (Fig. 8d, images 1
and 2).
(x) Before surgical implantation, it is necessary to trim away the excess collagen sheet and cut a
suitable length of tube for the experiment. Place the tube under a dissecting microscope and
use a surgical scalpel to cleanly trim any excess collagen (Fig. 8d, image 3).
(xi) Determine a suitable length of collagen tube along the scaffold. Pick a region that is cylindrical
in nature (likely the middle section). Use a surgical scalpel to cleanly cut across the tube to
yield the required length for the particular application (Fig. 8d, image 4).
c CRITICAL STEP Trimming the tube is a particularly difficult step, probably requiring the
assistance of an experienced surgeon. Be extremely careful not to cut into the lumen of the
tube. Doing so will result in leakages when the tube is perfused.
(xii) Observe the patent lumen under phase contrast with an inverted microscope (Fig. 8d,
image 5).
(xiii) Transfer the densified collagen tube to the six-well plate.
(xiv) Store the collagen tube in William’s E+ medium in the incubator until ready. The surfaces of
the tubes can be further seeded with cells at this point.
j PAUSE POINT Unseeded collagen tubes can be stored in William’s E+ medium or PBS at
4 °C for up to 3 months.
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Seeding COs onto scaffolds
40 To seed COs onto densified collagen sheets, see option A. To seed COs onto densified collagen
tubes, see option B. For seeding COs onto PGA scaffolds, which are available commercially (see
‘Materials’ section), see option C (Fig. 1d).
c CRITICAL The use of an optimal CO line is essential for scaffold seeding. Suboptimal lines will
result in reduced cell attachment, proliferation and long-term viability. All CO lines should express
the biliary markers CK19, CK7, Sox9 and GGT (Fig. 6a,b) and display ALP and GGT activity
(Fig. 6c,d). Healthy CO lines should require passaging every 5 d (Fig. 5b, image 1). CO lines that fail
to meet these criteria should not be considered for scaffold seeding. See the ‘Troubleshooting’
section for Steps 10, 11, 29 and 30 for guidance on how to improve the quality of a suboptimal
CO line.
(A) Seeding on densified collagen sheets ● Timing ~2 h 35 min–4 h
c CRITICAL Collagen scaffolds must be of an optimal quality to be used for seeding. Batch-test the
stock collagen solution used for collagen densification for cell attachment and proliferation
and confirm that the densification process has completed fully (see ‘Troubleshooting’ section for
Step 39A) and the scaffold has not dried out during storage to ensure the quality of the collagen
scaffolds.
c CRITICAL For long-term storage, maintain the collagen scaffolds in PBS to prevent them from
drying out.
(i) Remove the PBS and place the collagen scaffold in a dry 24-well tissue culture plate; then place
it in an incubator for 30 min–1 h, or until the PBS has evaporated and residues on the surface
are no longer visible.
c CRITICAL STEP Drying the scaffold before seeding is necessary, as the presence of excess
liquid on the scaffold’s surface may prevent cell attachment. This step is required both if the
scaffold has been stored long term and if seeding takes place immediately after fabrication of
the densified collagen scaffold.
c CRITICAL STEP Allowing the scaffold to dry for a prolonged period following evaporation of
the medium/PBS may affect the collagen fiber micro-architecture.
(ii) Remove the organoids from the Matrigel domes using cell recovery solution and incubate
them on ice for 30 min as described in Steps 16–26. An optimal seeding density of
1.5 × 106 cells/cm2 has been observed to give confluent scaffolds over a short period of time;
the number of wells required for the required surface area should be calculated using the
following formula:
Number of cells ¼ Scaffold surface cm2  ´ 1:5 ´ 106 cells=cm2
(iii) Aspirate the supernatant and resuspend the pellet in an adequate volume of William’s E+
medium supplemented with 500 ng/ml R-spondin, 50 ng/ml EGF, 100 ng/ml DKK-1 and
10 μM Y27632.
c CRITICAL STEP For the seeding solution, a cell density of 5 × 104 cells/μl is recommended.
For example, a pellet of 1 × 106 cells, equivalent to ~10 confluent wells, is resuspended
in a volume of 20 µl. Once seeded on a scaffold surface of 0.65 cm2, this should allow the cells
to form a confluent layer in ~2 weeks’ time, with slight variations depending on the
organoid line.
(iv) Gently pipette up and down with a p20 pipette 30–40 times to mechanically dissociate the
organoids into small clumps (~10–20 cells per clump) and obtain a homogeneous solution.
? TROUBLESHOOTING
(v) Seed the cells by directly pipetting this solution onto the scaffold’s surface with a p10 pipette
(Fig. 9b, images 3(i) and 3(ii)).
c CRITICAL STEP To achieve a homogeneous attachment, it is recommended to seed multiple
5-µl aliquots in different positions all over the scaffold surface.
? TROUBLESHOOTING
(vi) After seeding on collagen scaffolds, keep the plate in a 37 °C incubator for 1–2 h to allow the
cells to attach to the scaffold.
c CRITICAL STEP Monitor the scaffolds every 30 min to avoid drying the cells out.
? TROUBLESHOOTING
(vii) Prepare 2 ml of William’s E+ medium supplemented with 500 ng/ml R-spondin, 50 ng/ml
EGF, 100 ng/ml DKK-1 and 10 μM Y27632 for each scaffold.
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(viii) To add the medium, tilt the plate and slowly add the medium from the bottom of the well
(Fig. 9b, image 5).
c CRITICAL STEP Medium must be added as slowly as possible, using a p1000 pipette. Care
must be taken to avoid disrupting the scaffold when adding the medium.
? TROUBLESHOOTING
(ix) Culture the seeded scaffold for 4 d before the first medium change, in order to maximize cell
attachment. After this period, replace the medium with 500 µl of William’s E+ medium
supplemented with 500 ng/ml R-spondin, 50 ng/ml EGF and 100 ng/ml DKK-1 every
other day.
c CRITICAL STEP When the medium is changed, all previous medium must first be aspirated.
Care must be taken to avoid disrupting the scaffold during medium aspiration.
c CRITICAL STEP COs will start growing and expanding on the scaffold after a first lag phase
(lasting ~4–5 d after seeding); then confluency should be reached in ~2 weeks, according to the
age of the cell line (Fig. 9d,e).
? TROUBLESHOOTING
(B) Seeding onto the lumen of densified collagen tubes ● Timing 2 h 30 min–3 h 30 min
(i) Working under aseptic conditions, transfer the densified collagen tube onto a dry 10-cm plate.
(ii) Leave it to dry under a class II biological safety cabinet for approximately half an hour, or until
almost all the residual PBS has evaporated.
c CRITICAL STEP Prepare the CO cell suspension as detailed in Step 40B(iii,iv)) during the
waiting time described in Step 40B(ii).
(iii) Passage the organoids as described in Steps 16–26. The number of wells required for the
desired tube area should be calculated using the following formula:
Number of cells ¼ Tube internal surface cm2  ´ 6:5 ´ 106 cells=cm2
c CRITICAL STEP For the seeding solution, a cell density of 2.5 × 104 cells/μl is recommended.
For example, a pellet of 6 × 105 cells, equivalent to ~6 confluent wells, is resuspended in a
volume of 25 µl. Once seeded in the lumen of a tube with a 1.5-cm length and 250-µm
diameter, a confluent layer of cells should form in ~4 weeks’ time, with slight variations
depending on the organoid line.
c CRITICAL STEP Seeding of the luminar surface of the densified collagen tubes requires a
greater cell density than seeding of flat scaffolds, as a higher proportion of the cells are likely to
be lost during the seeding process and so cells should be seeded in excess to guarantee
adequate seeding of the whole tube area.
(iv) Resuspend the cells in 25 μl of William’s E+ medium with 50 ng/ml EGF and 10 μM Y27632.
(v) Use a p20 pipette to carefully break the COs into small clumps (10–20 cells).
c CRITICAL STEP Failure to break the COs into small enough clumps (Supplementary Fig. 2,
image 2) will result in the cells failing to form a confluent monolayer on the luminal surface of
the tube.
? TROUBLESHOOTING
(vi) Using a 34-gauge Hamilton removable needle and a pair of fine forceps, cannulate the tube
with the 34-gauge needle. For best results, this should be done under a dissecting microscope
(Fig. 10b, image 2).
c CRITICAL STEP Cannulation of the tube should ideally be performed by an experienced
surgeon. Improper attempts at cannulation can result in disruption of the construct wall
beyond repair.
(vii) Use a p200 pipette to transfer the cell suspension to a 25- or 50-μl Hamilton syringe.
c CRITICAL STEP It is highly advisable to use Hamilton syringes, as recommended in the
‘Equipment’ list, or some other model of small-volume syringes with removable needles and
no dead space. This is due to the very low volume of cell suspension required for seeding,
which is smaller than the dead space in standard needles.
(viii) Slowly depress the plunger on the syringe to deposit the cell suspension in the lumen of the
tube while simultaneously removing the needle from the tube in order to distribute the cells
evenly along the tube lumen (Fig. 10b, image 3).
? TROUBLESHOOTING
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(ix) Incubate the freshly seeded tube in a covered 10-cm plate at 37 °C without medium for up to
an hour to allow cell attachment.
? TROUBLESHOOTING
(x) Transfer the tube to a six-well plate.
(xi) Prepare 2 ml of William’s E+ medium supplemented with 500 ng/ml R-spondin, 50 ng/ml
EGF, 100 ng/ml DKK-1 and 10 μM Y27632.
(xii) Tilt the plate and use a p1000 pipette to add the medium slowly to the side of the well until the
tube is covered.
c CRITICAL STEP Mediummust be added as slowly and carefully as possible, to avoid disruption
of the newly attached cells. Care must be taken to avoid touching the tube with the pipette.
? TROUBLESHOOTING
(xiii) Culture the seeded tube for 4 d before the first medium change, in order to maximize cell
attachment. After this period, replace the medium with 2 ml of William’s E+ medium
supplemented with 500 ng/ml R-spondin, 50 ng/ml EGF and 100 ng/ml DKK-1 every 4 d in
order to reduce the disruption caused by medium change.
c CRITICAL STEP When changing the medium, all previous medium must first be aspirated.
Care must be taken to avoid disrupting the tube during medium aspiration.
c CRITICAL STEP Maintain the construct in culture. A confluent layer of cells should form in
~4 weeks, depending on the age of the cell line (Fig. 10c,d).
? TROUBLESHOOTING
(C) Seeding on PGA scaffolds ● Timing 2 h 10 min–4 h 10 min
(i) Place the PGA scaffold, with a thickness of 1 mm and density of 50 mg/cm3, in 1 M NaOH for
10–30 s.
(ii) Sterilize the scaffold by immersion in 70% (vol/vol) EtOH for 30 min.
(iii) Air-dry the PGA scaffold in a six-well tissue culture plate under a sterile class II biological
safety cabinet for a further 30 min (Fig. 9c, image 1).
c CRITICAL STEP Ensure that all traces of NaOH and EtOH are gone from the scaffold before
beginning seeding. Improper drying can lead to cell death and failure to attach to the scaffold.
(iv) Remove the COs from organoid culture and prepare a suspension of small clumps as described
in Step 40A(ii–iv).
c CRITICAL STEP Given the pore size of the electrospun PGA, it is important that the CO
clumps be no smaller than 40–60 cells per clump, as small cell clumps will fall through the
pores of the scaffold and not be retained.
? TROUBLESHOOTING
(v) Gently pipette up and down with a p20 pipette 10–20 times in order to obtain a homogeneous
cell suspension with CO clumps of ~40–60 cells per clump.
? TROUBLESHOOTING
(vi) Seed the cells onto the PGA scaffold as described in Step 40A(v–x) (Fig. 9c, images 3(i) and 3(ii)).
? TROUBLESHOOTING
Characterization of COs
41 To analyze COs using IF, follow option A. To analyze COs by flow cytometry, follow option B. To
extract RNA for qPCR, follow option C.
(A) Immunofluorescence ● Timing ~3 d
(i) Aspirate the William’s E+ culture medium.
(ii) Add 1 ml of 4% (vol/vol) PFA per well.
c CRITICAL STEP PFA should be added gently to the side of the well so as to avoid disrupting
the Matrigel dome.
(iii) Incubate at 4 °C for 20 min to fix the cells.
? TROUBLESHOOTING
(iv) Aspirate the PFA.
c CRITICAL STEP The PFA should be aspirated with a p1000 pipette to avoid disruption of the
Matrigel dome.
(v) Wash twice in PBS. Each wash should take 10 min.
j PAUSE POINT The CO plate can be sealed and kept at 4 °C for up to 4 weeks.
(vi) Prepare a solution of 10% (vol/vol) donkey serum and 0.1% (vol/vol) Triton X-100 in PBS.
? TROUBLESHOOTING
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(vii) Add 1 ml of this solution to each organoid well and incubate the plate at room temperature
for 1 h to block and permeabilize the COs.
? TROUBLESHOOTING
(viii) Dilute the primary antibodies in a solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol)
Triton X-100 in PBS.
(ix) Add 500 μl of primary antibody solution per CO well.
(x) Stain the COs overnight at 4 °C.
(xi) Wash the COs three times with 1% (vol/vol) donkey serum and 0.1% (vol/vol) Triton X-100
in PBS. Each wash should take 45 min.
(xii) Dilute the secondary antibodies in a solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol)
Triton X-100 in PBS.
(xiii) Add 500 μl of secondary antibody solution per CO well.
(xiv) Stain the COs overnight at 4 °C.
c CRITICAL STEP The CO plates should be wrapped in foil to prevent exposure of the
secondary antibodies to light.
? TROUBLESHOOTING
(xv) Aspirate the secondary antibody solution.
(xvi) Prepare a 1:10,000 (vol/vol) solution of Hoechst 33258 in PBS.
(xvii) Incubate the COs in this Hoechst 33258 solution for 10 min at room temperature.
? TROUBLESHOOTING
(xviii) Aspirate the Hoechst 33258 solution.
(xix) Wash the COs three times with PBS. Each wash should take 45 min.
(xx) Add a final 1 ml of PBS per CO well and image the COs immediately or store the plate at
4 °C until ready for analysis.
j PAUSE POINT The plates can be stored at 4 °C for up to 3 months, provided the stained
wells have an adequate covering of PBS and the plates are properly sealed.
(xxi) Image using a confocal microscope. All of our IF images (Figs. 6a and 11a,c,e) were acquired
using a Zeiss LSM 700 confocal microscope. ImageJ 1.51h software (Wayne Rasband,
NIHR; http://Imagej.nih.gov/ij) was used for image processing such as merging of different
channels.
(B) Flow cytometry ● Timing 5.5 h
(i) Preparation of a single-cell suspension. Passage the organoids as described in Steps 16–24.
(ii) Resuspend the pellet in 1 ml of William’s E+ medium and centrifuge at 444g for 4 min at
room temperature.
(iii) Prepare a solution of Accutase (prewarmed to 37 °C) with 4 mg/ml DNase I and 10 μM
Y27632.
c CRITICAL STEP Omission of DNase I and Y27632 can lead to cell clumping and greatly
reduced viability.
(iv) Aspirate the supernatant and resuspend the pellet in 1 ml of Accutase solution.
(v) Incubate the cells at 37 °C for up to 5 min to produce a single-cell suspension.
c CRITICAL STEP Examine the cells under a microscope halfway through to check the
progress of the dissociation
? TROUBLESHOOTING
(vi) Add 1 ml of William’s E+ medium or 1% (wt/vol) BSA in PBS with 4 mg/ml DNase I and
10 μM Y27632 to the cell suspension.
(vii) Centrifuge the cells at 444g for 4 min at room temperature.
(viii) Resuspend the pellet in 1 ml of William’s E+ medium or 1% (wt/vol) BSA in PBS with
4 mg/ml DNase I and 10 μM Y27632.
(ix) Filter through a 40-μm filter.
c CRITICAL If performing flow cytometry on a live cell population, skip Step 40B(x–xv)
and go directly to Step 40B(xvi–xxix) (staining of a single-cell suspension for flow
cytometry).
? TROUBLESHOOTING
(x) Centrifuge the cells at 444g for 4 min at room temperature.
(xi) Resuspend the pellet in 1 ml of 4% (vol/vol) PFA.
(xii) Incubate the cells at 4 °C for 15 min to fix the cells.
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(xiii) Add 1 ml of 1% (wt/vol) BSA in PBS.
(xiv) Centrifuge the cells at 444g for 4 min at room temperature.
(xv) Resuspend the pellet in 1 ml of 1% (wt/vol) BSA in PBS.
c CRITICAL STEP Cells should be handled very carefully after fixation to avoid damage. Pellets
should be resuspended by flicking of the centrifuge tube (as opposed to pipetting), and all
pipetting should be done slowly.
j PAUSE POINT After fixation, cells can be stored at 4 °C for up to 2 d.
(xvi) Staining a single-cell suspension for flow cytometry. If staining for cell-surface markers only,
prepare a 1:20 dilution of FcR block in 1% (wt/vol) BSA in PBS.
(xvii) If staining for intracellular markers, prepare a 1:20 dilution of FcR block in 1% (wt/vol) BSA in
PBS with 0.1% Triton X-100 (vol/vol).
(xviii) Centrifuge the cells at 444g for 4 min at room temperature and resuspend the pellet in 200 μl
of diluted FcR block.
(xix) Incubate at room temperature for 30 min.
(xx) Prepare a master mix of all antibodies (if using conjugated antibodies) or all primary
antibodies (if using separate primary and secondary antibodies) in 1% (wt/vol) BSA
in PBS.
c CRITICAL STEP An aliquot of the cell suspension (at least 1 × 105 cells) should be used
as an unstained control. If using separate primary and secondary antibodies, another
aliquot must be used for a secondary-only control. Both aliquots should be kept at 4 °C until
required.
(xxi) Centrifuge the cells at 444g for 4 min at room temperature.
(xxii) Resuspend the pellet in 200 μl of master mix solution.
(xxiii) If using conjugated antibodies, incubate at 4 °C for half an hour. If using primary antibodies,
incubate at room temperature for an hour.
(xxiv) If using conjugated antibodies, wash the cells three times in 1% (wt/vol) BSA in PBS and filter
through a 40-μm filter before analyzing the sample on the flow cytometer.
(xxv) If using unconjugated antibodies, wash the cells three times in 1% (wt/vol) BSA in PBS. Each
wash should take 5 min.
(xxvi) Prepare a solution of all secondary antibodies in 1% (wt/vol) BSA in PBS.
(xxvii) Resuspend the cells in 200 μl of secondary antibody solution and incubate at room
temperature for 1 h.
c CRITICAL STEP The secondary-only control should also be stained at this point.
c CRITICAL STEP The cells should be kept in the dark to prevent exposure of the secondary
antibody to light.
(xxviii) Wash the cells three times in 1% (wt/vol) BSA in PBS. Each wash should take 5 min.
(xxix) Resuspend the cells in 200 μl of 1% (wt/vol) BSA in PBS and filter through a 40-μm filter
before analyzing the sample on a flow cytometer. All our flow cytometric analyses were
performed on a FACS Cyan flow cytometer and analyzed using FlowJo v.10.4.2.
(C) RNA extraction ● Timing ~2 h
(i) If isolating RNA from an established CO line, first remove COs from organoid culture as
described in Steps 16–25. If isolating RNA from a suspension of primary cells, go straight to
Step 40C(ii).
(ii) Centrifuge the cells at 444g for 4 min at room temperature.
(iii) Aspirate the supernatant and resuspend the pellet in 350 μl of RNA lysis buffer.
c CRITICAL STEP Ensure that the lysed cell suspension is fully homogenized.
(iv) Transfer the lysed cell suspension to a prelabeled 1.5-ml Eppendorf tube and store the tube
immediately at −80 °C.
c CRITICAL STEP A delay in transferring the lysed sample to −80 °C storage can result in
degradation of RNA quality.
j PAUSE POINT Samples in RNA lysis buffer can be stored at −80 °C for >1 year until needed.
(v) Thaw the samples on ice.
(vi) Use the GenElute Mammalian Total RNA Miniprep Kit to extract RNA from the samples
according to the manufacturer’s instructions.
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Troubleshooting
Troubleshooting advice can be found in Table 1.
Table 1 | Troubleshooting table
Step Problem Possible reason Solution
2A(iii) Very few or no cells are
collected after
mechanical dissociation
Cell detachment during PBS washes Reduce the number of washes
If the tissue has been in cold storage solution for longer
than 2–4 h, consider omitting the wash step. Aspirate any
excess bile with a p1000 pipette instead
Centrifuge the PBS to collect the cells detached during
the washes
2A(ix, xii) Pellet contains too
much debris
Forceful scraping of the tissue can
mechanically dissociate part of the
fibrous tissue, as well as biliary
epithelia
Scrape the tissue very gently and avoid scraping the same
area of tissue more than twice
Where possible, remove large debris with a p1000 pipette
before centrifugation
2A(x) Cells do not form a pellet
in Step 2A(x) after
mechanical dissociation
Inadequate wash Increase the number of PBS washes before mechanical
dissociation
Remnants of bile and/or debris in
the cell suspension
Ensure that the tissue is adequately washed before you start
mechanical dissociation
Use a p1000 pipette to remove large pieces of debris before
transferring the cells to a 50-ml centrifuge tube
Cells are lost during the
wash steps
Washing was done in PBS or
medium with inadequate protein
content
Use only complete William’s E+ medium during the wash
steps or 1% (wt/vol) BSA in PBS
2A(xviii), 2B(v) Organoids do not form
following plating
Poor cell viability (PCV) due to
tissue drying during the
dissection steps
Dissect the tissue as quickly as possible and submerge it in
medium as soon as dissection is complete
PCV due to stress of mechanical
dissociation
Avoid vigorous scraping of the tissue resulting in cell death
Avoid vigorous washes and pipetting resulting in increased
cell stress and/or death
PCV due to prolonged cold storage Process the tissue as soon as possible after surgical excision
PCV due to lack of necessary
cytokines in the medium
Ensure that the medium contains 150 ng/ml EGF and 10 μM
Y27632 at every stage
PCV due to poor quality of tissue
culture medium and reagents
(Matrigel or cytokines)
Batch-test Matrigel and medium components
Always store Matrigel and cytokines at −80 °C
Avoid repeat freeze–thaw cycles of cytokines and do not




Organoids do not form
once the tissue is plated
PCV due to tissue drying during the
dissection steps
Complete the dissection step as quickly as possible
PCV due to stress of mechanical
dissociation
Ensure that the dissected liver pieces are as small as
possible so they can fit into the tip of a p1000 pipette
without difficulty
PCV due to prolonged cold storage Process the tissue as soon as possible after surgical excision
PCV due to lack of necessary
cytokines in the medium
Ensure that the medium contains 150 ng/ml EGF and 10 μM
Y27632 at every stage
PCV due to poor quality of tissue
culture medium and reagents
(Matrigel or cytokines)
Batch-test Matrigel and medium components
2D(v) Poor viability of cells
before EpCAM sorting
Prolonged enzymatic dissociation Examine the cells every 10 min during the dissociation.
Ensure that the dissociation is stopped as soon as a single-
cell suspension is obtained and the majority of liver cells
have been released from the extracellular matrix
(Supplementary Fig. 2b, image 4)
Vigorous pipetting to dissociate cell
clumps, resulting in cell death
Dissociate cell clumps gently. Prolong enzymatic digestion if
vigorous pipetting is required
Prolonged cold storage Process the tissue as soon as possible after surgical excision
2D(v, vii) Cells clumping during or
after dissociation to a
single-cell suspension
DNA fragments in the suspension
originating from non-viable cells
cause cholangiocytes to clump
Monitor the cells closely during dissociation. If cells show
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Table 1 (continued)
Step Problem Possible reason Solution
Following filtering, the cells should be resuspended in 1%
(wt/vol) BSA in PBS supplemented with 4 mg/ml DNase I
and 10 μM Y27632
2D(xv) Substantial loss of cells
after single-cell
dissociation
Cell adhesion to the surfaces of the
centrifuge tube during
centrifugation or MACS sorting
Resuspend cells in sterile 1% (wt/vol) BSA in PBS with 4
mg/ml DNase I and 10 μM Y27632
Prime centrifuge tubes with 1% (wt/vol) BSA in PBS
before use
2D(xxiv) Blockages during the
MACS sorting
Cell clumps remain in the cell
suspension
Filter the sample immediately before running on the MACS
cell sorter
6 Matrigel does not form a
dome but attaches to the
side of the well during
plating
Remnants of solidified Matrigel
blocking the pipette tip and
preventing uniform dispensation of
the gel
Change pipette tip
8, 30 Cells attach to the
bottom of the plate
Delay in inverting the plate after
plating of the cells
Ensure that the plates are adequately prewarmed
Delay in Matrigel solidification due
to low plate starting temperature,
allowing cell clumps to gravitate to
the bottom of the plate
Ensure plating occurs on a plate heater to allow the Matrigel
to solidify as quickly as possible. Keep the plates inverted
for 30 min in a 37 °C incubator
10, 11 Cells form small spheres
lacking a lumen after
plating
Overly dense initial plating,
preventing organoid expansion
Passage the cells earlier than 5 d and plate at a reduced
density
Add 2 μM FSK to the medium
21 Matrigel remnants are




Incubation time was too short Ensure that the cells have been incubated for the full 30 min
in cell recovery solution and that the volume of ice is
adequate to keep the cells at 4 °C
10, 11, 29 Cells demonstrate signs









Events during passaging could be
causing stress to the cells:
dissociating the organoids too
vigorously during Step 29 or
prolonged duration of passaging,
stressing the cells by delaying
return to optimal culture conditions
Avoid vigorous dissociation during passaging and minimize
delays during passaging
Suboptimal batch of Matrigel Batch-test new lots of Matrigel
Suboptimal quality of the cytokine
medium components used
Store all stock solutions at 4 °C and do not use stock
solutions made more than 3 months earlier. Where
applicable, do not use stock solutions beyond their expiry
date. Store all cytokines at −80 °C
Mycoplasma contamination Test organoid cultures for Mycoplasma contamination
Delay in passaging the cells
(Supplementary Fig. 4b)
Passage COs when 80% confluent with no signs of
organoid collapse, typically every 5 d. Plates should be
observed daily to determine the optimum time for
passaging
Overly dense plating, preventing
organoid proliferation
(Supplementary Fig. 4b)
Passage the cells earlier than the typical 5 d and ensure that
the cells are plated more sparsely at the next passage
Additional cytokines needed Increase the working concentration of EGF used during
maintenance to up to 100 ng/ml
Add FSK at a 2 μM working concentration (0.2 μl/ml of a
10-mM stock)
Add HGF at a 50 ng/ml working concentration
35 Stock collagen solution is
highly viscous upon
arrival
If the stock collagen solution is
stored at temperatures < 2 °C, it
can appear to have gelled
Warm the stock collagen solution to room temperature until
the collagen solution is liquid. Once liquid, store at 4 °C
36, 39A(ii) Collagen precursor
solution solidifies in the
mixing tube.
Solution mixing occurs too slowly Before starting, cool all the reagents to 4 °C
The room temperature is too high Mix the solution in an ice bath
39A(vii, viii) Collagen gel
densification stops
prematurely
The absorbent paper wadding has
poor contact with the collagen gel
and so cannot remove water
effectively
Remove the paper wadding from the specimen tube and
flatten the end in contact with the collagen gel. Once
sufficiently flat, return it to densification chamber
Table continued
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Table 1 (continued)
Step Problem Possible reason Solution
As the paper wadding absorbs
water, it expands and becomes
wedged in the specimen tube,
preventing further densification
Gently remove the paper wadding from the specimen tube
and replace it with a fresh roll with a slightly reduced
diameter
39A(ix) Following densification
steps and removal of
paper wadding, the
specimen tube is empty
Collagen solution has been
prematurely absorbed into the
paper wadding before gelation
Repeat the process and extend the time for collagen
gelation from 30 min to 1 h
Test gelation by carefully pressing the metal spatula against
the top surface. Only add paper wadding once you are sure
that the collagen has gelled
39A(xi) Collagen sheet was not
attached to paper
wadding on its final
removal
After the removal of the wadding,
the collagen sheet remains at the
bottom of the specimen tube
The scaffold can be removed carefully with a pair of
tweezers or by some PBS flushed into the specimen tube
Once removed from the
densification chamber,
the lower part of the
scaffold retains a gel-like
structure
Densification has been stopped
prematurely, causing the lower part
of the collagen sheet to retain a
higher water content
Return the scaffold to the densification chamber and
continue the densification process with fresh paper wadding
39B(ii) Before collagen gelation,
the level of the collagen
solution has dropped
The collagen precursor solution is
leaking out of the bottom of the
funnel of the densification chamber
Keep the chamber upright and carefully tighten the screws
such that the base is firmly attached to the funnel.
Add an extra volume of collagen precursor solution until the
funnel is once again full
The level of the collagen
gel has dropped below
the top of the
metallic wire
The volume of collagen above the
wire was unable to stop the collagen
gel from dropping below the wire
Use scissors to remove a couple of millimeters of length
from the top of the metallic wire.
Repeat the collagen gelling process
39B(v) The level of the collagen
gel has not dropped to
the top of the
metallic wire
The paper towels at the base are not
in sufficient contact with the gel and
so water is not being drawn out
Repeat the process. When loosening the screws, do not
displace the base away from the funnel, thereby keeping the
paper towels in contact with the bottom of the collagen gel
39B(v, vii, viii) Collagen gel has not
densified after 24 h
There has been insufficient
evaporation of water from the
collagen gel to form a tube
Use sterile tweezers to repeat the process of peeling the
collagen gel from the chamber walls. One should observe a
1- to 2-mm spacing between the collagen gel and funnel
walls. Continue densifying until a tube forms
The humidity of the incubator may be high and so an
insufficient volume of water has evaporated from the
collagen gel. Continue step 39B(vii), monitoring the














Add medium very carefully. Tilt the plate and hold the
pipette against the side of the well to avoid disrupting the
Matrigel dome. Add the medium slowly, using a p1000
pipette
Low cell number. Optimal cell
number and attachment potential
may vary between lines
Optimize the seeding density for each CO line
Prolonged incubation, leading to cell
death and drying
Monitor the scaffolds closely after seeding and before
addition of medium. Check the scaffolds every 30 min to
ensure that the seeding solution has not evaporated
Small clump size, leading to loss of
cells through the pores of the PGA
scaffold
Optimize the clump size when seeding PGA scaffolds
Single cells or very small clumps
floating in the seeding solution and
preventing attachment
Pipette more slowly and for fewer times when breaking the
COs into small clumps
Remnants of EtOH or NaOH in PGA
scaffolds, leading to cell death in
PGA scaffolds
Increase the drying time to ensure that all traces of NaOH
and EtOH are gone (PGA scaffolds only)
Excessive breaking of the CO
clumps, reducing cell viability
Use a p200 pipette instead of a p20 to break the
CO clumps
Pipette more slowly when breaking the CO clumps
Table continued
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Table 1 (continued)







The seeding volume is too big Immediately retrieve the spilled solution and seed it again
onto the scaffold
The seeding has occurred too close
to the edge
Reduce the total volume of cell suspension used during
seeding
40B(v) CO clumps form
organoid-like 3D
structures rather than a
monolayer
CO clumps were not dissociated to
a sufficiently small size





Rapid addition of the cell suspension
with inadequate needle withdrawal
Dispense cells slowly, simultaneously withdrawing the




Low cell density on the
scaffold
The cells may have been seeded too
sparsely
Increase the cell density




Poor cell survival and/or
expansion on the scaffold
Cells are washed away during
medium change
Increase the amount of medium to 1 ml and change it very
carefully every 4 d
Y27632 was not added to
the medium
Ensure that fresh Y27632 is added to the medium when
seeding
Suboptimal CO line All CO lines should express the biliary markers CK19, CK7,
Sox9 and GGT (Fig. 6a,b) and display ALP and GGT activity
(Fig. 6c,d). Healthy CO lines should be proliferating at a rate
requiring passaging every 5 d (Fig. 5b, image 1). Do not
attempt scaffold seeding with a CO line that does not meet
these criteria. See the Troubleshooting advice for Steps 10,
11 and 29 for recommendations on how to improve the
quality of a suboptimal CO line
Suboptimal collagen batch for
collagen scaffolds
Batch-test all new lots of collagen solution (collagen
scaffolds only)
Suboptimal quality of cytokines,
medium components or
collagen stock
Store all stock solutions at 4 °C and do not use stock
solutions made more than 3 months previously. Where
applicable, do not use stock solutions beyond their expiry
date. Store all cytokines at −80 °C
Remnants of EtOH or NaOH in PGA
scaffolds, leading to cell death in
PGA scaffolds
Increase the drying time (70 min) to ensure that all traces
of NaOH and EtOH are gone (PGA scaffolds only)
Prolonged incubation, leading to cell
death and drying
Monitor the scaffolds closely after seeding and before
addition of medium; check the scaffolds every 30 min to
ensure that they have not dried out
41A(iii) Staining appears weak or
non-specific
The 4% (vol/vol) PFA may have
degraded
Store 4% (vol/vol) PFA at 4 °C and do not use it for longer
than 1 month
Samples may have been fixed for
too long
Reduce fixation time. Do not attempt to fix too many
samples at one time, to avoid accidental over-fixation
41A(vi) Nuclear and intracellular
staining is poor
The cells are not properly
permeabilized, preventing adequate
penetration of the antibody
Increase the concentration of Triton X-100, e.g., 0.3%
(vol/vol) Triton X-100 or 0.5% (vol/vol) Triton X-100
41A(vii, xiv) High levels of non-
specific and background
staining
Blocking time may have been
too short
Increase blocking time, e.g., to 1 h
Secondary antibody incubation may
have been too long
Incubate secondary antibodies for 1 h at room temperature
instead of overnight at 4 °C
41A(xvii) DAPI staining is unclear Incubation with DAPI may not have
been long enough
Increase incubation with DAPI to 20 or 30 min
41B(v) COs do not dissociate
into a single-cell
suspension
Cell clumping and/or poor viability Increase the concentration of DNase I in the Accutase
solution
Ensure that all pipetting is done as slowly and carefully as
possible
CO clumps are not breaking up into
single cells during the 5-min
incubation period
Ensure that the Accutase solution is prewarmed
Prolong incubation (e.g., 7–10 min)
41B(ix) Single-cell suspension
forms clumps
Concentration of DNase I is too low Increase the concentration of DNase I, e.g., to 6 mg/ml
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Timing
The timings below are estimates based on the approximate time required for a researcher with
experience in this protocol to complete each of the steps. When attempting this protocol for the first
time, researchers may find that aspects of the Procedure take longer to complete.
Step 1, tissue collection: 1–8 h
Step 2A, derivation of ECOs from deceased organ donors: 1 h 20 min–1 h 50 min
Step 2A(i–viii), washing, dissecting and scraping the tissue: 20–30 min
Step 2A(ix–xv), wash steps and optional red blood cell lysis: 20–40 min
Step 2A(xvi–xviii), organoid plating: 40 min
Step 2B, derivation of ECOs through ERCP brushings: 30 min
Step 2C(i and ii), tissue dissection: 10–20 min
Step 2C(iii–vi), washing and plating preparation: 10–15 min
Step 2C(vii and viii), plating: 10 min
Step 2D(i–iii), preparing the tissue for digestion: 10 min
Step 2D(iv–vii), digestion and filtering: ~1 h
Step 2D(viii–xvi), red cell lysis, washing and cell counting: 20–30 min
Step 2D(xvii–xxvii), MACS sorting and plating: ~1 h
Steps 3–10, plating of primary cholangiocytes in organoid format: 10–40 min
Steps 11–14, changing medium for maintenance of CO lines: variable, depending on cell line; hands-on
time is 20 min every 48 h
Steps 15–21, removal of organoids from Matrigel: 40 min
Steps 22–26, washing and splitting the pellet: 10 min
Steps 28–30, plating the cells: 45 min
Steps 31–38, preparation of 5 mg/ml collagen gel: 10 min
Step 39A(i–vi), preparation of the densification chamber: ~45 min
Step 39A(vii–ix), collagen densification: 1 h
Step 39A(x–xiv), removal and storage of the densified collagen scaffold: ~10 min
Step 39B(i and ii), loading chamber with collagen and gelation: 40 min–1 h
Step 39B(iii–vii), collagen densification: 4–24 h
Step 39B(viii–xiv), removal and storage of the densified collagen tube: ~30 min
Step 40A(i), drying of the collagen scaffold: 30 min–1 h
Step 40A(ii–iv), preparation of the COs for seeding: 45 min
Step 40A(v), scaffold seeding: 15 min
Step 40A(vi), waiting step before medium addition: 1–2 h
Step 40A(vii–ix), medium addition: 5 min
Step 40B(i and ii), drying of collagen tube: 30 min–1 h
Step 40B(iii–v), preparation of the COs for seeding: 45 min
Step 40B(vi–viii), tube cannulation and cell seeding: 30 min
Step 40B(ix), cell attachment: 30 min–1 h
Step 40B(x–xiii), addition of medium: 15 min
Step 40C(i–iii), preparation of the PGA scaffold: ~1 h
Step 40C(iv and v), preparation of CO suspension: 40 min
Step 40C(vi), seeding of the PGA scaffold, waiting, and medium addition: ~1.5–2.5 h
Step 41A(i–v), organoid fixation: 40 min
Step 41A(vi–ix), blocking and primary antibody addition: ~90 min
Step 41A(x), primary antibody staining: overnight
Step 41A(xi–xiii), washing and secondary antibody addition: ~2 h 30 min
Step 41A(xiv–xv), secondary antibody staining: overnight
Step 41A(xvi–xxi), washing and nuclear staining: ~2 h 40 min
Step 41B(i–x), preparation of a single-cell suspension: 60 min
Step 41B(xi–xv), fixation: 30 min
Step 41B(xvi–xix), blocking: 45 min
Step 41B(xx–xxiv), staining with conjugated antibodies: 45 min
Step 41B(xxv–xxix), staining with separate primary and secondary antibodies: 2 h 30 min
Step 41C(i and ii), cell lifting: 40 min
Step 41C(iii and iv), RNA lysis: 10 min
Step 41C(v and vi), RNA extraction: 1 h
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Anticipated results
We describe a protocol for the isolation of primary biliary epithelial cells from a variety of clinical
samples, their propagation as COs and the generation of bioengineered biliary tissue by seeding of
these organoids on PGA or densified collagen scaffolds. Our cholangiocyte isolation methods (ERCP,
mechanical scraping, EPCAM sorting) result in a >95% pure (CK7+/CK19+) population of isolated
cholangiocytes (Figs. 2e, 3d and 4e). Furthermore, 95% of plated samples derived from excised bile
ducts (when appropriately flushed of bile after excision) and 100% of samples derived from gall-
bladders, liver biopsies and ERCP brushings yield robust CO lines within 5 d of initial plating
(Supplementary Table 1). CO lines can be derived from EpCAM+ liver samples with an approximate
efficiency of 66% (Supplementary Table 1). Although it is important to derive lines from fresh, highly
viable primary tissue to ensure the most reliable results, robust, highly proliferative CO lines can also
be derived from poor-quality samples with low cell numbers (Supplementary Fig. 5). CO lines can
subsequently be passaged approximately every 5 d and can typically be split in a 1:4–1:6 ratio for
further expansion, analysis or cryopreservation.
The resulting organoids consist of a near-homogeneous (>99%) population of cholangiocytes
(Fig. 6e). They express biliary markers such as CK19, CK7, Sox9 and GGT (Fig. 6a) at levels
comparable to those of primary tissue (Fig. 6b) in the absence of hepatic markers such as albumin
(Fig. 6a). Furthermore, CO lines exhibit key cholangiocyte functions, such as ALP and GGT activity
(Fig. 6c,d). COs also display functional secretory capacity, as measured by the luminal secretion of
rhodamine 123 (see Fig. 2a–c in ref. 4) and bile acid transport, as measured by export of the
fluorescently labeled bile acid CLF (see Fig. 2d–f in ref. 4). In addition, COs respond appropriately to
hormonal signals such as secretin and somatostatin (see Fig. 2i,j in ref. 4). For further validation, COs
can be transplanted under the kidney capsule of immunocompromised mice, where they form tubular
structures retaining expression of biliary markers such as CK7 and CK19 and are capable of long-
term survival (see Supplementary Fig. 7 in ref. 4).
COs can be seeded onto both densified collagen and PGA scaffolds to form bioengineered biliary
tissue. In addition, COs can be seeded onto the lumen of tubular densified collagen scaffolds (Fig.
11e). The efficiency of cell attachment following seeding is variable among CO lines. However,
following attachment, the cells demonstrate a unique potential to expand and fully populate the
scaffold. Therefore, it is always possible to generate confluent constructs by varying how long the
scaffolds are maintained in culture. The resulting tissue expresses key cholangiocyte markers such as
CK19 and CK7 (Fig. 11a,c,e) and exhibits biliary function such as GGT activity (Fig. 11b,d,f). These
constructs can be used to successfully reconstruct or repair the biliary tree of immunocompromised
mice (see Figs. 4 and 6 in ref. 4) while retaining the expression of biliary markers and function
following transplantation (see Figs. 4 and 6 in ref. 4).
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary
linked to this article.
Data availability
The authors declare that the main data supporting this study are available within the article.
Additional data are available from the corresponding authors upon request.
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